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Abstract
Acute liver failure (ALF) is a devastating condition with a high associated mortality rate.
Paracetamol hepatotoxicity remains the leading cause of ALF in the developed world. The
studies outlined in this thesis explore the current management of ALF, and systematically
review the prognostic tests currently used in paracetamol-induced ALF. Using a database of
over 900 acute liver injury patients, the impact of unintentional paracetamol overdose is
retrospectively analysed, demonstrating a strong association between this mode of
paracetamol overdose and adverse clinical outcomes, including the requirement for
emergency orthotopic liver transplantation.
Current prognostic tests for severe paracetamol-induced hepatotoxicity have been criticised
for their relatively low sensitivity, with the result that not all patients who might benefit
from tertiary level care are identified. This thesis demonstrates that the development of the
Systemic Inflammatory Response Syndrome (SIRS) or extrahepatic organ failure is strongly
associated with death following paracetamol overdose. Due to their very high sensitivity in
this condition, both the SIRS and Sequential Organ Failure Assessment scores have potential
as future gatekeepers to improve the triage of paracetamol overdose patients, thereby
delivering tertiary level care to those most likely to require emergency transplantation.
A greater understanding of the pathophysiological links between the initial hepatic injury
and development of the SIRS could help to identify novel biomarkers for ALF, and help
guide future therapeutic avenues. Using serum samples from a prospectively collected
cohort of acute liver injury patients, this thesis identifies two novel biomarkers, serum
ferritin and the long pentraxin PTX3, which show a strong association with outcome
following paracetamol hepatotoxicity. These biomarkers illustrate the importance that the
innate immune system plays in the pathogenesis of paracetamol-induced ALF, and identifies
several exciting areas for future cellular and animal-based studies.
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Chapter 1: The current management of acute liver failure
1.1 Introduction
Acute liver failure (ALF) is a rare disorder characterised by catastrophic loss of liver cell
function. It remains one of the most challenging medical emergencies, due to the multiorgan
nature of the disease, the rapid evolution of the clinical condition, the need for
multidisciplinary supportive interventions, and the requirement for the clinician to
accurately prognosticate in order to best utilise orthotopic liver transplantation (OLT) as a
life-saving treatment. Despite advances in supportive care, spontaneous survival without
OLT is as low as 20%, therefore early recognition and prompt transfer of potential transplant
candidates to tertiary centres with intensive care and liver transplantation expertise is vital.
1.2 Definition
ALF refers to the abrupt loss of hepatic cellular function in a patient without pre-existing
liver disease, with the subsequent development of coagulopathy, jaundice and
encephalopathy. In 1970, Trey and Davidson defined fulminant hepatic failure as a
"potentially reversible condition, the consequence of severe liver injury, with an onset of
encephalopathy within 8 weeks of the appearance of the first symptoms and in the absence
of pre-existing liver disease".(Trey and Davidson 1970) Flowever, since the initial symptoms
of liver failure are frequently non-specific and open to subjective bias, ALF was redefined
based upon the time taken to develop hepatic encephalopathy (HE) after the first appearance
of jaundice; the terms 'hyperacute', 'acute', and 'subacute' liver failure referring to a
jaundice-to-encephalopathy interval of 0- 7, 8-28, and 29-84 days respectively.(O'Grady,
Schalm, Williams 1993) This distinction is useful in guiding prognosis since, paradoxically,
the time to onset of encephalopathy is negatively correlated with outcome despite the
increased incidence of cerebral oedema in hyperacute liver failure. Hepatitis A and B,
paracetamol, and ischaemic insults typically present as hyperacute liver failure, and have a
relatively good spontaneous survival rate of 36%, whereas idiosyncratic drug reactions and
indeterminate causes present later, with only a 14% survival rate without OLT.(Gimson
1996) Severe acute liver injury, with elevated transaminases and coagulopathy, typically
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precedes hyperacute liver failure but it is HE, the cardinal feature of the progression to ALF,
which defines the condition and is of major prognostic significance.
1.3 Incidence and aetiology
The accurate reporting of ALF is hampered by the heterogeneous nature of the syndrome
and by the lack of an International Classification of Diseases code for ALF. This means that
the incidence is probably under reported but has been estimated at 2800 cases per annum in
the US or approximately 3.5 deaths per million population.(Hoofnagle and others 1995;
Poison and Lee 2005) Within Scotland, the incidence of paracetamol-induced ALF has been
estimated at 8.4 cases per annum per million population.(Newsome and others 2001b) The
syndrome of ALF is not a single clinical entity, and may be precipitated by a wide variety of
hepatic insults (Table l.l).(Sass and Shakil 2005) These insults have a marked geographical
and socioeconomic variation, with the most common aetiologies in Europe and North
America being paracetamol and idiosyncratic drug reactions, whereas developing countries
have a higher preponderance of acute viral aetiologies (Table 1.2). Specific insults also
demonstrate geographical variation, with staggered accidental paracetamol overdoses
predominating in the US, whereas single, intentional, overdoses are more common in the
UK.(Larson and others 2005; Makin, Wendon, Williams 1995) The early identification, where
possible, of the underlying aetiology of ALF is crucial since several causes of ALF such as
paracetamol (N-acetyl cysteine (NAC)), Amanita phalloides poisoning (penicillin and
silibinin), fulminant hepatitis B (lamivudine), herpes simplex virus (HSV) (acyclovir), and
pregnancy (delivery) have specific treatments and the prognosis between different
aetiologies varies considerably.(Heard 2008; Klein and others 1989; Kumar and others 2007;
Miyake and others 2008; Montalbano, Slapak-Green, Neff 2005)
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Aetiological category Specific causes
Viral
HAV, HBV +/- HDV, HEV, HSV,
Human herpes virus 6, CMV, EBV, VZV,
parvovirus B19, yellow fever
Drug/ toxin induced
(dose-dependent)
Paracetamol, Amantina phalloides, tetracyclines,
Bacillus cereus, carbon tetrachloride,
Drug/ toxin-induced
(idiosyncratic)
Halothane, anti-tuberculous therapy, sulphonamides,
coamoxiclav, macrolides, valproate, NSAIDs, disulfiram,
thalidomide, (3-interferon, HAART, Ecstasy, cocaine, herbal
remedies etc
Vascular
Ischaemic hepatitis, Budd-Chiari, right heart failure,
venoocclusive disease
Metabolic Wilson's disease, acute fatty liver of pregnancy, HELLP
Miscellaneous
Autoimmune hepatitis, malignant infiltration,
sepsis, heat stroke
Others Cryptogenic, primary graft non-function post-OLT
Table 1.1: Selected aetiologies of ALF
Abbreviations: HAV, hepatitis A virus; HBV, hepatitis B virus; HDV, hepatitis delta virus;
HEV, hepatitis E virus; HSV, herpes simplex virus; CMV, cytomegalovirus; EBV, Epstein-
Barr virus; VZV, Varicella zoster virus; HELLP, haemolysis, elevated liver enzymes and low
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1.4 Clinical features
The initial clinical features of ALF may be non-specific, and may include anorexia, fatigue,
abdominal pain, jaundice, and fever before progressing to HE.(Shakil and others 2000) The
'type A' HE associated with ALF (types B and C HE are associated with portosystemic
bypass and cirrhosis respectively) is graded from 1 to 4 on clinical features and neurological
signs (Table 1.3).(Ferenci and others 2002) This grading is clinically robust and increasing
grades of HE have a strong negative correlation with outcome. The pathogenesis of HE (and
subsequent cerebral oedema) in ALF is incompletely understood, and differs from the
encephalopathy seen in chronic liver disease, but hyperammonaemia, systemic
inflammation, and loss of cerebral blood flow (CBF) autoregulation all appear to accelerate
progression.(Bernal and others 2007a; Butterworth 2002; Rolando and others 2000)
Ammonia, produced from glutamine by enterocytes, enters the systemic circulation via the
portal vein, but is poorly cleared by the failing liver, and this is exacerbated by the coexistent
renal failure, reduced hepatic urea synthesis, and impaired skeletal muscle function seen in
ALF.(Wendon and Lee 2008) Astrocytes detoxify ammonia by converting it to glutamine
which leads to osmotic swelling, and this cytotoxic process appears to be the main
pathophysiological driver of cerebral oedema in ALF.(Gimson 1996; Haussinger and others
2000; Ranjan and others 2005) Hyponatraemia, frequently seen in patients with ALF, may
potentiate this process, possibly via aquaporin-4.(Cordoba, Gottstein, Blei 1998; Rama Rao
and Norenberg 2007) Additionally, cerebral hyperaemia, potentially mediated by pro¬
inflammatory cytokines, increases intracranial blood volume, further compromising cerebral
perfusion.(Antoniades and others 2006; Wright and others 2007) Interestingly, case reports
have directly implicated liver-derived toxins in this process.(Jalan and others 2002)
The evolution to grade III/IV HE is a grave prognostic sign as this group are at risk of
intracranial hypertension, and subsequent brain herniation.(Clemmesen and others 1999) In
addition, intracranial hypertension compromises cerebral perfusion pressure (CPP), defined
as the difference between mean arterial pressure and intracranial pressure (ICP). A CPP >60
mmHg is considered crucial to maintain normal neurological functioning and periods >2
hours with a CPP <40 mmHg is considered by some centres to preclude liver
transplantation.(Hoofnagle and others 1995) Clinical signs suggestive of increasing ICP
include worsening of HE, systemic hypertension and bradycardia (Cushing reflex), altered
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pupillary reflexes, and decerebrate rigidity. All of these clinical signs occur late in the
clinical course, when therapeutic interventions may be ineffective, and this has led to the
direct monitoring of ICP in patients with ALF.

































Asterixis; ataxia Abnormal 8-11
IV
Coma; unable to test
mental state
Decerebration Abnormal <8
Table 1.3: Classification of HE (Amodio and others 2004)
Abbreviations: EEG, electroencephalogram; GCS, Glasgow Coma Scale.
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1.4.1 Intracranial pressure monitoring
There remains some controversy over the use of ICP monitoring in ALF, due to the lack of
consensus over treatment goals, the associated risks of bleeding and infection, and the lack
of randomised trial data supporting improved survival. However, continuous monitoring
permits rapid, targeted, treatment to be initiated and several groups now include ICP
monitoring as part of their standard ALF protocol, particularly in potential OLT
candidates.(Hoofnagle and others 1995; Keays, Alexander, Williams 1993) Intracerebral
bleeding occurs in between 8-10% of cases, although fatal bleeds occur considerably less
frequently.(Blei and others 1993; Vaquero and others 2005) Calculation of cerebral oxygen
consumption using a jugular bulb catheter may provide additional information through
continuous, indirect, assessment of cerebral blood flow.(Goetting and Preston 1990) This
involves the retrograde passage of a fine-bore catheter into the jugular vein until the tip
reaches the jugular bulb; venous saturations >85% (normal range 55-70%) representing a
hyperaemic cerebral circulation.
1.4.2 Treatment for raised ICP
The goal of medical management of cerebral oedema should be to keep the ICP<20 mmHg
and the CPP>70 mmHg, by reducing brain volume or cerebral blood flow (CBF). Basic
manoeuvres include elevation of the head of the bed to no more than 30° and minimising
painful stimuli including suctioning.(Davenport, Will, Davison 1990) Hyperventilation
produces, at best, a transient restoration of cerebral blood flow autoregulation by lowering
PaCCh and its prolonged use in ALF patients has been questioned.(Ede and others 1986)
Established therapies for raised ICP include mannitol and barbituates such as
thiopentone. (Canalese and others 1982; Forbes and others 1989) More limited evidence
supports the use of hypertonic saline, propofol sedation, and indomethacin.(Murphy and
others 2004; Tofteng and Larsen 2004) Unrandomised studies from Edinburgh have
advocated the use of moderate hypothermia (32-33 °C) in advanced ALF as a means of
reducing ICP prior to, and during, transplantation and this appears to offer a therapeutic
option which targets many of the proposed triggers for elevated ICP in ALF.(Jalan and
others 1999; Jalan and others 2003; Jalan and others 2004; Wendon and Lee 2008) Further
studies are required to clarify the optimal extent and duration of hypothermia and to
exclude a negative impact from hypothermia upon sepsis, coagulopathy, and cardiac
stability.
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1.5 Haemodynamic, respiratory, and renal instability
ALF is characterised by a hyperdynamic circulation, with markedly reduced systemic
vascular resistance, increased cardiac output, and hypotension, which frequently
necessitates vasopressor support in addition to fluid repletion.(Bihari and others 1985) As
yet, the optimal fluid and vasopressor strategy remains uncertain, but most centres use
crystalloid resuscitation followed by norepinephrine infusions to maintain adequate
perfusion pressures and cerebral oxygenation, although this strategy may not significantly
improve oxygen delivery.(Wendon and others 1992) Over-zealous norepinephrine use
should be avoided since this may exacerbate cerebral hyperaemia due to the loss of CBF
autoregulation in ALF.(Larsen and others 2000) Terlipressin, a vasopressin synthetic
analogue, has been evaluated in several small studies which produced conflicting results
regarding its effects upon CBF, ICP, and systemic haemodynamic parameters.(Eefsen and
others 2007; Shawcross and others 2004)
Critical-illness related corticosteroid insufficiency (CIRCI) may exacerbate the
haemodynamic instability seen in ALF, with a negative correlation between illness severity
and the response to short synacthen testing in a cohort of 45 patients with acute liver
injury.(Flarry, Auzinger, Wendon 2002) Corticosteroid treatment of patients with low
baseline Cortisol levels ('hepatoadrenal syndrome') in a liver intensive care unit resulted in
reduced vasopressor requirements and mortality, but it is worth noting that adrenal
insufficiency was commoner in patients with chronic liver disease or post-OLT in this study
than in the ALF patients.(Marik and others 2005) There is insufficient evidence at this stage
to recommend routine treatment of CIRCI in liver patients, and the use of synacthen tests to
diagnose CIRCI is not recommended.(Marik and others 2008)
Radiographic changes suggestive of pulmonary oedema occur in a high proportion of ALF
cases, and the development of severe acute lung injury is associated with a poor
prognosis.(Baudouin and others 1995; Trewby and others 1978) Treatment of ARDS using a
protective ventilatory strategy is more problematic in ALF because increases in positive end
expiratory pressure may exacerbate cerebral oedema and hepatic congestion. (Sass and
Shakil 2005)
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Renal failure in ALF is multifactorial, related to acute tubular necrosis, hypoperfusion, use of
contrast agents and, in paracetamol-induced ALF, direct nephrotoxicity.(Blantz 1996) The
Systemic Inflammatory Response Syndrome (SIRS) has recently been shown to predict renal
dysfunction in non-paracetamol induced ALF.(Leithead and others 2009) Management
should focus on prevention of renal failure through maintaining adequate systemic blood
pressure, prompt identification and treatment of infections, and judicious use of contrast
agents, since once established, the prognosis is considerably poorer. Continuous, rather than
intermittent, methods of extracorporeal support are preferred to minimise circulatory and
cerebral fluctuations.(Davenport, Will, Davidson 1993) Flypophosphataemia is frequent in
ALF and may be linked to hepatic regeneration; persistently elevated phosphate levels
suggest failure of this regenerative process and have been associated with a poorer
prognosis in paracetamol-induced ALF.(Knochel 1989; Schmidt and Dalhoff 2002) Reduced
hepatic glycogen stores and hyperinsulinaemia contribute to hypoglycaemia which
complicates up to 40% of ALF cases, and continuous glucose administration is frequently
required. Oral or enteral feeding is vital, but the markedly increased energy expenditure
seen in ALF makes adequate nutritional support difficult to institute effectively in
established liver failure.(Walsh and others 2000)
1.6 Coagulopathy
The coagulopathy of ALF is complex and remains poorly characterised, but is undoubtedly
of prognostic significance.(Harrison and others 1990a; Izumi and others 1996; O'Grady and
others 1989) ALF is characterised by prolongation of prothrombin time, quantitative and
qualitative platelet dysfunction, and, in paracetamol-induced ALF, hypofibrinogenaemia
and reductions in coagulation factors II, V, VII and X.(Kerr and others 2003) However,
despite the severity of the coagulopathy, clinically significant spontaneous bleeding is
relatively unusual in ALF, even during liver transplantation.(de Boer and others 2005;
Munoz and others 2008) The defective production of procoagulant factors is compensated
for in part by underproduction of anticoagulant proteins protein C, protein S, and
antithrombin III whilst factor VIII production is upregulated, possibly in extrahepatic
sites.(Hollestelle and others 2005; Lisman and Leebeek 2007) Plasminogen activator
inhibitor-1 levels are grossly elevated in ALF suggesting hypofibrinolysis, and this was
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supported by a recent murine study where heparin pre-treatment significantly reduced
hepatic fibrin deposition following paracetamol poisoning and significantly attenuated
paracetamol-induced hepatotoxicity.(Ganey and others 2007a; Pernambuco and others 1993)
The bleeding risk in ALF has been overstated, and the prophylactic administration of large
volumes of fresh frozen plasma (FFP) in ALF is unnecessary, interferes with prognostic
scoring systems, and may worsen cerebral oedema or volume overload.(Caraceni and Van
Thiel 1995; Stravitz 2008) Several pilot studies have suggested that recombinant factor VII
may be superior to FFP for clinically significant bleeding in ALF, but further evaluation is
required before this expensive treatment can be universally recommended.(Kalicinski and
others 1999; Shami and others 2003) At present, FFP, platelet and cryoprecipitate infusions
should be reserved for use in actively bleeding patients or prior to planned invasive
procedures.(Fontana 2008)
1.7 Infection
The SIRS, and, when precipitated by infection, sepsis, have been shown to have a strong
negative impact on HE progression, renal function, and mortality in ALF.(Anonymous 1992;
Leithead and others 2009; Rolando and others 2000a) Bacteraemia is present in up to 80% of
ALF patients who have enhanced susceptibility to infection due to the presence of
indwelling lines and catheters, impaired complement and opsonisation function, and
impaired innate immunity.(Wyke and others 1980) The majority of infections are caused by
Gram-negative enteric organisms, staphylococci, and fungal infections.(Rolando and others
1990; Rolando and others 1991) The role of bacterial gut translocation, important in
cirrhosis, is unclear at present, since prospective randomised trials of oral and enteral gut
decontamination in ALF have failed to add additional benefit over parenteral antibiotic
regimens alone.(Balzan and others 2007; Rolando and others 1993; Rolando and others 1996)
Fungal infections are commonly under recognised and are particularly important in ALF
patients who have received prolonged courses of antibiotics or have renal
dysfunction.(Rolando and others 1991) Close surveillance for infection should be
maintained in all ALF patients with frequent chest radiographs and cultures of blood, urine,
and sputum, but prophylactic antibiotics should probably be reserved for those patients
with high-grade encephalopathy, renal dysfunction, or those awaiting OLT.(Rolando and
others 1993; Stravitz 2008)
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1.8 Specific therapies in ALF
1.8.1 N-acetyl cysteine
When used early as an antidote after a single, intentional paracetamol overdose, NAC is
extremely effective at replenishing hepatic glutathione stores and preventing severe N-
acetyl-p-benzoquinone imine induced hepatotoxicity and liver failure.(Heard 2008) The
evidence for NAC in patients with establishing hepatotoxicity or ALF is less robust, and is
based upon a retrospective study from King's College Hospital and a small randomised
controlled trial from the same centre.(Harrison and others 1990b; Keays and others 1991)
Initial studies suggested that NAC improved oxygen delivery and consumption in ALF, but
this assertion has subsequently been challenged.(Harrison and others 1991; Walsh and
others 1998) Furthermore, the optimal duration of NAC therapy in these patients is unclear,
since prolonged NAC therapy was recently shown to impair murine liver regeneration and
worsen outcome following paracetamol poisoning.(Yang and others 2009) The benefit of
NAC in non-paracetamol induced ALF is even less clear, and whilst a recent multicentre
randomised controlled trial (RCT) has demonstrated marginally improved spontaneous
survival in patients with Grade I-II HE, the intergroup differences and use of one-sided p
values in this study are of concern.(Lee and others 2009)
1.8.2 Penicillin and silibinin
Mycetismus (mushroom poisoning), most commonly from Amanita genus mushrooms, is a
medical emergency. Amantinin toxin, recycled via the enterohepatic circulation, interrupts
hepatocyte messenger RNA synthesis and causes dose-dependent hepatotoxicity. Initial
promising reports describing charcoal haemoperfusion in the treatment of Amanita
poisoning have not been replicated.(Wauters, Rossel, Farquet 1978) Penicillin G (250
mg/kg/day) and silibinin (20-50 mg/kg/day) are effective when administered early in the
course of the disease, but severe cases may require emergency OLT.(Broussard and others
2001; Klein and others 1989)
1.8.3 Lamivudine
Fulminant hepatitis B is frequently associated with delta virus coinfection.(Gomes-Gouvea
and others 2009) Previous case reports utilised foscarnet in the treatment of fulminant
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hepatitis B, but now increasing evidence supports the efficacy of lamivudine in this
situation, even in pregnant patients.(Hedin and others 1987; Kumar and others 2007; Miyake
and others 2008; Price and others 1986; Tillmann and others 2006)
1.8.4 Delivery
The syndrome of haemolysis, elevated liver enzymes, and low platelets (HELLP) and acute
fatty liver of pregnancy (AFLP) are the pregnancy-related liver disorders most commonly
associated with ALF, although preeclampsia can occasionally result in hepatic rupture and
infarction. There is increasing evidence that preeclampsia, HELLP, and AFLP represent a
spectrum of the same disease, with similar clinical and pathophysiological correlations
including increased vascular tone and platelet aggregation.(Rahman and Wendon 2002)
Foetal deficiency of the mitochondrial enzyme long-chain 3-hydroxyacyl-CoA
dehydrogenase results in maternal accumulation of medium- and long-chain fatty acids, and
similar mutations of the mitochondrial trifunction protein have been linked to both HELLP
and AFLP.(lbdah and others 1999; Treem and others 1994; Wilcken and others 1993)
Preeclampsia, HELLP, and AFLP all carry significant risk of both maternal and foetal
mortality, and severe cases should be managed in tertiary centres capable of dealing with the
potential obstetric and hepatic complications. The mainstay of treatment of all three
conditions is delivery, but close post-partum observations of both mother and infant are
important to detect any haemorrhagic complications or continued deterioration of
laboratory parameters. (Lee and Brady 2009; Pereira and others 1997)
1.8.5 Aciclovir
Whilst HSV has high seroprevalence amongst the general population, HSV-related hepatitis
is a rare cause of ALF (1.4% in one 13-year cohort study) but is most commonly seen
amongst immunosuppressed and pregnant patients.(Ichai and others 2005) The diagnosis of
HSV-ALF is frequently made late, with a resultant high mortality rate. A high index of
suspicion must be maintained to screen for potential cases amongst young,
immunosuppressed or pregnant individuals presenting with transaminitis, since prompt
treatment with intravenous acyclovir is effective in many cases.(Levitsky and others 2008;
Montalbano, Slapak-Green, Neff 2005)
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1.8.6 Plasmapheresis and D-penicillamine
Fulminant Wilson's disease represents a rare, but important cause of ALF, and the diagnosis
can be intimated by the presence of a low alkaline phosphatase to bilirubin ratio, AST:ALT
ratio >2.2 and haemolytic anaemia.(Korman and others 2008; Sallie and others 1992) Isolated
cases report the successful use of plasmapheresis and chelation therapy in the treatment of
fulminant Wilson's, although these remain a bridge to transplantation rather than definitive
therapies.(Asfaha and others 2007; Rodriguez Farina and others 2003) Plasmapheresis
appears to reduce arterial ammonia levels, and has occasionally been utilised in the
treatment of aetiologies of ALF other than Wilson's disease, but the side-effects of treatment
can be significant and no mortality benefit has been demonstrated to date.(Barshes and
others 2005; Clemmesen and others 2001; Lepore and Martel 1970)
1.8.7 Other treatments
Other treatments such as insulin/glucagon, prostaglandin E2 and corticosteroids (even in
fulminant autoimmune hepatitis), have failed to show significant benefit in ALF and are not
recommended. (Anonymous 1979; Cattral and others 1994; Harrison and others 1991; Ichai
and others 2007; Woolf and Redeker 1991)
1.8.8 Artificial and bioartificial liver devices
Liver assist devices have received much attention over recent years in the hope they can
provide an effective 'bridge' to transplantation or recovery of liver function. The initial
artificial liver support devices were essentially filters designed to remove toxins through
haemodialysis or adsorption using charcoal and failed to show a survival benefit in
ALF.(0'Grady and others 1988) The Molecular Absorbent and Recirculating System (MARS)
system utilises a hollow fibre, double-sided, albumin-impregnated dialysis membrane to
extract protein-bound toxins into the albumin dialysate. (Barshes and others 2005) Initial
reports suggested improvements in both systemic and cerebral haemodynamic parameters
and improvements in HE in patients with ALF and acute-on-chronic liver failure.(Ben
Abraham and others 2001; Mclntyre and others 2002; Schmidt and others 2003; Sorkine and
others 2001) More advanced systems, such as Prometheus™, involve fractionated plasma
separation and adsorption whilst bioartificial liver systems include living human or porcine
hepatocytes incorporated in an extracorporeal circuit to add synthetic function to the process
of detoxification. At least 12 RCTs of these devices have been performed and they have been
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systematically reviewed twice; overall, these devices improve HE but have no mortality
benefit in ALF, but may improve outcome in acute-on-chronic liver failure.(Kjaergard and
others 2003; Liu and others 2004)
1.8.9 Liver transplantation
Although never subjected to a RCT, OLT has been recommended for the treatment of ALF
since 1983.(Anonymous 1984) Emergency OLT for ALF now accounts for 5-12% of all liver
transplantation activity and is the only treatment to date to substantially alter the mortality
of the condition.(O'Grady 2005a) Patient survival following OLT for ALF is generally poorer
than those transplanted for chronic liver failure, particularly in the setting of pre-transplant
renal failure, but is of the order of 65-80% 1-year survival.(Barshes and others 2006; Farmer
and others 2003; Lidofsky 1993) Alternatives to standard OLT are being refined, including
living donor grafts and auxiliary liver transplantation (where part of the native liver is left in
situ after partial liver transplantation in the hope that native liver regeneration can permit
later cessation of immunosuppression).(Campsen and others 2008; Chenard-Neu and others
1996) Whilst a promising therapy for paracetamol-induced ALF, auxiliary transplantation
fails to remove the diseased native liver leading to concerns over continuing haemodynamic
and neurological instability. The limited timescales and the dramatic nature of the disease
progression involved mean that the possibility of coercion of potential living donors in the
setting of ALF is of significant ethical concern. Additionally, ALF patients are at particular
risk of small for size syndrome and therefore the larger right lobe from the donor is usually
transplanted, increasing the risk of donor morbidity or mortality.(Umeshita and others 2003)
1.9 Prognostication to guide OLT in ALF
The decision to super-urgently list an ALF patient for OLT is rarely easy- the inherent risks
associated with delaying listing for OLT must be balanced against the potential for
spontaneous recovery with medical therapy alone, the risks of surgery in the context of an
acute critical illness, the scarcity of donor grafts and the requirement (except after auxiliary
liver transplantation) for lifelong immunosuppression.(Chenard-Neu and others 1996)
Furthermore, up to 60% of paracetamol-ALF patients meeting poor prognostic criteria are
deemed unsuitable to undergo OLT due to coexistent psychiatric or medical conditions
likely to preclude long-term graft and/or patient survival, such as resistant alcohol or drug
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dependence or previous persistent treatment non-compliance.(Simpson and others 2009)
Accurate prognostication in ALF is therefore vital, and many proposed mathematical,
serological, radiological, and histological variables have been proposed, including the Model
for End-Stage Liver Disease (MELD) score, which has improved organ allocation in chronic
liver disease (Table 1.4).(Wiesner 2004; Zaman and others 2006) Major methodological flaws
exist with many of these studies, which are often unblinded, retrospective, and prone to
spectrum bias.(Ding and Buckley 2008) Furthermore, many authors equate liver
transplantation with death, falsely elevating the positive predictive value of the test in
question.(Bailey, Amre, Gaudreault 2003) In 1989, O'Grady and colleagues developed the
'King's College Criteria' from a retrospective cohort of 588 patients with grade II-IV HE
admitted to that institution.(O'Grady and others 1989) The criteria recognise the prognostic
importance of the aetiology of ALF, with separate criteria for paracetamol-ALF and other
aetiologies (Table 1.5). These criteria are remarkable for their robustness and accuracy
despite numerous attempts to improve on their diagnostic accuracy (Table 1.4). The
paracetamol criteria have recently been modified by the addition of lactate, although several
authors have questioned the overall benefit of this modification. (Bates and others 2007;
Bernal and others 2002; Schmidt and Larsen 2006) The King's College Criteria have also been
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Non-paracetamol
List for transplantation if:
• PT> 100 seconds (INR>6.5) irrespective of HE grade
Or anv 3 out of 5 of the following:
• Unfavourable aetiology: (Seronegative hepatitis, Wilson's disease, idiosyncratic
drug reaction, halothane)
• Age <10 or >40 years
• Jaundice to encephalopathy interval > 7 days
• PT>50 seconds (INR>3.5)
• Bilirubin >300pmol/L
Paracetamol Modified criteria
List for transplantation if: Strongly consider listing for OLT if:
• Arterial pH< 7.3 • Arterial lactate>3.5 mmol/1 after early fluid
resuscitation
Or all 3 of the following occur
within a 24-hr period:
List for transplantation if:
• Arterial pH<7.3, or arterial lactate>3.0 mmol/1
after adequate fluid resuscitation
• Grade III-IV HE
• PT>100 sees (INR>6.5)
• Serum creatinine>300
pmol/L
List for transplantation if all 3 of the following occur
within a 24-hr period:
• Grade III-IV HE
• PT>100 sees (INR>6.5)
• Serum creatinine>300 pmol/L
Table 1.5: The KCH poor prognostic criteria for paracetamol and non-paracetamol
aetiologies of ALF as applied in the UK as transplant criteria.(Bernal and others 2002;
O'Grady and others 1989)
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1.10 Conclusions
ALF remains a truly challenging condition to manage, and requires early recognition and
transfer of patients to specialist centres offering intensive multidisciplinary input in order to
effectively manage the myriad complications of the syndrome, and, in some cases, offer liver
transplantation. The challenges ahead are to further elucidate the pathophysiology behind
liver cell death and the ensuing multiorgan failure of ALF, which in turn may help improve
prognostic models. Further multicentre controlled trials of artificial and bioartificial liver
support systems are needed before recommendations can be made regarding their clinical
utility in ALF.
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Chapter 2. Prognostic tests of paracetamol-induced acute liver failure: a
systematic review and meta-analysis
2.1 Introduction
Paracetamol toxicity remains the leading cause of ALF in the developed world, accounting
for over 40% of cases in selected case series.(Bernal and others 2009; Ostapowicz and others
2002) Whilst the vast majority of patients recover spontaneously following paracetamol
overdose, a small number develop severe acute liver injury, HE and consequently, ALF.
Despite significant advances in supportive care, the only effective treatment for the
condition remains emergency OLT. The decision to transplant a patient with paracetamol-
induced ALF involves balancing the inherent risks associated with delaying listing for OLT
against the potential for spontaneous recovery with medical therapy alone, the risks of
surgery in the context of a rapidly evolving critical illness, the scarcity of donor grafts, and
the requirement for lifelong immunosuppression. Furthermore, the psychosocial
implications of paracetamol overdose cases are considerable, with over 30% of patients that
fulfil transplant criteria unsuitable for OLT due to severe psychological illness, or coexistent
chronic alcohol or drug dependency.(Simpson and others 2009) Accurate prognostication in
ALF is therefore vital to utilise OLT effectively and prevent unnecessary transplantation,
whilst procuring donor organs in a timely fashion for those most likely to benefit.
In 1989 O'Grady and colleagues developed the 'King's College Criteria' (KCC) in an attempt
to determine which patients with paracetamol and non-paracetamol-induced ALF have a
poor prognosis with medical therapy alone, and will therefore benefit most from OLT (Table
1.5).(O'Grady and others 1989) The original KCC for paracetamol-induced ALF were highly
specific, but have been criticised for their relatively low negative predictive value (Renner
2007) and, since up to 26% of patients with paracetamol toxicity are medically unfit to
undergo surgery at the point they fulfil the KCC,(Simpson and others 2009) modifications to
these criteria now utilise arterial lactate (>3.5 mmol/L after early fluid resuscitation or >3.0
mmol/L after adequate fluid resuscitation) in an attempt to extend the time-window for
acquisition of a suitable graft.(Bernal and others 2002)
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Over recent years a plethora of alternative prognostic variables have been proposed, in an
attempt to improve, or replace, the KCC (see Table 1.4). These criteria variously involve
radiological,(Yamagishi and others 2005) histological, (Baeg and others 1988)
serological,(Schiodt and others 2005; Schmidt and Dalhoff 2005) or mathematical
(Cholongitas and others 2006a; Kremers and others 2004; Yantorno and others 2007) indices,
but their assessment is complicated by the use of OLT; due to the inevitably imperfect nature
of current listing criteria a small proportion of ALF patients are transplanted who would
have spontaneously survived, invalidating further assessment of that particular patient.
Studies evaluating the prognostic accuracy of a particular variable should therefore exclude
transplanted patients from subsequent analysis.
The purpose of this systematic review was to critically evaluate existing prognostic criteria
for predicting death without transplantation in paracetamol-induced ALF, to update
previous studies in this area,(Bailey, Amre, Gaudreault 2003; Ding and Buckley 2008) and to
examine the accuracy of the more recently described prognostic variables.
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2.2 Methods
2.2,1 Search Strategy and Study Selection
A systematic review of the medical literature using MEDLINE (1950 to June 2009), EMBASE
(1980 to June 2009), and CINAHL (1982 to June 2009) was performed to identify studies
recruiting adult (>age 16 years) patients that evaluated prognostic markers of paracetamol-
induced ALF. Potential studies were identified by combining the search terms
"acetaminophen" and "paracetamol" (as both Medical Subject Headings (MeSH) and free text
terms) using the set operator OR. Prognostic studies of ALF were identified, and combined
using the set operator OR, by using the terms "Kings adj3 College adj3 Criteria", "Clichy$",
"APACHE$", "lactate", "Gc-globulin", "alpha-fetoprotein", "phosphate" and "MELD" (all free
text terms) and the McMaster expert search strategy for prognostic studies. These studies
were combined using the set operator AND with papers evaluating studies on "liver failure",
"hepatic encephalopathy" or "liverfailure, acute" (all MeSH). The search was limited to human
studies without language restrictions. Abstracts of the studies identified by the initial search
were evaluated for appropriateness to the study question by two independent reviewers
(DC, KS) and all potentially relevant papers were obtained and evaluated in detail. The
bibliographies of these studies and relevant review articles were screened to perform a
recursive search of the literature, and abstract books of international liver conferences from
the preceding 4 years were hand-searched for potentially relevant studies.
Selected studies were required to report mortality data on cohorts of patients admitted to
hospital with acute severe liver injury or ALF secondary to paracetamol overdose (see table
2.1 for study eligibility criteria). Acute severe liver injury was defined as severe
hepatotoxicity (serum alanine aminotransferase (ALT) levels>1000 U/mL and co-existent
coagulopathy), whilst ALF required the additional presence of HE, in patients without pre¬
existing liver disease. Unselected cohorts of patients with mixed etiologies of acute liver
injury were eligible for inclusion if separate data for paracetamol overdose patients were
available. Case control studies and studies comparing ALF patients with chronic liver
disease patients were excluded due to potential bias in favour of the prognostic variable in
question,(Altman 2001) as were studies where transplantation and death were combined as a
single end-point. Studies were required to include more than 25 patients with paracetamol-
induced acute liver injury, since the majority of studies in this area include the KCC as a
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prognostic variable in addition to the main variable studied, and smaller studies may
invalidate analysis.(Perel and others 2006) All potential articles were assessed independently
by two researchers according to eligibility criteria, which were defined prospectively, and
disagreements resolved by consensus.
• Adult patients (aged > 16 years) presenting with acute severe liver injury or ALF
attributed to paracetamol hepatotoxicity
• Cohort studies
• Included >25 patients with paracetamol hepatotoxicity
• Mortality data recorded
• Data for death and liver transplantation considered separately
Table 2.1 Eligibility criteria for included studies
2.2.2 Data extraction and quality assessment
Data were extracted using predesigned forms by two separate reviewers (DC and KJS) on to
a Microsoft Excel spreadsheet (Microsoft Corp, Redmond, WA, USA), and any discrepancies
were resolved by consensus. The following data were extracted for each study: setting,
country and geographical region, year(s) conducted, retrospective or prospective design,
inclusion criteria, definitions of paracetamol-induced liver injury, definitions of ALF, total
number of subjects included, total number of subjects with paracetamol-induced ALF or
acute liver injury, total number of subjects with paracetamol-induced ALF transplanted,
duration of follow-up, prognostic score used, timing of application of the prognostic score,
and outcome definitions. Study quality was assessed semi-quantitatively according to six
potential sources of bias that can be encountered in studies of prognostic variables (Hayden,




Study population adequately represents the population of
interest; source population adequately described; sampling
timeframe, place and period of recruitment described;
inclusion and exclusion criteria described
Follow-up
Adequate study completion rate; loss to follow-up not
associated with key characteristics; reasons for loss to follow-
up described; no important differences between participants
completing/not completing study
Prognostic factor
Prognostic measure clearly defined; continuous data reported
and any cut-points described and appropriate; method and
setting of measurement of prognostic factor identical for all
patients; adequate proportion of study population has
prognostic factor measured
Outcome measurement
Clear definition of outcome measure of interest described and
recorded, including duration of follow-up; outcome measure
valid; outcome measure identical
Confounding
All important confounders measured and accounted for at all
stages of study design, performance and analysis
Analysis
Sufficient presentation of data to permit assessment of
analytical analysis; appropriate model-building, study design
etc.; no selective reporting of results
Table 2.2 Quality assessment of included studies (adapted from Hayden 2006 (Hayden,
Cote, Bombardier 2006))
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2.2,3 Data synthesis and analysis
Prognostic tests evaluating the outcomes of survival without transplantation or death
without transplantation following paracetamol-induced liver injury were assessed
individually. From each study cohort the total number of subjects dying without OLT, total
number of subjects surviving without OLT, and total numbers of subjects fulfilling or not
fulfilling the prognostic variable in question were extracted and 2x2 contingency tables
constructed. The sensitivity, specificity, and diagnostic odds ratio (DOR) with their 95%
confidence intervals (CI) were calculated for each test using Microsoft Excel (Microsoft Corp,
Redmond, Washington, USA) and checked using Meta-DiSc version 1.4 (Universidad
Complutense, Madrid, Spain). The value of a DOR ranges from zero to infinity, with higher
values indicating better discriminatory test performance, and is calculated from the
following formula: sensitivity/(l- sensitivity) / (1- specificity)/specificity.(Glas and others
2003) Where required, a zero cell correction of 0.5 was added to all cells to prevent
computational problems arising where proportions were equal to zero.(Dinnes and others
2005) Where two or more studies analysed a particular prognostic marker, data were pooled
using a random effects model and the pooled DOR calculated. Heterogeneity between
studies was assessed using the I2 statistic with a cut off of 50%, and the x2 test with a P value
< 0.10, used to define a statistically significant degree of heterogeneity. We explored study
setting and study design as potential reasons for heterogeneity.(Higgins and others 2003)




The search strategy identified 6507 studies of which 104 were potentially eligible for
inclusion and were retrieved for further analysis (Figure 2.1). Of these, 14 were considered
eligible for inclusion,(Anand, Nightingale, Neuberger 1997; Bates and others 2007; Bernal
and others 1998; Bernal and others 2002; Bernal and Wendon 2003; Bernal and others 2007;
Izumi and others 1996; Larson and others 2005; Mitchell and others 1998; O'Grady and
others 1989; O'Grady and others 1991; Schmidt and Dalhoff 2005; Schmidt and Larsen 2006;
Zaman and others 2006) including two studies published in abstract form only.(Bates and
others 2007; Bernal and others 2007) Characteristics of included studies are provided in
Table 2.3. Cohen's kappa test for inter-observer agreement was excellent at 0.86 (95% CI
0.75-0.98).
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The eligible studies evaluated a total of 1960 patients with paracetamol-induced acute liver
injury or ALF. Three (Izumi and others 1996; Mitchell and others 1998; Schmidt and Dalhoff
2005) studies had complete temporal overlap with other studies from the same unit;
however, these studies were included for their evaluation of unique prognostic markers
separate to the KCC. There was only one multicentre study.(Larson and others 2005) Five
(Anand, Nightingale, Neuberger 1997; Bates and others 2007; Bernal and others 1998; Bernal
and Wendon 2003; Zaman and others 2006) studies evaluated patient cohorts
retrospectively, whilst five (Bernal and others 1998; Bernal and others 2007; Mitchell and
others 1998; Schmidt and Dalhoff 2005; Schmidt and Larsen 2006) studies developed
prognostic test thresholds retrospectively (usually from receiver operator characteristic
(ROC) curve analysis). No studies blinded observers to patient outcome or other potentially
confounding prognostic data; and only two (Bernal and others 2002; O'Grady and others
1989) validated their prognostic marker in a separate cohort. Consequently, six (Anand,
Nightingale, Neuberger 1997; Bates and others 2007; Bernal and others 1998; Bernal and
others 2007; Izumi and others 1996; Zaman and others 2006) of the 14 studies were graded as
poor and seven (Bernal and others 2002; Bernal and Wendon 2003; Larson and others 2005;
O'Grady and others 1989; O'Grady and others 1991; Schmidt and Dalhoff 2005; Schmidt and
Larsen 2006) as moderate quality (Table 2.3). The 14 eligible studies analysed a total of 22
different prognostic markers or variations thereof. The sensitivity, specificity, and DORs of













































































































































Bernal2002 Schmidt2006 Bates2007 POOFED
97/21 91/46 69/17
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2.3.1 King's College Criteria
A total of 13 studies evaluated the original KCC for paracetamol-induced ALF, either as
separate elements (arterial pH<7.3 or concurrent grade III/IV HE, serum
creatinine>300pmol/L and prothrombin time (PT)>100 seconds) (Anand, Nightingale,
Neuberger 1997; O'Grady and others 1989) or as a whole, (Bates and others 2007; Bernal and
others 1998; Bernal and others 2002; Bernal and Wendon 2003; Izumi and others 1996; Larson
and others 2005; Mitchell and others 1998; O'Grady and others 1991; Schmidt and Dalhoff
2005; Schmidt and Larsen 2006; Zaman and others 2006) including a total of 1929 patients.
One study (Larson and others 2005) evaluated the KCC only on admission. After exclusion
of studies with complete temporal overlap with other studies,(Izumi and others 1996;
Mitchell and others 1998; Schmidt and Dalhoff 2005) pooled specificity of the KCC was high,
at 94.6% (95% CI 93.0-95.9), but the pooled sensitivity was relatively poor at 58.2% (95% CI
53.1-63.3). The pooled DOR for the KCC was 27.7 (95% CI 9.2-83.5) (Table 2.4). The
summary ROC curve is shown in Figure 2.2. The area under the curve (AUC) was calculated
as 0.91 (95% CI 0.79-0.99), suggesting good performance of the KCC overall.(Jones and
Athanasiou 2005) The accuracy of the KCC improved when studies originating from KCH
were analysed separately from those outside KCH (DOR 43.9 (95% CI 17.6-109.3) for KCH-
based studies vs. DOR 16.5 (95% CI 3.5-77.8) for non-KCH-based studies). Statistically
significant heterogeneity (I2=87%) existed between individual study results, though this fell
to 79% after exclusion of the single multi-centre study,(Larson and others 2005) and to 64%
after exclusion of studies from outside KCH.
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2.3.2 Lactate modifications to the KCC
The original study (Bernal and others 2002) that evaluated arterial lactate in the prognosis of
paracetamol-induced ALF reported similar specificity, but improved sensitivity, when
compared with the original KCC. However, two (Bates and others 2007; Schmidt and Larsen
2006) subsequent studies evaluating arterial lactate alone failed to replicate this high
prognostic accuracy (Table 2.4), with pooled DORs of 12.2 (95% CI 4.0-37.4) and 22.8 (95% CI
2.5-210.0) for the early and post-resuscitation lactate values respectively. This was mainly
due to the reduced specificity seen in the two studies from outside KCH. Combination of
the KCC with a post-resuscitation lactate value >3.0 offered higher prognostic accuracy in
the original lactate study (Bernal and others 2002) but this was not replicated in a subsequent
evaluation.(Schmidt and Larsen 2006)
2.3.3 Other prognostic markers
Several other markers, all evaluated in single studies, appeared to offer improved prognostic
accuracy when compared with the KCC, with low serum alpha-fetoprotein (AFP) (DOR
419.1),(Schmidt and Dalhoff 2005) 24-hour post-admission Acute Physiology and Chronic
Health Evaluation II (APACHE II) score (DOR 143.0),(Mitchell and others 1998) serum
interleukin-6 (IL-6) levels (DOR 66.0),(Bernal and others 2007) Model for End-Stage Liver
Disease (MELD) score (DOR 58.8),(Zaman and others 2006) and serum phosphate (DOR
33.9) (Bernal and Wendon 2003) all outperforming the KCC (Table 2.4). However, further
studies would be required to replicate these findings to confirm or refute whether these
other markers are indeed superior to the KCC.
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2.4 Discussion
This systematic review and meta-analysis has demonstrated that the original KCC for
paracetamol-induced ALF have high pooled specificity (94.6%), but low pooled sensitivity
(58.2%) in determining prognosis in patients with paracetamol-induced ALF. Additionally,
the benefit of the arterial lactate modifications to the KCC (Bernal and others 2002) is
questionable according to these data. Other proposed prognostic markers, in particular AFP,
APACHE II scores, and serum IL-6 levels, showed encouraging prognostic accuracy but
were only evaluated in single studies of variable quality.
This review is limited by the quality of the included studies, which had significant
heterogeneity and were generally of poor or moderate quality, with only two (Bernal and
others 2002; O'Grady and others 1989) studies validating their prognostic model
prospectively in a separate cohort. ALF is a rare syndrome and, as a result, many studies
were small and retrospective in nature. Continuous variables were frequently analysed
retrospectively using cut-off values designed to maximise AUC values, a method which
assumes constant risk amongst the 'high' and 'low' risk groups.(Perel and others 2006)
Several studies attempted to evaluate multiple prognostic markers retrospectively using the
same cohort, an approach which increases the risk of obtaining a statistically significant
result by chance. Another potentially confounding issue is the lack of international
standardisation of laboratory variables, such as prothrombin time (PT) and creatinine, and
changes to assay reagents over the time course of these studies.(Newsome and others 2001a)
We also appreciate that exclusion of studies where transplantation and death were deemed
equivalent may have introduced spectrum bias, since prognostic tests are usually applied in
settings where OLT is available. This problem is difficult to circumvent given that
emergency OLT will never be subjected to a clinical trial, but, given the reduced quality-of-
life seen following transplantation for paracetamol-induced ALF, the accumulated risks of
immunosuppression, and the scarcity of liver donors,(Ding and Buckley 2008) accurate
calculation of the specificity of each prognostic test is vital in order to minimise
inappropriate transplantation.
This study expands upon a recent systematic review (Ding and Buckley 2008) evaluating the
KCC for paracetamol-induced ALF by including additional prognostic markers. The former
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study found spectrum bias in studies originating from KCH, with increased spontaneous
survival amongst patients listed for transplantation, but not receiving a graft, compared with
those meeting criteria but never listed, suggesting that a 'healthier' cohort may be
preferentially transplanted in KCH. The current data confirm the increased prognostic
accuracy of the original KCC in studies originating from KCH compared with studies from
other units, with a higher pooled DOR in KCH-based studies compared with that from
studies conducted in other units. This raises further questions regarding the overall
generalisability of the KCC to patients with paracetamol-induced ALF treated outside KCH.
The heterogeneity of the included studies evaluating the KCC was partly due to a
multicentre US study (Larson and others 2005) which explicitly applied the KCC solely at
the time of admission, rather than dynamically throughout admission as originally
intended. (O'Grady and others 1989; O'Grady 2007) Whilst early and accurate
prognostication in ALF is vital in order to permit timely listing for OLT, application of the
KCC solely at admission reduces the time available for the disease to evolve and may
introduce spectrum bias. Given that the median time taken to fulfil the KCC following
admission to a tertiary liver transplant unit is 12 hours,(Bernal and others 2002) application
of the KCC solely at admission may explain the low sensitivity of the criteria in the US
study, whilst concerns have also been expressed about the prophylactic use of fresh frozen
plasma (FFP) in this US study and the potential confounding effects upon PT.(O'Grady
2005b) Furthermore, 48% of cases resulted from unintentional overdoses in this US study, a
type of overdose seen less frequently in the UK.(Makin and Williams 2000) It may be that
repeated ingestion of supratherapeutic doses of paracetamol over a protracted time course
disrupts liver function subacutely, so that patients are less likely to develop the profound
acidosis or concurrent severe coagulopathy, renal dysfunction, and encephalopathy required
to fulfil the KCC, but have at least as poor a prognosis as an intentional overdose at a single
time point. Future prognostic scoring systems may therefore need to take the pattern of
paracetamol overdose into account in addition to traditional biochemical parameters. This
concept is further explored in chapter 3.
The value of the addition of post-resuscitation arterial lactate to the KCC (Bernal and others
2002) is questioned by this study. Only two additional (Bates and others 2007; Schmidt and
Larsen 2006) studies, one of which was reported in abstract-form, that reported this
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modification fulfilled eligibility criteria for inclusion, but these studies suggest little benefit
from this. Furthermore, the reduced specificity of the lactate criteria undermines the
traditional benefit of the KCC in 'ruling in' a hopeless prognosis. The presence of systemic
inflammation, with or without sepsis, is increasingly recognised as important in
ALF,(Rolando and others 2000b) but hyperlactataemia can result from numerous other organ
sources and therefore, perhaps not surprisingly, arterial lactate is a relatively non-specific
prognostic indicator in paracetamol-induced ALF. Within critical care settings, the use of
APACHE II and Sequential Organ Failure Assessment (SOFA) scores to monitor organ
dysfunction have greater recognition than the KCC, and are attractive as early prognostic
markers in ALF.(Cholongitas and others 2006b) APACHE II, in particular, showed
encouraging prognostic accuracy but was only evaluated in a single eligible study.(Mitchell
and others 1998) One (Larson and others 2005) additional study evaluating APACHE II
scores was excluded from this particular analysis as the prognostic scoring reported in the
study could not be reconstructed into a 2x2 table; this study is also notable for the atypical
nature of the patient cohort as outlined above. Given that APACHE III, SIRS, and SOFA
scores all performed less well than the KCC (albeit in single studies), the role of these
markers may be to permit earlier identification of a high-risk cohort requiring transfer to
tertiary centres that offer liver transplantation, rather than as definitive transplant listing
criteria (see chapter 4).
Persistently elevated serum phosphate or reduced AFP levels may reflect failure of hepatic
regeneration, and therefore could help predict a poorer outcome in paracetamol-induced
ALF. Serum AFP showed high prognostic performance in one (Schmidt and Dalhoff 2005)
study, whilst serum phosphate showed equivalence with the KCC in one (Bernal and
Wendon 2003) retrospective study from KCH. Other authors, (in studies where
transplantation was equated with death and hence excluded from this study), have
demonstrated conflicting results with serum phosphate,(Gow, Sood, Angus 2003;
Macquillan and others 2005; Ng, Davidson, Bathgate 2004; Schmidt and Dalhoff 2002) so
further evaluation of both serum AFP and phosphate in future studies would be
worthwhile. The MELD scoring system has been widely adopted for organ allocation in
chronic liver disease and has shown encouraging prognostic accuracy in non-paracetamol
ALF.(Dhiman and others 2007; Katoonizadeh and others 2007; Kremers and others 2004;
Wiesner 2004) More limited data exist regarding the use of MELD in paracetamol-induced
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ALF, but one additional study (excluded from this analysis as the 2x2 table was not
reconstructable) suggested that its use may be limited by a high false positive rate.(Wei and
others 2007)
In summary, this systematic review and meta-analysis has demonstrated that the original
KCC for paracetamol-induced ALF have high pooled specificity, but low pooled sensitivity
in determining prognosis in patients with paracetamol-induced ALF. The KCC had reduced
prognostic accuracy when applied outside of KCFI and were occasionally applied only at
admission. The reduced specificity of the KCC following the addition of arterial lactate calls
into question the benefit of this modification, suggesting that re-evaluation of this as a
prognostic marker is required. Urgent consideration should be given to the design of a high-
quality, prospective study evaluating the KCC, APACHE II scores, and markers of hepatic
regeneration, such as serum AFP and phosphate, in paracetamol-induced ALF. Given the
relatively rare nature of ALF, such a study is likely to require cooperation between several
large centres, and argues the need for a collaborative network of tertiary hospitals
experienced in the management and prognostication of ALF, similar to that developed by
the Acute Respiratory Distress Syndrome Network program.(Anonymous 2000)
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Chapter 3: Overdose pattern and outcome in paracetamol-induced
acute severe hepatotoxicity
3.1 Introduction
Previous studies and chapter 1 have highlighted the major contribution of paracetamol as a
cause of ALF in the UK, North America, and Europe.(Bernal 2003; Larson and others 2005;
Wei and others 2007) However, there are significant differences in the epidemiology of
paracetamol-induced ALF in North America compared with the UK. Data from the USA,
covering 1990-1999, suggested paracetamol overdose was responsible for 56,000 emergency
department visits, 26,000 hospital admissions, and 458 deaths each year.(Nourjah and others
2006) Approximately 12,650 (22.6%) emergency department visits, 2240 (8.6%) admissions,
and 100 (21.8%) deaths were due to unintentional paracetamol ingestion.(Nourjah and
others 2006) Against this background the US Acute Liver Failure Study Group reported that
unintentional overdose was the most common pattern of ingestion in patients with ALF,
responsible for 48% of all overdoses, and reported similar outcomes between intentional and
unintentional overdoses.(Larson and others 2005) These data contrast with the pattern of
overdose reported in the UK. In the KCH series, 92% of paracetamol-induced ALF occurred
after ingestion at a single time point with suicidal intent.(Makin, Wendon, Williams 1995)
Contradictory data have also been presented regarding the outcome of ALF induced by
accidental (unintentional) overdose of paracetamol, with increased mortality,(Gyamlani and
Parikh 2002) or similar outcomes,(Larson and others 2005; Makin and Williams 2000) being
reported. Lastly, in those series reporting increased mortality in patients following
accidental paracetamol poisoning, it is unclear if this excess mortality is associated with this
pattern of overdose per se or other clinical features such as organ failure or alcohol
consumption prevalent in this population.(Gyamlani and Parikh 2002)
The aim of this cohort study was to analyse the incidence and outcome of unintentional
paracetamol overdoses compared with intentional overdoses utilising prospectively defined
data collected from 938 patients with acute severe liver injury admitted to the Scottish Liver
Transplantation Unit (SLTU).
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3.2 Patients, methods, and definitions
3.2.1 Patients
The cohort retrospectively analysed were from 938 patients admitted to the SLTU between
1st November 1992 and 31st October 2008 with suspected severe acute liver injury. Severe
acute liver injury was defined as sudden deterioration in liver function with associated
coagulopathy in the absence of a history of chronic liver disease, whilst the term ALF (i.e.
fulminant liver failure) was restricted to those patients developing HE.(0'Grady, Schalm,
Williams 1993) Guidelines for accepting patients from referring hospitals were based on
previously published criteria and have remained unchanged over the time course of the
study.(Bernal and others 1998) These admission criteria included: HE; progressive
coagulopathy with a PT >50 seconds; INR >5; or in the case of paracetamol overdose, PT in
seconds greater than time in hours post overdose; persistent metabolic acidosis despite
adequate fluid resuscitation; hypoglycaemia; or deteriorating renal function in the presence
of severe liver injury. Following admission a detailed clinical history, examination, and
laboratory investigations were performed, with imaging studies and transjugular liver
biopsy undertaken where clinically indicated. Laboratory investigations were repeated at
daily intervals or more frequently in patients with rapidly progressive liver failure.
Patients admitted to the SLTU are managed using a standard protocol as previously
described, which is reviewed on an annual basis.(Simpson and others 2009) Patients with
paracetamol poisoning have continuous infusion of NAC (6.25mg/kg/hr) until the INR is less
than 2. Coagulopathy is not routinely corrected unless there is excessive bleeding.
Hypotension is treated with volume expansion and inotropic support and monitored by
frequent hemodynamic assessment. Elective ventilation is initiated in patients with Grade III
or IV HE or where there is progressive respiratory failure. Renal replacement therapy (RRT)
is instituted utilising continuous veno-venous hemofiltration in oliguric patients with
progressive rise in serum creatinine or those who are anuric. Antibiotic and anti-fungal
treatments are prescribed in all patients admitted to the intensive care unit. Nutrition is
provided by nasogastric feed if the patient was intubated. Intra-cranial pressure monitoring
is considered in all intubated and ventilated patients who may be transplant candidates.
Treatments for cerebral oedema include mannitol, therapeutic hypothermia, and
thiopentone.
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The KCC are used in this unit and throughout the UK to determine patients who will most
likely die without 0LT.(0'Grady and others 1989) The KCC were modified in 2006 within
the UK to include arterial lactate concentration in patients with paracetamol overdose, as
reviewed in chapter 2.(Bernal and others 2002) OLT was considered in all patients meeting
the modified KCC in conjunction with their medical condition and psychological
assessment. If accepted as transplant candidates, patients are 'super-urgently' listed with UK
Transplant and prioritised for the next available compatible organ.
3.2.2 Methods
Since its inception in 1992, the SLTU has prospectively collected and maintained a dedicated
database of all acute liver injury patients admitted to the unit. Data recorded in this database
includes details of patient history, clinical examination, and laboratory results along with
therapeutic interventions, including intensive care admission, need for RRT, or inotropic
support. The following variables were recorded at the time of SLTU admission: temperature,
pulse, white cell count (WCC), platelet count, INR, serum electrolytes, serum bilirubin,
serum ALT, serum albumin, arterial hydrogen ion, bicarbonate, and arterial lactate. Where
available, the paracetamol preparation, admission hospital serum paracetamol level, number
of tablets, type (whether accidental or intentional) and timing of overdose, delay to
presentation, and use of NAC were all recorded. Background information such as alcohol
use and dependency, illicit drug use, pre-existing psychiatric history, and employment was
obtained by the admitting medical team from a variety of sources including, where possible,
the patient, the patient's family, and the patient's general medical practitioner. The suicidal
ideation of each patient was assessed by detailed interview of the patient (when the absence
of HE permitted this) by the specialist transplant psychiatric liaison team prior to any
decisions regarding listing for OLT, with corroborating evidence obtained from the patient's
family and general practitioner where possible. Where available, further information was
obtained from review of the medical and psychiatric notes from the referring hospital.
3.2.3 Definitions
Paracetamol overdose was prospectively assigned as the cause of acute severe liver injury if
there was a clear history of ingestion of potentially toxic amounts of paracetamol (>4g/day)
within 7 days of presentation; admission hospital serum paracetamol levels were >10mg/L;
or serum ALT level was >1000 IU/L within 7 days of a history of paracetamol ingestion
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irrespective of the serum paracetamol concentration.(Larson and others 2005) Paracetamol
overdose was only accepted as the cause of acute severe liver injury after exclusion of other
potential aetiologies, in particular the presence of other hepatotoxic drugs or substances,
hepatitis A and B, autoimmune hepatitis, and Wilson's disease.
An intentional overdose was defined as a cumulative dose of paracetamol >4 grams ingested
over 4 hours or less with the objective of self-harm; unintentional overdose was defined as a
paracetamol overdose ingested when self-harm was not the aim. Single overdose was an
overdose (>4g) taken at a single defined time point whilst a staggered overdose described
ingestion of two or more supratherapeutic paracetamol doses over a time interval of greater
than eight hours resulting in a cumulative dose of >4 grams per day. Mixed overdose
described more than one type of tablet being taken at or during the time of the overdose,
whilst compound overdose described overdose of compound tablets which included
paracetamol such as co-proxamol or co-dydramol. Alcohol abuse was locally defined as
alcohol consumption >56 units/week for men and >42 units/week for women, twice the
current Governmental sensible drinking limits.(Department of Health 1995) Outcome was
defined as spontaneous survival without transplant, death without transplant, survival with
transplant, and death with transplant. When undertaking survival analysis, survival was
assessed at 30 days or at hospital discharge if this occurred earlier, whilst death and OLT
were considered equivalent.
3.3 Statistical analysis
All patient data were prospectively recorded in the SLTU ALF database. Statistical analysis
was retrospectively performed using SPSS software (SPSS 16.0, Chicago IL, USA) and
Graphpad Prism (GraphPad Software Inc., La Jolla, CA). Data values are presented as
median and interquartile range (IQR) or percentages unless otherwise stated. Continuous
data were compared using analysis of variance or the Kruskal-Wallis test for non-normally
distributed variables. Categorical data were analysed using Chi-squared tests or Fishers
exact test. Stepwise logistic regression was used to determine factors predictive of death or
LT in paracetamol-induced acute severe liver injury patients. Only variables with p <0.10
were included in the multivariate analysis. Actuarial probability curves were constructed
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using the Kaplan-Meier method and compared with log-rank testing. A two-sided p value of
less than 0.05 was considered statistically significant.
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3.4 Results
3.4.1 Overall study population
Over a 16 year period (November 12th, 1992 -November 11th, 2008) 938 patients were
admitted to the SLTU with suspected severe acute liver injury, of whom 663 (70.7%) were
prospectively classified as having paracetamol-induced hepatotoxicity. 614 (92.6%) had a
history of potentially toxic paracetamol consumption (>4g/day). 628 patients (94.7%) had an
ALT >1000 IU/L (ALT >3500 in 526 (79.3%)) and 512 (77.2%) had detectable paracetamol in
serum. Only 4 of these 663 patients (0.6%) fulfilled only one criterion for paracetamol-
induced liver injury. All 4 of these patients had a history of ingestion of potentially toxic
quantities of paracetamol but serum paracetamol was undetectable and ALT<1000 IU/L.
Two of these patients had a clear history of a single ingestion of a large quantity of
paracetamol with suicidal intent and two had a history of staggered unintentional
paracetamol ingestion. The latter two became encephalopathic, one fulfilled KCC and both
died without transplant. The two former patients survived without OLT. These 4 patients
have been included in subsequent analysis as paracetamol cases. Baseline demographic and
clinical characteristics of the paracetamol study group are outlined in table 3.1.
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SLTU admission characteristic
(n= 663 unless otherwise stated)
Value
Sex (male/female) 315/348 (47.5/52.5%)















Paracetamol level (mg/L) (n=561) 60.5 (20-130)
Mixed overdose (n=620) 316(51.0%)
Associated alcohol with overdose (n=590) 264 (44.7%)
Alcohol abuset(n=581) 263 (45.3%)
Previous psychiatric history (n=577) 244 (42.3%)
Active drug abuse (n=623) 96 (15.4%)
Previous overdose (n=619) 242 (39.1%)
Unemployed at time of overdose (n=606) 289 (47.7%)
Time from overdose to SLTU admission
(hours) (n=414)
52 (40-67)
Table 3.1. (continued overleaf) Admission characteristics of 663 subjects with
paracetamol-induced acute severe liver injury.
Data are presented as median (IQR) or numbers (%) as appropriate,
t >56 units/week (male); >42 units/week (female)
Abbreviations: WCC, white cell count; ALT, alanine aminotransferase; PT, prothrombin
time; SLTU, Scottish Liver Transplantation Unit.
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SLTU admission characteristic
(n= 663 unless otherwise stated)
Value
Received NAC in referring hospital (n=644) 559 (86.8%)
WCC (xl09/L) 10.7 (7.6-14.5)
O





Creatinine (umol/L) 134 (84-234)
c £
O «




Bilirubin (umol/L) 83 (58-113)
"O
< Albumin (g/L) 35 (31-39)




















Table 3.1 (continued). Admission characteristics of 663 subjects with paracetamol-
induced acute severe liver injury.
Data are presented as median (IQR) or numbers (%) as appropriate,
t >56 units/week (male); >42 units/week (female)
Abbreviations: WCC, white cell count; ALT, alanine aminotransferase; PT, prothrombin
time; SLTU, Scottish Liver Transplantation Unit.
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3.4.2 Clinical presentation
Of the 663 paracetamol cases, 520 (78.4%) had been transferred to the SLTU from a total of 14
separate health authorities, with the remaining 143 patients transferred from local hospitals
or from wards within the Royal Infirmary of Edinburgh. In those patients (414/663, 62.4%) in
whom accurate timings could be obtained, presentation to emergency services occurred at a
median of 23 hours post final paracetamol ingestion (range 1-130 hours). Female admissions
accounted for 348 (52.5%) of admissions, with 315 (47.5%) males admitted. The median age
at admission was 35 (IQR 27-45) years for males and 34 (IQR 24-44) years for females.
Information regarding NAC use in the referring hospital was available for 644/663 (97.1%) of
patients, of whom 559 (86.8%) had received intravenous NAC, at a median time from last
paracetamol ingestion of 23.75 (IQR 10-44) hours. A total of 263/581 (45.3%) patients had a
history of chronic alcohol abuse, with 264/590 (44.7%) of patients taking alcohol
concomitantly with their overdose. In those patients (n=606) in whom an employment
history could be obtained, 289 (47.7%) patients were unemployed, 220 (36.3%) were
employed, and 27 (4.5%) were in full time education. A total of 244/577 (42.3%) patients had
a prior history of psychiatric illness and 242/619 (39.1%) had taken a previous overdose. A
total of 96/623 (15.4%) patients admitted to current recreational drug use. A total of 301
(45.4%) of paracetamol-induced acute liver injury patients were encephalopathic on
admission, and a further 43/362 (11.9%) went on to develop HE during admission. A total of
344 (51.9%) of patients therefore developed HE, and thus ALF, at some point during their
illness.
3.4.3 Intentional versus unintentional overdoses
Of the 610 (92%) patients in whom a clear overdose history could be obtained, 500/610 (82%)
reported an intentional (suicidal) overdose, whilst 110/610 (18%) subjects denied suicidal
ideation and were classified as unintentional overdoses (table 3.2). Unintentional overdose
subjects were significantly older (median 40 (IQR 30-48) years) compared with intentional
overdose patients (33 (24-43) years, p<0.001), had a lower admission paracetamol level (34.7
(15.9-57.5) mg/L vs. 75.6 (25.4-148.2) mg/L. p<0.001), and were more likely to have consumed
narcotic/paracetamol compound analgesics (37.6% vs. 24.7%, p<0.001). Information
regarding the reasons for overdose was available for 82/110 (74.5%) of unintentional
overdoses. The most common rationale for overdose was for relief of pain, including
abdominal pain (n=26), headache (n=17), musculoskeletal pain (n=17), toothache (n=5), chest
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pain (n=2), and dysmenorrhoea (n=l). Other causes for overdose included accidental
overdose during chemical intoxication (n=5), non-specific systemic illness (n=4), limb abscess
(n=2), iatrogenic overdose (n=2), and one overdose taken unintentionally by a patient with
cognitive impairment. Of the 52 subjects who had consumed compound analgesics or taken
mixed overdoses unintentionally, the majority (29/52, 55.8%) had used codeine
phosphate/paracetamol compounds (co-codamol), an analgesic available over the counter
(OTC) in pharmacies in the UK at a dose of 8/500mg, and only by prescription at higher
doses. A total of 8 subjects had overdosed on prescribed compound analgesics, namely
dextropropoxyphene/paracetamol (coproxamol, n=5) and dihydrocodeine
tartrate/paracetamol (codydramol, n=3). A total of 5 cases had overdosed on both co-
codamol and coproxamol. The remaining compound overdose cases had used
aspirin/paracetamol OTC compounds (n=6). Of the mixed overdoses, 3 cases had taken non¬
steroidal anti-inflammatories and paracetamol, 2 had used aspirin and paracetamol, whilst a
further 3 cases had taken paracetamol with benzodiazepines. The remaining 6 cases had
taken mixed overdoses of other prescription medications and paracetamol.
Unintentional overdose patients were significantly more likely to have consumed
paracetamol in a staggered fashion (90.8% vs. 10.6%, p<0.001), and to have taken a lower
cumulative paracetamol dose (11 (5-29) g vs. 27.5 (20-45) g, p<0.001). Unintentional overdose
subjects were also more likely to have a history of chronic alcohol abuse (40.8% vs. 20.8%,
p<0.001), and to have consumed alcohol with their overdose (52.5% vs. 42.7%, p=0.037), but
were less likely to have a prior psychiatric history (24.5% vs. 46.2%, p<0.001). Unintentional
overdose subjects had significantly lower admission ALT levels (3931 (2036-7184) IU/L vs.
8295 (5257-10920) IU/L, p<0.001) but had significantly more deranged serum sodium (133
(130-137) mmol/L vs. 136 (133-138), p=0.001), creatinine (203 (110-327) pmol/L vs. 114 (81-207)
pmol/L, p<0.001), and albumin (31 (24-35) g/L vs. 37 (33-41) g/L, p<0.001) levels. Subjects
consuming paracetamol unintentionally were significantly less likely to have received
treatment with NAC prior to transfer to the SLTU (80.4% vs. 89.6%, p=0.008). Unintentional
overdose patients were more likely to develop HE (59.1% vs. 47.4%, p=0.027) and had more
systemic organ failure, such as requirement for renal replacement therapy (41.8% vs. 28.4%,
p=0.048), or need for mechanical ventilation (52.7% vs. 38%, p=0.005), than intentional
overdose patients. Unintentional overdose subjects were also more likely to fulfil the KCC
(36.4% vs. 26%, p=0.034), but were subsequently less likely to undergo OLT (15% vs. 32.3%,
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p=0.044). Overall spontaneous survival (57.3% vs. 74.4%, p<0.0001) was significantly worse in
the unintentional patient group (figure 3.1). Similar results were obtained when
transplanted patients were excluded from analysis (X2=18.0, p<0.0001, figure 3.2). Subgroup
analysis of ALF patients (n=344) revealed significantly lower spontaneous survival rates
amongst unintentional (30.7%) and unknown (16.7%) overdose cohorts compared with
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3.4.4 Patients with unobtainable overdose history
In 53 (8.0%) patients, no clear history of suicidal intention (or otherwise) could be obtained,
despite attempts to interview the patient, the patient's family, and by liaison with the
referring hospital. In the majority (72%) of cases, this was due to the patient having HE on
arrival and being unable to provide a history. These patients tended to be older (median 40
(33-50) years vs. 34 (25-44) years, p=0.020) and were more likely to be female (67.9% vs.
51.1%, p=0.033) compared with the other 610 overdose patients. However, there were no
significant differences between these two groups in: the number of tablets consumed; the
proportions consuming alcohol concomitantly with their overdose; the proportions with a
previous overdose history; the proportions with a history of drug abuse. Of the 53 patients
in whom a history was unobtainable, 19 (35.8%) were mechanically ventilated on arrival, 7
(13.2%) were in grade I1I-IV HE, and 12 (22.6%) had grade I-II HE. These 53 patients required
significant levels of organ support, with 39 (73.6%) requiring mechanical ventilation, 29
(54.7%) renal replacement therapy, and 30 (56.6%) pressor support. These patients had a
particularly poor clinical outcome, with 27 (50.9%) fulfilling the KCC, 31 (58.5%) dying


















































Figure 3.1. Survival curves of patients with paracetamol-induced acute severe liver
injury according to the pattern of overdose.
Survival curves were significantly different when compared using log-rank testing















































Figure 3.2. Survival curves of patients with paracetamol-induced acute severe liver
injury according to overdose pattern, after exclusion of transplanted patients.




Intentional 237 147 124 116 111 109 108
Unintentional 65 36 26 23 22 21 20
Unknown 42 17 10 9 9 8 7
Figure 3.3. Survival curves of patients with paracetamol-induced acute liver failure
according to the pattern of overdose.
Survival curves were significantly different when compared using log-rank testing
(p=0.0008). OLT was considered equivalent to death.
3.5 Prognostic accuracy of the KCC in different patterns of paracetamol
overdose
The prognostic accuracy of the KCC was determined for the entire paracetamol ALF cohort
(n=344), then separately for ALF patients with intentional (n=237) and unintentional (n=65)
overdoses (Table 3.3). Although the KCC had high specificity for both overdose patterns, the
sensitivity in predicting outcome was considerably better for intentional overdoses (89.9%,
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3.6 Predictors of death in paracetamol-induced acute liver injury
In view of the significant differences in a number of prognostic variables between the
different overdose subgroups, logistic regression analysis of SLTU admission parameters
including patterns of overdose was performed to determine independent predictors of death
or LT in paracetamol-induced acute severe liver injury (Table 3.4). Univariate analysis
identified increasing age (p<0.001), WCC (p<0.001), PT (p<0.001), serum creatinine (p<0.001),
H+ (p<0.001), and hyponatraemia (p=0.011) as potential predictors of death/OLT.
Unintentional overdoses (p=0.001), the absence of clinical history (p<0.001), the presence of
encephalopathy on admission (p<0.001), and thrombocytopaenia (p<0.001) were also
potentially significant after univariate analysis. Acute or chronic alcohol abuse was not
predictive of a poorer outcome, nor was lack of treatment with NAC in the referring
hospital. Multivariate analysis identified encephalopathy on admission (odds ratio (OR)
4.50, 95% confidence intervals (CI) 2.76-7.34), increasing WCC (OR 1.04; 95% CI 1.02-1.06),
admission PT (OR 1.03; 95% CI 1.02-1.04), and admission creatinine (OR 1.00; 95% CI 1.00-
1.01) as independently predictive of death/OLT. Both unintentional overdoses (OR 1.91; 95%
CI 1.07-3.43), and overdoses where there was no reliable history (OR 6.65; 95% CI 1.78-24.81)
were independently predictive of a poor outcome. Other independent predictors were
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3.7 Discussion
In this chapter the impact of suicidal ideation upon patient outcome is analysed using a
large cohort of paracetamol-induced acute severe liver injury patients. Using prospective
definitions of overdose pattern, intentional (suicidal) overdose was the commonest pattern
of paracetamol ingestion, accounting for 75.4% of all paracetamol cases. However, despite
lower admission paracetamol and ALT levels, patients with unintentional overdose had
significantly reduced survival compared with intentional overdoses. Additionally, the KCC
were less sensitive in predicting outcome in unintentional overdose cases. Both
unintentional overdoses and 'unknown' overdoses, where no clear history could be
obtained, were independently associated with increased mortality. These data suggest that
the pattern of overdose should be taken into account when assessing patients with
paracetamol-induced hepatotoxicity, and that, irrespective of their admission paracetamol
levels, those patients with unintentional overdose should be managed as high-risk cases due
to their significantly increased mortality.
The strengths of this study include the large number of patients, the single centre nature of
the study, and the prospectively defined criteria of overdose. The SLTU represents a single
referral and management facility for all patients in Scotland with ALF irrespective of their
suitability for liver transplantation, and the Scottish population has remained relatively
stable at 5.1 million over the period of the study. However, not all ALF cases occurring in
Scotland will have been transferred to the SLTU during the course of the study due to
medical instability precluding safe patient transfer.(Blair and others 1998) Criteria for patient
admission have remained largely unchanged during the time course of the study, further
reducing patient heterogeneity, a recognized problem in previous cohort studies of
paracetamol hepatotoxicity.(Schiodt and others 1997; Walker 1998) The overall mortality
rate of 32.7% represents selection bias for the more severe paracetamol cases in Scotland,
since admissions to the SLTU are determined by severity of liver dysfunction, rather than on
the basis of a history of paracetamol consumption or number of tablets consumed. This latter
point is of particular note since intentional and unintentional paracetamol overdoses
represent considerably different patient populations with regards to demographics, timing
of presentation, and degree of organ dysfunction at presentation. Suicidal patients often
present to a hospital setting as a direct result of the psychological consequences of their
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overdose, rather than as a result of symptoms; in contrast, unintentional overdoses usually
present because of morbidity, and therefore tend to be systemically unwell at presentation.
Our study partially eliminates this problem through a gatekeeper mechanism (see chapter
4), but inevitably introduces referral bias, since only those patients with potentially
reversible organ failure are accepted.
Defining paracetamol as a cause of hepatotoxicity is recognised as particularly difficult in
cases where there is no obvious suicidal intent or patients are unable to give a history.
Prospective definitions were used for paracetamol hepatotoxicity and overdose subgroups,
but some of the unintentional overdoses in our cohort may still represent other, unidentified,
primary causes of hepatotoxicity in whom paracetamol was taken to relieve systemic
malaise. However, paracetamol overdose was not simply used as a 'catch-all' diagnosis in
the absence of an alternative diagnosis- seronegative hepatitis represented 63/938 (6.7%) of
all cases during this study, none of whom were classified as paracetamol-induced
hepatotoxicity (data not shown). It is also recognised that some unintentional cases will have
been disguised suicides, especially since 'accidental' overdoses are associated with both
chronic alcohol abuse and underlying depression.(Makin and Williams 2000) Indeed, this
analysis would suggest potential suicidal motives behind large overdoses of paracetamol,
particularly if not taken as a compound analgesic. The ability and time available to obtain a
detailed psychiatric history to confirm intent is limited by the rapid clinical progression of
paracetamol-induced ALF, and by the development of HE, but, given that the lack of a
detailed history regarding suicidal intent is in itself an independent predictor of poor
prognosis, this further emphasises that such cases should be treated as high-risk.
Previous studies have suggested that accidental paracetamol overdose is associated with
increased mortality.(Gyamlani and Parikh 2002; Schiodt and others 1997) However, this
poorer prognosis is not a universal finding in other cohort studies of paracetamol
hepatotoxicity.(Larson and others 2005; Makin and Williams 2000) The recently published
multicentre cohort analysis from the US Acute Liver Failure Study group found similar
survival in 131 unintentional patients (72% 3 week survival) compared with 122 intentional
patients (71% 3 week survival).(Larson and others 2005) This difference in survival
compared with these data does not relate to differences in transplant rates, but may be due
to the increased frequency of renal dysfunction in the SLTU cohort compared with the US
80
series. It was recently reported that renal dysfunction on admission in patients with ALF is a
significant predictor of poor outcome in this cohort.(Leithead and others 2009) Another
important potential confounding factor is alcohol abuse, given that unintentional overdose
patients in our cohort were not only more likely to abuse alcohol chronically, but were also
more likely to consume alcohol acutely at the time of overdose. However, neither acute nor
chronic alcohol abuse were independent predictors of death or OLT on multivariate analysis.
The association of alcoholism with other confounding factors, such as delayed presentation,
increased paracetamol dosage, and older age, may account for the poorer outcomes
previously reported in alcoholics following paracetamol overdose. (Schiodt and others 2002;
Schmidt, Dalhoff, Poulsen 2002) Furthermore, since alcoholism is a recognised risk factor for
disguised suicidal overdose,(Suokas and Lonnqvist 1995) some parasuicidal attempts in
alcoholic patients may have been misclassified as unintentional overdoses. Another
important element in the prognosis of unintentional overdoses is likely to be the time period
prior to treatment with NAC ('time to NAC'). These data demonstrate that unintentional
overdoses are less likely to receive NAC in the referring hospital, although this was not an
independent risk factor for poor outcome. Delayed 'time to NAC' is a recognised
independent risk factor for poor outcome following single time point paracetamol
overdose,(Schmidt, Dalhoff, Poulsen 2002) and delayed presentation is thought to be more
common amongst alcoholics.(Read, Tredger, Williams 1986) Given the increased frequency
of both alcoholism and staggered overdoses amongst the unintentional overdose cohort, it is
likely that absence of, or delayed treatment with, NAC in the referring hospital was at least
partially responsible for the poorer outcome in this group. As a result, patients with acute
liver injury and a history of unintentional supratherapeutic paracetamol ingestion should be
treated as high-risk irrespective of serum paracetamol levels, and commenced on NAC
treatment whilst other aetiological investigations are pending.
Admission HE, coagulopathy, renal failure, thrombocytopaenia, leucocytosis, and increasing
age, as well as unintentional or unknown patterns of overdose, predicted a poorer outcome
in the paracetamol overdose patients as a whole. Whilst many of these factors are well
established as predicting a poorer outcome in paracetamol-induced ALF,(0'Grady and
others 1989) the impact of overdose pattern upon outcome has not been examined in depth.
Reanalysis of the data including only ALF patients, or after exclusion of transplanted
patients, did not significantly affect the impact of overdose pattern upon outcome. The
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effects of overdose pattern appear to be independent of patient age, alcohol intake, renal
failure, and HE, but this requires confirmation in other patient cohorts. The increasingly
recognised deleterious effects of the systemic inflammatory response following paracetamol
hepatotoxicity may explain the predictive nature of leucocytosis seen in this study.(Liu,
Govindarajan, Kaplowitz 2004; Rolando and others 2000; Schmidt and Larsen 2006)
Increasing age has previously been recognized as an independent risk factor for poor
outcome following paracetamol overdose,(Schmidt 2005) and the older age of the
unintentional and unknown overdose cohorts may represent either an increased frequency
of this deleterious overdose pattern amongst older patients, or a lower threshold for the
development of severe hepatotoxicity following paracetamol overdose in older subjects.
There is an increased frequency of unintentional overdose in this cohort compared with data
previously published from King's College in which only 8% of paracetamol overdoses were
due to accidental ingestion.(Makin, Wendon, Williams 1995) Due to the potential selection
bias associated with this study, it cannot be concluded that the nationwide incidence of
unintentional paracetamol overdoses is increasing, but this question deserves attention due
to the poor outcome seen in this overdose subgroup. The increased proportions of
unintentional overdoses seen in this study compared with the King's College study may also
reflect temporal changes associated with legislation affecting the availability and packaging
of paracetamol that followed the publication of the King's College series,(Hawton and others
2004) or differences due to socioeconomic factors and the increased rates of chronic alcohol
abuse in the Scottish population compared with the rest of the UK.(Leon and McCambridge
2006) The KCC identify patients with increased risk of death following paracetamol
poisoning and are the "transplant criteria" in use throughout the UK to determine patient
prognosis.(Bernal and others 2002; O'Grady and others 1989) Within the unintentional
cohort the KCC are specific, but lack sensitivity, for paracetamol-induced ALF, suggesting
that alternative prognostic criteria may be required following this pattern of
overdose.(Antoniades and others 2006; Chung, Sitrin, Te 2003; Dabos and others 2005;
Schiodt and others 2005; Schmidt and Dalhoff 2005; Schmidt and Larsen 2007; Yantorno and
others 2007)
In conclusion, unintentional paracetamol overdose is independently associated with
increased mortality compared with intentional overdose. This pattern of overdose is
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associated with older age, acute and chronic alcohol abuse, and a staggered pattern of
overdose. Despite lower admission ALT and paracetamol levels, unintentional overdose
patients have increased systemic dysfunction and poorer clinical outcomes compared with
intentional overdoses. The KCC are less sensitive in predicting outcome in unintentional
overdose and alternative prognostic criteria may be required for this subgroup.
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Chapter 4: The temporal evolution of the Systemic Inflammatory
Response Syndrome (SIRS) and Sequential Organ Failure Assessment
(SOFA) scores following paracetamol overdose
4.1 Introduction
The preceding chapters have outlined the importance of paracetamol as the main
aetiological factor responsible for ALF in the developed world.(Larson and others 2005)
Paracetamol-induced ALF is strongly associated with the development of the SIRS and a
subsequent cascade of complications including HE, coagulopathy, and multiple organ
dysfunction syndrome.(Rolando and others 2000a) As outlined in chapter 2, several studies
have examined the prognostic accuracy of multiorgan failure assessment scores such as
SOFA and APACHE II scores to predict outcome following paracetamol
hepatotoxicity,(Cholongitas and others 2006a; Mitchell and others 1998; Schmidt and Larsen
2006) but these studies have tended to apply the prognostic test in question at the point of
hospital admission, rather than in relation to the time from overdose. This inevitably
introduces confounding since many patients present to hospital following paracetamol
overdose due to psychological, rather than physical, morbidity. Therefore, a better
understanding of the temporal evolution of the SIRS and multiorgan failure following
paracetamol overdose could improve prognostication in this condition. No studies exist
which examine the temporal relationship between the initial hepatotoxic insult (i.e.
paracetamol overdose) and development of the SIRS and multiorgan failure. The aims of
this chapter were to examine these temporal changes in a cohort of patients who required
tertiary level care after taking a single intentional paracetamol overdose. It was hypothesised
that the absence of a SIRS response or extrahepatic organ injury following overdose would
be associated with a low risk of in hospital mortality, and that the SIRS and SOFA scores
could therefore act as quantitative triage instruments to identify those patients at lower risk
of requiring emergency OLT.
4.2 Patients, methods, and definitions
The cohort retrospectively analysed were 100 consecutive single time point intentional
(defined as a paracetamol overdose (>4g) taken at a single defined time point with the
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objective of self-harm) paracetamol overdoses admitted to the SLTU with acute liver injury
between April 2003 and December 2009. Specifically exclusion criteria included patients with
staggered overdoses, or overdoses taken accidentally in an attempt to relieve pain, due to
the confounding temporal and diagnostic problems associated with these
overdoses.(Gyamlani and Parikh 2002) Paracetamol overdose was defined as described in
chapter 3 as at least 2/3 of: a history of ingestion of potentially toxic amounts of paracetamol
(>4g/day); detection of paracetamol in the serum >10mg/L; or a serum ALT level> 1000 IU/L
within 7 days of a history of paracetamol ingestion irrespective of the serum paracetamol
concentration.(Larson and others 2005) All 100 patients fulfilled all of these three criteria.
Other definitions were as described in chapter 3. Since the purpose of this study was not to
develop transplantation listing criteria, death and OLT were considered equivalent when
undertaking survival analysis.
4.2.1 Prospective validation cohort
The prognostic accuracy and threshold values of the SIRS and SOFA scores identified by the
retrospective analysis were prospectively validated in a cohort of paracetamol-induced acute
liver injury patients admitted to the Royal Infirmary of Edinburgh between March 2009 and
July 2010. Admission laboratory and clinical parameters, including temperature,
encephalopathy grade, mean arterial pressure, leucocyte count, platelet count, INR, serum
electrolytes, serum bilirubin, and serum ALT were prospectively recorded in a dedicated
database, and the SOFA and SIRS scores calculated as described below. The clinical team
caring for these patients was unaware of the results of this study.
4.3 Laboratory parameters
Retrospective analysis of all hospital electronic laboratory records was performed to obtain
all standard haematological, biochemical, and coagulation samples obtained for each patient
during the first 10 days of admission. The timing of each sample was noted from either the
laboratory receipt or the clinical notes, and the corresponding haemodynamic and clinical
parameters for each sampling time point retrieved from the clinical notes. These data were
then individually compared against the reported time from overdose for each patient, and
the laboratory and clinical values for each 6-hour period post-overdose recorded in a
dedicated database. Where laboratory data were available more frequently than 6-hourly,
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the most deranged laboratory values were used. The data from these 6-hour periods were
then pooled to obtain median and IQRs for each parameter for patients who died or required
OLT, and for patients who survived spontaneously.
4.3.1 SIRS
The presence of the SIRS was defined as two or more of: temperature <36°C or >38°C, heart
rate >90 beats/minute, leucocyte count <4 x 109/L or >12x 109/L, and tachypnoea > 20
breaths/minute or PaCCte <4.3 kPa.(Anonymous 1992) The daily presence or absence of the
SIRS, and the number of the SIRS components fulfilled, were retrospectively calculated for
each patient by correlating the daily leucocyte count with the most abnormal temperature
and heart rate recorded during each corresponding day of admission. Respiratory rate was
only included for non-ventilated patients, as the majority of patients in the SLTU are
electively mechanically ventilated following the development of grade III or IV HE. The
presence of infection, defined as positive blood, urine, or sputum cultures and/or ascitic
fluid polymorphonuclear count >250/mm3 and/or radiological evidence of infection, was
documented as were prescriptions for antimicrobial or antifungal agents.
4.3.2 Organ failure
Organ failure was assessed using the SOFA score, which assesses six organ systems;
(hepatic, renal, coagulation, cardiovascular, respiratory, and central nervous) and provides a
graded score from 0-4 points for each organ system (Table 4.1).(Vincent and others 1996)
The SOFA score was calculated for each 24-hour period following overdose, with the most
deranged values for each parameter in each 24 hour period used. Organ failure was defined
as a SOFA score >3 points for the organ concerned (Table 4.1). In sedated patients, the
assumed Glasgow Coma Score during periods of sedation hold was used to evaluate the
neurological status. Due to potential confounding, SOFA scores were not calculated
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4.4 Statistical Analysis
Statistical analysis was performed using SPSS (SPSS 16.0, Chicago IL, USA) and Graphpad
Prism (GraphPad Software Inc., La Jolla, CA). Data values are presented as median +/- IQR
or percentages unless otherwise stated. Outcome was defined as spontaneous survival to
discharge without transplant, death without transplant, survival with transplant, and death
with transplant. ROC analysis was used to identify optimum threshold values to
discriminate non-survivors. Continuous data were compared using either analysis of
variance or the Kruskal-Wallis test if inter-group variances were unequal, with post-hoc
Dunn's testing used to compare selected groups. Categorical data were analysed using Chi-
squared tests or Fishers exact test. Bonferroni corrections were undertaken for repeated
measures. Results were considered statistically significant when p <0.05.
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4.5 Results
4.5.1 Patients and details of overdose
A total of 100 patients (46 male, 54 female) admitted to the SLTU between April 2003 and
December 2009 were included in the study. During this period, a total of 347 patients had
been admitted, of whom 111 were classified as 'non-paracetamol' cases, 62 patients had
taken a staggered paracetamol overdose, 45 patients had overdosed on paracetamol
accidently, and in the remaining 29 cases the details of the paracetamol overdose were
unclear. The median patient age of the 100 included patients was 34 (IQR 24-43) years. A
total of 83 patients were transferred to the SLTU from outlying health boards, at a median
time of 50 (36-66.5) hours following overdose. The remaining patients were admitted to the
SLTU from wards within the Royal Infirmary of Edinburgh or from local hospitals. The
median ingested paracetamol dose was 25 (17.5-41) g. All 100 patients received NAC
treatment at their local hospital, at a median time from overdose of 22.75 (9.5- 42.25) hours.
A total of 47 (47%) of patients had taken a mixed overdose. As shown in table 4.2, none of
these demographic parameters or potential confounders differed significantly between
survivors and patients who died/required OLT. Other baseline demographic and clinical
characteristics of the paracetamol study group are outlined in table 4.2.
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56 (37-146) 70 (24-145) 0.545
Mixed OD 8 (38.1%) 39 (49.4%) 0.115
Previous OD 8 (57.1%) 14 29 (46.0%) 63 0.388
Active drug
abuse
















41.0 (29.5-49.0) 53.0 (45.5-67.0) 0.045
Table 4.2. Demographics of study population and details of paracetamol overdose.
Data are presented as median (+/- interquartile range) or percentages as appropriate
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4.5.2 Hepatic encephalopathy & other outcomes
A total of 29 (29.0%) of paracetamol-induced acute liver injury patients were
encephalopathic on admission to the SLTU, and a further 18/71 (25.4%) went on to develop
HE during admission. A total of 47 (47%) patients therefore developed HE, and thus ALF, at
some point during their illness. Of these patients, 22 (46.8%) subsequently met the modified
KCC, at a median time from overdose of 51.5 (39-73) hours from overdose. Of these 22
patients, 3 were transplanted, 14 died without OLT, and 5 recovered spontaneously. A total
of 4 patients died without meeting the modified KCC. The sensitivity, specificity, and DOR
of the KCC were 81.0 (95% CI 65.0- 90.7), 93.7 (95% CI 89.4- 96.3), and 62.9 (95% CI 15.7-
251.3) respectively. Of the non-transplanted patients who met the KCC, a total of 13 patients
were excluded from listing for OLT due to active and resistant alcohol dependence (11
patients) and active intravenous drug abuse (2 patients). A total of 4 patients were listed but
subsequently deemed medically unfit to survive OLT, whilst a further two patients showed
clear signs of spontaneous recovery and were delisted prior to an organ becoming available.
As shown in table 4.3, on admission patients who later died or were transplanted were
significantly more coagulopathic, had lower serum albumin, and had significantly higher
serum creatinine levels compared with spontaneous survivors. A significantly greater
proportion of patients who died or were transplanted required multiple organ support, such
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4.5.3 Temporal relationship between overdose and liver injury
The temporal relationship between overdose and serum ALT (as a marker of hepatic
necrosis) was determined for each six-hour period post overdose for patients who died or
were transplanted (n=21) and for spontaneous survivors (n=79). As shown in figure 4.1,
there was no significant difference in median peak ALT levels between survivors (10500
(7564-13650) IU/L) and patients who died or were transplanted (8540 (6220-12800) IU/L,
p=0.125), whilst at several time points mean ALT levels were significantly lower in patients
who died compared with survivors. Similarly, the median time from overdose to maximum
ALT level was similar in both survivors (66 (54-72) hours) and patients who died/were
transplanted (60 (42-72) hours, p=0.276). The AUC was similar for both survivors (650305 IU)
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4.5.4 SIRS and temporal relationship to overdose
The relative proportions of patients exhibiting a SIRS response at each 24 hour period post
overdose, and the maximum number of SIRS components fulfilled, for the two groups of
patients was then explored. These data are displayed in table 4.4 and figure 4.2. By 48 hours
post overdose, a total of 27/40 (67.5%) patients had mounted a SIRS response, with a
mortality rate in the SIRS group of 44.4%, compared with 7.7% for those patients not
mounting a SIRS response (Fisher's p=0.020). By 72 hours post-overdose, a total of 58/85
(68.6%) patients had developed a SIRS during admission, with a mortality rate of 28.8%,
compared with a mortality rate of only 3.7% (1/27 patients, Fisher's p=0.007) in patients
without a SIRS by 72 hours. By 96 hours, a SIRS had occurred in 70 (70%) patients, with a
mortality rate of 30% in this group; compared with a mortality rate of 0% in the 30 patients
without the SIRS (Fisher's p=0.001). There were no significant differences in the proportions
of male and female patients developing the SIRS by 96 hours post overdose (p=0.149). The
sensitivity, specificity, and DORs of the SIRS occurring by each time point post-overdose are
shown in table 4.4. In total, 74 (74%) of patients developed the SIRS post-overdose, but this
occurred significantly earlier following overdose in patients who died (median 43 (28.5-61)
hours, n=21) compared with patients who survived (60 (36.5-81) hours, n=53, p=0.05). In
contrast, the presence of the SIRS at the time of hospital admission, or at the development of
HE, resulted in reduced sensitivity and DORs compared with the values obtained at 48, 72,





























































































Figure 4.2. Mortality rate in relation to the changes in systemic inflammatory response
syndrome (SIRS) score during the first 96 hours following single time point
paracetamol overdose.
Numbers above the bars indicate number of deaths.
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4.5.5 Temporal relationship between overdose and SOFA score
SOFA scores could be calculated for 99/100 patients. SOFA scores ranged from 1 to 15 by 48
hours post-overdose, 0-17 by 72 hours, and 1-18 by 96 hours post-overdose. Median SOFA
score (+/- IQR) was significantly higher in patients who died or were transplanted at each of
these three time points (48 hours: 9 (6.25-12.25) vs. 5 (3-7), p=0.009; 72 hours: 12.5 (8.75-17) vs.
5 (3-7), p<0.001; 96 hours: 15 (9-19) vs. 5 (3-8), p<0.001). The number of organ systems failing
by both 72 (p=0.0003) and 96 (p<0.0001) hours post-overdose was significantly related to
mortality, which ranged from 5.9% for patients without any organ system failure at 72 hours
post-overdose to 71.4% for those patients with 3 or more organ system failures at this time
point, figure 4.3. ROC analysis showed an area under the curve of 0.80 (95% CI 0.65-0.95),
0.90 (95% CI 0.82-0.97), and 0.91 (95% CI 0.85-0.98) at 48, 72, and 96 hours post-overdose
respectively, figure 4.4. The optimal SOFA score thresholds for discriminating non survivors
at these three time points were >4 at 48 hours, >6 at 72 hours, and >7 at 96 hours respectively.
A SOFA score >7 at any time during the first 96 hours post overdose also predicted outcome
with excellent accuracy, with a significantly higher maximum SOFA score amongst patients
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No of organ failures 0 12 3+
No of patients 28 35 14 15
Figure 4.3. Association between mortality rate and the number of organ failures
identified by the Sequential Organ Failure Assessment (SOFA) score at (A) 48, (B) 72,
and (C) 96 hours following single time point paracetamol overdose.
Numbers above the bars indicate number of deaths.
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4.5.6. Evaluation of previously reported SOFA thresholds
A previous report also evaluated SOFA scores following paracetamol overdose, and reported that a
SOFA score >8 early after admission, or >12 at the onset of HE, were the most discriminatory
thresholds for determining prognosis.(Schmidt and Larsen 2006) Evaluation of these thresholds was
therefore performed in this cohort, with the results shown in table 4.5 and figure 4.4. At admission,
the area under the ROC for SOFA was 0.80 (95% CI 0.68-0.93), but using a threshold of >8 to predict a
poor prognosis resulted in a low sensitivity of 38.1 (95% CI 23.7- 48.7). The area under the ROC for
SOFA at the onset of HE (n=47) was 0.71 (95% CI 0.56- 0.86), with a low sensitivity of 23.8 (95% CI
12.2- 34.2) when using a discriminatory threshold of >12.
4.5.7 Development of the modified SOFA score
Univariate analysis of the individual components of the SOFA score at 72 and 96 hours post-overdose
was performed to identify those components which best predicted an adverse outcome (table 4.6). All
the organ failure components except the hepatic failure element were strongly associated with
mortality, so a modified SOFA score, which excluded points for hepatic failure, was computed. ROC
analysis of this modified SOFA score showed an area under the curve of 0.81 (95% CI 0.67-0.95), 0.90
(95% CI 0.84-0.97), and 0.91 (95% CI 0.84-0.98) at 48, 72, and 96 hours post-overdose respectively. A
modified SOFA threshold score of >3 at 48 hours, and >4 at 72 hours, improved upon the specificity of
the original SOFA score at both these time points without affecting sensitivity. A modified SOFA
threshold score of >5 at any point during the first 96 hours following overdose was highly predictive
of death or OLT, with a sensitivity of 95.0 (95% CI 78.7-99.1), specificity of 76.9 (95% CI 72.8-78.0), and
negative predictive value of 98.4 (95% CI 93.0-99.7) (table 4.7).
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Variable
72 hour univariate 96 hour univariate
OR (95% CI) n=84 V OR (95% CI) n=92 V
Sex (male) 0.90 (0.33-2.50) 1.00 1.58 (0.59-4.24) 0.360
Age (>40 years) 0.77 (0.25-2.36) 0.78 1.03 (0.99-1.07) 0.102
SIRS (yes/no) 10.52 (1.66-64.80) 0.009 00 (3.26- °°) <0.001
SOFA (per 1 additional
unit)
1.42 (1.22-1.65) <0.001 1.39 (1.21-1.60) <0.001
Cardiovascular
failure
















9.21 (2.79-30.39) 0.001 40.00 (9.06-176.54) <0.001







22.50 (5.56-91.10) <0.001 25.00 (4.37-142.90) <0.001
Hepatic failure 0.55 (0.16-1.88) 0.255 1.06 (0.35-3.20) 0.574
Table 4.6. Risk factors for inhospital mortality at 72 and 96 hours post-paracetamol
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4.5.8 Association between SIRS and SOFA scores
We then explored whether those patients with high SOFA scores also manifested a SIRS
response. The presence of the SIRS appeared crucial to the development of extrahepatic
organ failure, with 32/63 (50.8%) patients with the SIRS by 96 hours post-overdose having
developed at least one extrahepatic organ failure, with 13/32 (40.6%) of these cases having >3
extrahepatic organ failures. In contrast, only 4/29 (13.8%) patients without the SIRS
developed one or more extrahepatic organ failures by 96 hours post-overdose. The median
(+/- IQR) SOFA score in those patients who manifested a SIRS response was significantly
higher (8 (5-15)) compared with those patients with no SIRS at that point (5 (3-6.25),
p=0.0011). There was a strong correlation between these two variables (Spearman's r=0.474,
p<0.0001), as shown in figure 4.5, with those patients who died tending to have both a SIRS




Figure 4.5. Association between Sequential Organ Failure Assessment (SOFA) scores
and the number of Systemic Inflammatory Response Syndrome (SIRS) components
fulfilled by 96 hours following single time point paracetamol overdose.
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4.5.9 Prospective validation of multiorgan failure scores
The prognostic accuracy of the SIRS and SOFA thresholds outlined above was then
examined in a prospectively collected cohort of paracetamol-induced acute liver injury
patients admitted to the Royal Infirmary of Edinburgh between March 2009 and July 2010. A
total of 38 patients were included, and their demographic details, admission laboratory
parameters, and clinical outcomes are outlined in table 4.8. All 7 patients who died or
underwent emergency OLT manifested a SIRS response, had a SOFA score >7, and had a
modified SOFA >5 within 96 hours of overdose. The specificity of the two SOFA predictors





Sex (male/female) 16/22 (42.1%/57.9%)
Age (years) 35 (26.5-44.5)
Received NAC in referring hospital 38 (100%)
>>





Platelets (xl09/L) 122 (71-192)
Admissionlab parameter
Creatinine (umol/L) 117 (61-241)
ALT (IU/L) 5198 (2974-7978)
Bilirubin (umol/L) 81 (32-113)
PT (seconds) 41 (29-73)
Ever encephalopathic (ALF) 18 (47.4%)
Grade 3-4 HE encephalopathy 12 (31.6%)
Mechanical ventilation 13 (34.2%)
KCC met 9 (23.7%)
SIRS response by 96 hours post-overdose 15 (39.5%)
SOFA score >7 by 96 hours post-overdose 14 (36.8%)





Spontaneous survival 31 (81.6%)
Died without transplantation 3 (7.9%)
Table 4.8. Validation cohort of 38 single time point paracetamol overdoses
4.6 Discussion
This chapter has explored the temporal relationship between paracetamol overdose and the
development of systemic inflammation and organ failure and further confirms that there is
little, if any, relationship between the degree of initial liver insult (in terms of ingested
paracetamol dose) and subsequent outcome,(Gregory and others 2010) and also confirms
that the magnitude of the serum ALT rise (as a marker of hepatic injury) bears no prognostic
significance in this condition. In contrast, development of the SIRS and subsequent organ
failure are both strongly associated with adverse clinical outcomes, and both SIRS and SOFA
scores are highly sensitive markers of poor outcome following paracetamol overdose. Due
to the high negative predictive values of both SIRS and SOFA, these scores may have a
future role as 'gatekeepers' when considering patient transfer to tertiary liver centres. The
risk of death was less than 2% in those acute severe liver injury patients without a SOFA
score >7 during the first 96 hours following paracetamol overdose.
Predicting individual prognosis accurately following paracetamol overdose is fraught with
difficulty.(O'Grady 2005) For a predictive model to be clinically useful, it should be easy to
use, accurate, reproducible, and accepted by clinical staff. Both SOFA and SIRS scores are
dynamic tests, which can be rapidly recalculated throughout admission, and are attractive as
prognostic indicators due to their widespread use in intensive care units and their ease of
use. Recently, the SOFA score was demonstrated to outperform liver-specific prognostic
scores in predicting outcome amongst a cohort of critically ill chronic liver disease
patients.(Das and others 2010) Although neither SIRS nor SOFA were originally developed
to predict outcome, the high sensitivity of these scores makes them attractive as a means of
identifying all those high-risk paracetamol overdose patients who might die without
transplant, although their relatively lower specificity suggests that they should not replace
the KCC as definitive listing criteria. Additionally, there are some specific limitations of
both SOFA and SIRS scores that should be addressed. The SIRS does not incorporate a
hepatic failure component at all, whilst the hepatic failure component (serum bilirubin) of
the SOFA score lacks specificity or the ability to differentiate acute from chronic hepatic
dysfunction. Indeed, of all the 6 organ failure components combined in the SOFA score, only
the hepatic failure element was not associated with an increased risk of death, a finding in
keeping with several previous studies of this scoring system.(Janssens U. and others 2000)
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The principal strength of this study lies in its novel evaluation of SIRS and SOFA scores in
relation to the timing of overdose, rather than in relation to the time of admission or the
onset of HE. The initial symptoms of ALF are often vague, and as a result there may be a
significant delay between the overdose and subsequent presentation to medical services.
Additionally, some patients present as a result of the psychological consequences of their
overdose, rather than as a result of physical morbidity. Attempting to apply a prognostic
score at the time of admission is therefore considerably hindered by patient heterogeneity.
Equally, accurately applying a prognostic score at the onset of HE may be problematic since
the presence or absence of HE is subjective, and subtle encephalopathy may be wrongly
interpreted as resulting from alcohol or narcotic withdrawal. In an attempt to minimise
clinical heterogeneity only single time point overdoses were selected, with the evolution of
systemic inflammation and organ failure examined in relation to this fixed time point. Using
this approach, it can be seen that the prognostic accuracy of both SIRS and SOFA scores are
enhanced compared with previous reports which applied these markers at either the time of
hospital admission or the onset of HE.(Cholongitas and others 2006b; Schmidt and Larsen
2006) Clearly, this approach is dependent upon the temporal accuracy of the patients'
overdose history, but previous studies have suggested that the patient history is usually
reliable following paracetamol overdose.(Waring and others 2008) Heterogeneity is further
reduced by the single centre nature of this study, where both criteria for patient admission
and clinical management protocols have remained largely unchanged during the time
course of the study.
However, this retrospective study has several limitations. Clearly, the results of this study
are not directly applicable to patients who have taken a staggered overdose, an increasingly
recognised subtype of paracetamol overdose (see chapter 3). Although this study has
examined the applicability of multiorgan failure scores in relation to time from overdose,
patients access treatment at different time points in their clinical evolution, which may
influence the development of the SIRS or organ failure. A further caveat is that patients were
transferred to the SLTU from a number of surrounding hospitals, each of which may have
had different management protocols, clinical expertise, and referral thresholds following
paracetamol overdose. Whilst the SLTU is the single referral point for all severe paracetamol
overdoses in Scotland, we recognise the possibility of selection bias and that some patients
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with severe organ failure secondary to paracetamol overdose may not have been transferred
to the SLTU. It is also recognised that not all of the patients in this study developed HE, and
therefore ALF. However, predicting the development of HE can be equally problematic, and
the mere absence of HE following severe acute liver injury does not preclude the
development of other complications such as acute kidney injury.(Pakravan and others 2009)
A further potential application for SIRS and SOFA scores may be as 'gatekeepers' to more
accurately determine requirements for tertiary level care amongst patients with
paracetamol-induced acute liver injury. In the SLTU, transfer criteria are based broadly
upon those used in a previous King's College study and upon guidelines previously
published by the British Society of Gastroenterology.(Devlin and O'Grady 1999) These
guidelines recognise that "A significant proportion of cases will make an unremarkable
recovery without intensive measures but this level of unnecessary transfer is justified if the
potential for transplantation, in what is often a narrow window of time, is to be realised".
Due to the rapid progression of hyperacute ALF (including aetiologies such as paracetamol
and ecstasy) and the risks involved in transferring patients with HE or with incipient
cerebral oedema, up to 50% of UK liver centre patients never develop HE. Developing
highly sensitive markers to identify high-risk hyperacute patients at an earlier time point,
prior to HE developing, could aid safe transfer, and equally the high negative predictive
value of the multiorgan scores outlined in this study could be used to safely manage patients
without the need for transfer. The modified SOFA score outlined above might be
particularly suited to this gatekeeper role given the improved specificity of this score
compared with the original SOFA, and the increasing recognition of the importance of
extrahepatic organ dysfunction following acute liver injury.(Parekh and others 2007; Wu and
others 2010)
In conclusion, this retrospective cohort study of 100 severe acute paracetamol-induced acute
liver injury patients has evaluated the incidence and temporal kinetics of both the SIRS and
SOFA scores following the paracetamol overdose, and has demonstrated that these markers
are highly sensitive at identifying patients with a poor prognosis. The high negative
predictive value of these markers was validated in a prospective cohort. Both the SIRS and
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SOFA scores deserve further evaluation and external validation as potential gatekeepers to
improve clinical decision making models following paracetamol overdose.
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Chapter 5. Increased circulating heavy ferritin and extreme
hyperferritinaemia in paracetamol-induced human acute liver injury
5.1 Introduction
The previous chapter highlighted that a SIRS response is a frequent phenomenon amongst
patients who go on to develop paracetamol-induced ALF. It is well recognised that
paracetamol-induced ALF is associated with disordered functioning of the cellular
components of the innate immune system, in particular monocyte-macrophages,(Holt,
Cheng, Ju 2008) dendritic cells,(Chen and others 2009) and neutrophils,(Liu and others 2006),
but a greater understanding of the pathophysiology of the SIRS response could allow earlier
identification of patients at risk of developing systemic complications following paracetamol
overdose. Additionally, a greater pathophysiological understanding of the SIRS response
could identify alternative biomarkers of poor prognosis and thereby improve outcomes by
accelerating use of multidisciplinary supportive interventions and hastening patient transfer
to tertiary liver centres.
Ferritin is a ubquitous 24-subunit iron-binding cytosolic protein expressed in most tissues
which is capable of sequestering up to 4500 Fe (III) atoms. Ferritin forms a spherical shell
consisting of variable amounts of heavy (H) and light (L) chain subunits, with H-rich tissue
ferritins found predominantly in heart and kidney, and L-rich forms predominating in liver
and spleen.(Torti and Torti 2002) In addition to tissue ferritins, small amounts of ferritin are
also found in serum, and are of great clinical value in the diagnosis and monitoring of iron
deficiency anaemia and iron overload states such as hemochromatosis.(Knovich and others
2009) Although elevated serum ferritin is characteristic of hemochromatosis, non-specific
increases in circulating ferritin also occur in diverse inflammatory conditions such as
atherosclerosis,(You and Wang 2005) malignancy,(Hazard and Drysdale 1977), chronic
kidney disease,(Kalantar-Zadeh, Kalantar-Zadeh, Lee 2006) and autoimmune
disease.(Recalcati and others 2008) Particularly remarkable elevations of serum ferritin are
seen in Still's disease,(Evensen, Swaak, Nossent 2007) and haemophagocytosis.(Emmenegger
and others 2005) A recent report suggested that serum ferritin may be an additional
prognostic marker to the MELD score in patients awaiting OLT.(Walker and others 2010)
Intense interest has focused upon a potential immunomodulatory role for H-ferritin, due to
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the immunosuppressive effects of ferritin upon both lymphoid (Harada and others 1987) and
myeloid (Broxmeyer and others 1989) cells, possibly through induction of interleukin (IL)-IO
production by lymphocytes.(Gray and others 2001) Historically, hyperferritinaemia was
noted to reflect the degree of hepatocellular damage more closely than serum transaminases
in a cohort of 25 patients admitted following paracetamol overdose,(Eastham, Bell, Douglas
1976) but ferritin levels have not been prospectively measured in paracetamol-induced ALF
patients. It was hypothesised that serum ferritin would be elevated in patients following
acute liver injury and that this might serve as an early prognostic marker.
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5.2 Methods
5.2.1 Retrospective cohort study.
Retrospective analysis of the SLTU acute liver injury database was performed to identify all
patients who had an admission serum ferritin and/or iron studies performed as part of a
liver aetiology screen between January 2002 and December 2008.
5.2.2 Prospective cohort study
The study was prospectively approved by the Scotland 'A' Research Ethics Committee.
Informed consent or assent was obtained from all patients or the patient's nominated next of
kin prior to study inclusion. A total of 47 adult (>16 years) patients admitted to the Royal
Infirmary of Edinburgh with ALF or acute liver injury were entered into the study. Acute
liver injury and ALF were defined as described in previous chapters. Admission laboratory
and clinical parameters, including encephalopathy grade, mean arterial pressure, WCC,
platelet count, INR, serum electrolytes, serum bilirubin, and serum ALT were prospectively
recorded in a dedicated database. The severity of hepatic and multiorgan dysfunction was
assessed according to the modified KCC and the APACHE II score respectively.(Bernal and
others 2002; Knaus and others 1985) Additionally, SIRS and SOFA scores were calculated
throughout admission. The requirement for, or development of, any of the following clinical
parameters during admission was documented: mechanical ventilation, treatment for
increased intracranial pressure, inotropic support, renal replacement therapy, or
hypoglycaemia.
5.2.3 Serum ferritin and cytokine measurements
Peripheral serum and plasma samples were collected sequentially in serum gel and
potassium- ethylenediaminetetraacetic acid containing plastic tubes (Sarstedt, Leicester, UK)
and centrifuged at lOOOg for 15 minutes at 4eC within one hour following collection. Plasma
and serum aliquots were immediately stored in polypropylene tubes at -80gC until analysis.
Samples were obtained from patients on admission, and then daily for the first five days, or
longer if clinically indicated. Serum ferritin was assayed on an automated immunoassay
system using a chemiluminometric endpoint with an acridinium ester - labelled polyclonal
goat anti-ferritin antibody and a monoclonal mouse anti-ferritin capture antibody (Advia
Centaur; Siemens Healthcare Diagnostics Ltd., Camberley, UK). Where necessary, samples
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were diluted and then reassayed. All samples were analysed in a blinded fashion. The
precision of this immunoassay was < 5% over the range of concentrations measured.
Serum IL-6, IL-8, and IL-10 measurements were performed using a cytometric bead array kit
and software (BD Biosciences, San Jose, CA.) performed according to the manufacturers
instructions. Briefly, serum-enhancement treated capture beads, test samples and standards
were added to a 96-well plate and agitated on a plate shaker. Following incubation together
for 1.5 hours, the supernatant was aspirated and phycoerythrin detection reagent added.
Following a further 1.5 hour incubation, cytokine analysis was performed on a FACSArray®
flow cytometer (BD Biosciences, San Jose, CA.).
5.2.4 Histological analysis
Tissue samples obtained from the hepatic explant were fixed in buffered formalin and
embedded in paraffin. Liver sections were stained with Perls' Prussian blue iron stain and
the distribution of stainable iron (hepatocytes, bile duct cells, and Kupffer's cells) was
recorded by a pathologist (Dr C Bellamy) in blinded fashion.
5.2.5 Western blotting for H- and L-ferritin
Snap frozen sections of previously archived healthy human liver were defrosted on ice,
homogenised with ice-cold lysis buffer, and subsequently heated to 100°C with Laemmli
buffer in a 1:2 ratio for 5 minutes prior to loading on 10.0% sodium dodecyl sulfate-
polyacrylamide gels. Similarly, serum samples were diluted 1:2 with Laemmli buffer, heated
to 100°C for 5 minutes and 5pL of each diluted boiled sample loaded on to duplicate gels to
provide a qualitative assessment of the presence or absence of ferritin isoforms. Following
electrophoresis, proteins were transferred to nitrocellulose membranes which were
subsequently blocked with 1 x Tris-buffered saline (TBS)/0.1% Tween-20/5% non-fat milk
powder for 2 hours prior to overnight incubation with either rabbit anti-Fl or rabbit anti-L
ferritin monoclonal antibodies (Abeam, Cambridge, UK). After washing with TBS/0.1%
Tween-20, the membranes were incubated for 1 hour at 4°C with horseradish peroxidase
labelled goat anti-rabbit secondary antibody (DakoCytomation, Carpinteria, CA.), and the
proteins identified using a chemiluminescent substrate staining kit (Pierce Biotechnology,
Rockford, IL.) and subsequent 10-second exposure to a photographic plate.
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5.3 Statistical Analysis
All data were prospectively recorded in the SLTU ALF database. Statistical analysis was
performed using SPSS software (SPSS 16.0, Chicago IL, USA) and Graphpad Prism
(GraphPad Software Inc., La Jolla, CA). Data values are presented as median +/- IQR or
percentages unless otherwise stated. Continuous data were compared using the student's t-
test or Mann-Whitney U test for non-normally distributed variables, and by analysis of
variance or the Kruskal-Wallis test when three or more groups were compared. Categorical
data were analysed using Chi-squared tests or Fishers exact test. The Bonferroni method was
used to adjust p-values to account for multiple comparisons. A two-sided p value of <0.05
was considered statistically significant.
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5.4 Results
5.4.1 Patient characteristics and outcomes
The initial retrospective analysis included 124 patients with acute liver injury in whom
serum ferritin and iron indices had been measured on admission to the SLTU. Paracetamol
overdose (POD) was the most common aetiology in this cohort; POD 71 (57.2%), non-POD
53 (42.7%). The demographics and admission laboratory parameters of these two patient
groups are outlined in table 5.1. Non-POD patients were significantly older and had higher
admission bilirubin levels, but lower serum ALT values, compared with POD patients. POD
patients were significantly more coagulopathic than non-POD patients. Most (100, 80.6%)
patients were transferred from other health boards in Scotland with the remaining 24
patients transferred from local hospitals or other wards within the Royal Infirmary of
Edinburgh. Most of the overdoses were taken in a suicidal attempt (51 patients, 71.8%). All
patients with POD received NAC prior to, or on admission to the SLTU. A total of 65 (52.4%)
patients (42 POD, 23 non-POD) never developed HE and were classified as having acute
liver injury rather than ALF, and all of these patients survived. In the 59 patients with ALF
(POD 29, non-POD 30) 25 (42.4%) recovered spontaneously (POD 16/29, 55.2%; non-POD
9/30, 30.0%) and 18 (30.5%) patients underwent emergency LT (POD 5/29, 17.2%; non-POD
13/30, 43.3%). Comparison of the clinical details of patients in whom ferritin was measured
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5.4.2 Extreme hyperferritinaemia is common in paracetamol-induced acute liver injury
Elevated serum ferritin (i.e. serum ferritin >300pg/L) was common in patients (109/124
patients, 87.9%) with acute liver injury; and increased serum ferritin levels were more
frequent in the POD (66/71 patients, 93.0%) compared with the non-POD cohort (43/53
patients, 81.1%, p=0.046). The absolute values for serum ferritin were also significantly
higher in patients with paracetamol-induced acute liver injury compared with non-
paracetamol group (table 5.1, figure 5.1). In addition, extreme elevations of serum ferritin (>
10 OOOpg/L) were more common in the POD group (36/71, 50.7% patients ferritin > 10
OOOpg/L; 2/71, 2.8% patients ferritin > 100 OOOpg/L) compared with the non-POD group (5/53,
9.4% patients ferritin > 10 OOOpg/L, no patient ferritin >100 OOOpg/L, p<0.001, Fishers exact
test for ferritin >10 OOOpg/L).
5.4.3 Disordered indices of iron metabolism are common in acute liver injury.
In view of the extreme elevation of serum ferritin in patients with acute liver injury analyses
of serum transferrin, iron, and transferrin saturations were performed in the retrospective
cohort where these had been measured (figure 5.1). Elevated serum iron (i.e. serum iron >
32pmol/L; 54/109 patients, 49.5%) was frequently observed in patients with acute liver
injury, and was more common in POD patients (POD 40/65, 61.5%; non-POD, 14/44, 31.8%,
p=0.002, Fishers exact test) . In contrast, transferrin levels were frequently reduced (serum
transferrin <2g/L) in patients with acute liver injury (81/104 patients, 77.9%). Reduced
transferrin concentrations (POD, 48/63 (76.2%) patients; non-POD, 33/41 (80.5%) patients,
p=0.606) were similarly observed in both groups. Comparing the absolute values for these
variables revealed significantly elevated iron and transferrin saturation in patients with
paracetamol-induced acute liver injury compared with the non-paracetamol group (table
5.1, figure 5.1).
Anaemia can occur relatively early in the clinical course of critically ill patients and is
characterised by reduced serum iron, transferrin and transferrin saturation and mildly
increased serum ferritin concentrations.(Walsh and Saleh 2006) Twenty three (18.7%)
patients in the retrospective cohort had haemoglobin levels <100g/L on admission (POD 13,
18.3%; non-POD 10, 18.9%, n.s.). In these patients low transferrin (<2g/L; 16/21 patients,
76.2%) and increased ferritin (>300pg/L; 18/23 patients, 78.3%) were relatively common but
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low serum iron (<14 pmol/L; 9/22 patients, 40.9%) and transferrin saturations (<15%; 3/21,
14.3%) were less frequently observed, suggesting the changes in iron indices in ALF are

































Figure 5.1 Admission serum ferritin and other iron indices following acute liver injury.
Retrospective analysis of SLTU ALF database parameters for serum (A) ferritin, (B) iron, (C)
transferrin and (D) transferrin saturation. Box and whiskers plots represent median, quartiles,
and extreme data values. *** p<0.001, Mann-Whitney U test; n.s. not significant
POD, paracetamol overdose (n=71); non-POD (n=53)
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5.4.4. Hvperferritinaemia in acute liver injury is not associated with significant hepatic
iron overload
Elevated serum ferritin and transferrin saturation are characteristic features of
hemochromatosis. Hepatic tissue removed during OLT was therefore examined for
significant iron overload. 18 patients underwent OLT in the retrospective cohort (5 POD, 13
non-POD). None of the explanted cases exhibited significant iron accumulation.
5.4.5 Correlation of serum ferritin with liver injury, function, and outcome
The initial analysis above revealed significant differences in serum ferritin between patients
with paracetamol and non-paracetamol induced acute liver injury. In addition, different
prognostic criteria are utilised in these two aetiological groups.(O'Grady and others 1989)
Analysis of the relationship between prognostic factors in paracetamol and non-paracetamol
aetiologies was therefore performed separately. It was considered that the elevated ferritin
levels in paracetamol patients might simply reflect underlying hepatic necrosis; however,
there was no significant correlation between admission serum ALT and ferritin levels
(Spearman's r=0.172, p=0.152). However, there was a weak correlation between ferritin and
hepatic dysfunction, as assessed by PT (Spearman's r=0.255, p=0.033). Serum ferritin was
significantly higher in paracetamol patients who died or were transplanted (38580 (6702-
54533) pg/L, n=13) compared with paracetamol patients who survived spontaneously (8030
(1700-28403) pg/L, n=58, p=0.011, Mann-Whitney U test). Similarly, admission ferritin levels
were significantly higher in those paracetamol patients who developed HE, and therefore
ALF, at some point during admission (18160 (3880-47305) pg/L, n=29) compared with
paracetamol acute liver injury patients (7725 (1566-24548) pg/L, n=42, p=0.038, Mann-
Whitney U test). Serum ferritin levels were similar in paracetamol patients with elevated
creatinine (creatinine >120pmol/L: 19777 (4886-45179) pg/L, n=20) compared with patients
with normal admission creatinine (creatinine <120pmol/L: 7930 (1742-30769) pg/L, n=51,
p=0.127, Mann-Whitney U test) on admission to the SLTU. Analysis of admission ferritin
levels in both cohorts of paracetamol patients to predict death or requirement for OLT
showed an area under the receiver operator characteristic (AUROC) of 0.722 (95%
confidence intervals 0.614-0.831, p=0.001), figure 5.2, compared with an AUROC for serum
ALT of 0.514 (95% CI 0.383-0.645, p=0.829). In contrast with the prognostic significance of
ferritin in paracetamol-induced acute liver injury, there were no significant differences noted
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in the non-paracetamol acute liver injury patients in those who survived spontaneously or
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5.4.6 Prospective study confirms significant hvperferritinaemia in paracetamol-induced
acute liver injury.
In view of the potential selection bias in analysis of retrospective data serum ferritin was
measured in 47 sequential cases of POD acute liver injury admitted to the SLTU. The
demographics and admission laboratory parameters and clinical outcomes of this cohort are
displayed in table 5.3. A total of 27 (57.4%) of these patients developed HE (grade III/IV in
19 (40.4%)), and 13 patients subsequently died or required emergency OLT. Serum ferritin
was elevated (i.e. serum ferritin >300 pg/L) in 40 patients (85.1%). Very high serum ferritin
was also frequently observed in this cohort (22/47, 46.8% patients had ferritin > 10 OOOpg/L,
2/47, 4.2% patients had ferritin > 100 OOOpg/L). Admission serum ferritin was again
significantly higher in patients who died or were transplanted (21151, (9443-40130) pg/L;
n=13) compared with spontaneous survivors (4237, (776-18020) pg/L; n=34; p=0.013, Mann-
Whitney U test). Similarly, admission ferritin levels were significantly higher in
paracetamol-induced ALF patients (15465 (6626-33245) pg/L, n=27) compared with
paracetamol acute liver injury patients (998.5 (424.3-12040) pg/L, n=20, p=0.005, Mann-
Whitney U test). Serial analysis of serum ferritin levels amongst paracetamol-induced ALF
patients who died or required liver transplantation (n=10) and spontaneous survivors (n= 14)
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Analysis of explanted liver tissue (n=5) again did not show significant iron accumulation.
Serum ferritin was significantly correlated with both PT (r=0.497, p<0.001) and ALT levels
(r=0.392, p=0.006). In this prospective cohort admission ferritin was also significantly
correlated with admission and maximal organ dysfunction scores (figure 5.4). Patients that
developed >2 SIRS components during admission also had elevated admission ferritin (SIRS
14980 (7390-36944) pg/L, n= 24; no SIRS, 1047 (518-18020) pg/L, n=23, p=0.008, Mann-
Whitney U test).(Anonymous 1992) There was no correlation with the acute phase response
as determined by circulating C-reactive protein, although ferritin was significantly
correlated with both proinflammatory (IL-6 and IL-8) and anti-inflammatory (IL-10) cytokine
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ALT (IU/L) 0.392 0.006
CRP 0.095 0.525
SOFA score 0.529 <0.001
APACHE II score 0.323 0.027
IL-6 (pg/mL) 0.442 0.006
IL-8 (pg/mL) 0.502 0.001
IL-10 (pg/mL) 0.349 0.030
Table 5.4. Correlation between serum ferritin and clinical and biochemical markers of
injury and inflammation.
CRP, C-reactive protein; SOFA, Sequential Organ Failure Assessment; APACHE, Acute
Physiology and Chronic Health Evaluation; IL, interleukin
Correlations between variables were analysed using Spearman's rank correlation.
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5.4.7 Elevated serum ferritin in acute liver injury is associated with significant levels of
circulating H-ferritin
Under normal physiological conditions, the majority of circulating serum ferritin is
composed of L-ferritin. Previous studies have suggested an immunomodulatory role for H-
ferritin, but to date, increased circulating H-ferritin has not been demonstrated in liver
disease.(Li and others 2010) Immunoblotting of serum from acute liver injury patients with
elevated circulating ferritin revealed circulating L-ferritin, but also significant amounts of H-
ferritin (figure 5.5). In contrast, no circulating H-ferritin was observed in healthy controls
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5.5 Discussion
This chapter reports extreme elevations of serum ferritin on admission in patients with
paracetamol-induced acute liver injury; more than 50% of patients had admission ferritins
greater than 10 000 pg/L, while some patients had ferritin concentrations greater than 100
000 pg/L. The elevated serum ferritins are some of the highest values ever reported in the
literature. Elevated serum ferritin was associated with increased serum iron concentrations,
elevated transferrin saturation, and reduced transferrin concentrations, particularly amongst
paracetamol patients. Increased serum ferritin was associated with a more complicated
clinical course and worse clinical outcomes in patients with paracetamol-induced acute liver
injury, but not those with non-paracetamol causes, suggesting a potential role for serum
ferritin as an early biomarker following POD. Elevated serum ferritin was correlated with
the degree of liver failure, as determined by PT, and with the presence of systemic
inflammation; suggesting that several parallel pathophysiological processes are involved in
the massive elevation of serum ferritin reported. In addition, for the first time, circulating
levels of the immunomodulatory H-ferritin are demonstrated in patients with paracetamol-
induced ALF, suggesting that ferritin may also play a pathophysiological role in the
systemic inflammation and multiorgan failure associated with paracetamol overdose.
This is one of the first studies to examine the significance of elevated circulating ferritin in
human acute liver injury. (Eastham, Bell, Douglas 1976) The significance of serum ferritin
has been explored in both retrospective and prospective cohorts of acute liver injury
patients. Additional strengths of this study include the single centre nature of the study and
the correlation of ferritin with other pro- and anti-inflammatory cytokines. However, this is
a small study and the results require confirmation in other, larger, prospectively collected
populations of acute liver injury patients. An important caveat to these retrospective data is
potential selection bias since many paracetamol cases in the SLTU database did not have
serum ferritin measured. This may reflect diagnostic confusion in some atypical
paracetamol cases, or may simply reflect the increased use of electronically ordered 'liver
screens' (which include serum ferritin) by admitting clinicians during more recent years.
Comparison was therefore made between paracetamol cases where ferritin had been
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measured with the remaining paracetamol cases, and no demographic differences between
the groups was noted, except a significantly lower proportion of single intentional
paracetamol overdose cases in the ferritin measurement group (table 5.2). Any potential
selection bias was reduced by additionally measuring serum ferritin prospectively in 47
cases of paracetamol induced liver injury sequentially admitted to the SLTU. Another caveat
to these data is the small number and heterogeneous nature of the non-paracetamol cohort.
This reflects the patient population referred to the SLTU, in which less than 30% of cases are
secondary to non-paracetamol causes.
Serum ferritin is elevated in a wide number of acute and chronic inflammatory conditions,
as well as non-specifically during critical illness.(Evensen, Swaak, Nossent 2007; Knovich
and others 2009; Rambod, Kovesdy, Kalantar-Zadeh 2008; Recalcati and others 2008; You
and Wang 2005) It could be argued that the elevated ferritins seen in this study are simply an
epiphenomenon reflecting the degree of underlying hepatic necrosis. Several factors argue
against this: firstly, the degree of elevation of serum ferritin is greatly beyond that normally
seen in patients with acute inflammatory conditions such as acute respiratory distress
syndrome, trauma or sepsis.(Garcia and others 2007; Sharkey and others 1999) Secondly, the
pattern of increased serum ferritin, transferrin saturations and iron and reduced transferrin
concentration is out of keeping with the anaemia of critical illness, making this explanation
unlikely.(Walsh and Saleh 2006) Thirdly, although serum ferritin correlated weakly with
ALT levels (in the prospective cohort only), ferritin appears more to reflect underlying
systemic immune activation (as judged by significant correlations with IL-6, IL-8, and IL-10)
and degree of organ injury than simply hepatocyte necrosis. This is reflected in the
significant AUROC value for ferritin compared with the non-discriminatory AUROC for
ALT. Elevated ferritin is also common in patients with chronic renal failure and relates to
clinical outcomes.(Rambod, Kovesdy, Kalantar-Zadeh 2008) The elevated serum ferritin is
thought to relate to chronic inflammation in this condition, but could also reflect impaired
urinary ferritin excretion.(Chow and others 1995) Elevated serum ferritin has also been
reported in patients with acute renal failure.(Gulcelik and Kayatas 2002) However, the levels
of ferritin reported in either acute or chronic renal failure are relatively mild compared with
the concentrations observed in this study, suggesting that additional mechanisms underlie
the hyperferritinaemia of acute liver injury. The increased ferritin levels could also reflect
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unrecognized haemochromatosis, and HFE gene testing was not performed in our cohorts to
exclude this possibility. However, none of the liver explants showed significant iron
overload, and the clinical presentation and degree of hyperferritinaemia in these patients
make unrecognised haemochromatosis very unlikely. Extreme elevations of serum ferritin
also occur in Still's disease and haemophagocytic lymphohisticytosis, a heterogeneous
disorder characterised by hyperferritinaemia, hypertriglyceridaemia, and multiorgan
failure.(Emmenegger and others 2005; Evensen, Swaak, Nossent 2007) Interestingly, the
latter rare condition may be induced by hepatitis virus infection and has been reported to
occur in children with ALF,(Natsheh and others 2001; Shneider, Selsky, Komp 1992) so
clinicians dealing with acute liver injury patients should remain vigilant for the possibility of
haemophagocytic lymphohisticytosis, particularly given the clinical similarities between
these conditions and severe sepsis, SIRS, and ALF.(Castillo and Carcillo 2009)
Despite the widespread use of ferritin as a marker of iron stores, surprisingly little is known
regarding its secretion, regulation, or cellular receptors.(Recalcati and others 2008) It is
recognised that the transcription of H- and L-ferritin subunits are selectively regulated in
response to inflammation, with H-ferritin mRNA in particular being induced by tumour
necrosis factor-a and IL-la in both mesenchymal and monocytic cells.(Fahmy and Young
1993) Hepatocytes,(Ghosh, Hevi, Chuck 2004) macrophages (Wesselius, Nelson, Skikne
1994) and Kupffer cells (Ono and Seno 1991) are all known to secrete ferritin, suggesting that
in addition to passive release from damaged hepatocytes, the elevated serum ferritin
observed in acute liver injury may also arise from active synthesis and release from
undamaged hepatocytes and the reticuloendothelial system. This study is the first to show
that H-ferritin is present in circulating form following acute liver injury. Interestingly,
treatment of human macrophages with IL-4 to induce an alternative (M2) macrophage
phenotype results in enhanced iron release,(Recalcati and others 2010) a finding which has
particular resonance for paracetamol-induced liver injury, where the pathophysiological role
of macrophages is increasingly recognised,(Possamai and others 2010) and where
alternatively activated macrophages are thought to infiltrate the liver following paracetamol
injury.(Holt, Cheng, Ju 2008)
Given the association between elevated ferritin and deleterious outcomes in paracetamol-
induced ALF it is tempting to speculate on the potential role for elevated ferritin in the
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pathogenesis of this condition. H-ferritin receptors have been identified on hepatocytes,
kidney cells, and B- and T-lymphocytes, and this receptor in humans has recently been
identified as transferrin receptor-l.(Li and others 2010) Exogenous ferritin is avidly taken up
by hepatocytes, a process which may stimulate apoptosis through the FasL/Fas
pathway.(Bresgen and others 2007) Recently, it was shown that at high concentrations
ferritin can also trigger necrotic hepatocyte death through increased lysosomal membrane
permeability,(Bresgen and others 2010) suggesting that ferritin might indirectly modulate
the type of cell death seen following paracetamol injury.(Gujral and others 2002) Ferritin can
also inhibit lymphocyte proliferation, downregulate chemokine signalling and the delayed
hypersensitivity response, and stimulate production of the immune regulatory cytokine IL-
10.(Wang and others 2010) Future studies should therefore explore whether
hyperferritinaemia contributes to the increased risk of infection following acute liver
injury.(Antoniades and others 2008; Berry and others 2010)
Increased serum ferritin is common in patients with chronic liver disease and has been
linked to mortality on the liver transplant waiting list.(Walker and others 2010) Elevated
serum ferritin is also common in patients with alcoholic hepatitis,(Bell and others 1994)
hepatitis C infection,(Ferrara and others 2009) and non-alcoholic fatty liver disease, and
future studies should therefore explore whether H-ferritin levels are also increased in these
conditions.(Licata and others 2009) However, the degree of hyperferritinaemia seen in
paracetamol-induced ALF patients suggests that much greater derangements of the innate
immune system occur in this condition. Significantly higher serum ferritin levels were
found in paracetamol patients who died or were transplanted compared with spontaneous
survivors. In contrast, analysis of the retrospective cohort revealed that admission serum
ferritin was not predictive of outcome in the non-paracetamol cohort. This may be due to the
rapid clinical evolution of the paracetamol-induced acute liver injury patients, with clinical
outcomes occurring much earlier in this group of patients compared with patients with non-
paracetamol induced acute liver injury. These data suggest that serum ferritin may have
potential as an early biomarker following paracetamol injury, particularly given its
widespread availability in clinical practice, but this possibility should be explored in larger
cohorts of paracetamol patients.
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In conclusion, this chapter demonstrates extreme hyperferritinaemia following acute liver
injury. Hyperferritinaemia was associated with a more complicated clinical course and
worse outcomes in patients with paracetamol-induced acute liver injury, and correlated with
the degree of liver failure and systemic inflammation. In addition, increased circulating
levels of the immunomodulatory H-ferritin are demonstrated in patients with paracetamol-
induced ALF. Future studies should explore the pathophysiological role of ferritin in acute
liver injury, and examine the utility of ferritin as a biomarker following paracetamol-
induced liver injury.
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Chapter 6. Circulating levels of the long pentraxin PTX3, but not
hepatocyte derived C-reactive protein, correlate with severity following
human acute liver injury
6.1 Introduction
The previous chapters, and other published studies, have highlighted the association
between development of the SIRS following both paracetamol and non-paracetamol induced
acute liver injury and deleterious clinical outcomes.(Leithead and others 2009; Rolando and
others 2000b; Vaquero and others 2003) As described previously, defective functioning of the
cellular components of the innate immune system, in particular monocyte-
macrophages,(Holt, Cheng, Ju 2008) dendritic cells,(Chen and others 2009) and
neutrophils,(Liu and others 2006) have all been implicated in the pathophysiology of ALF,
but to date, few studies have focused upon the humoral arm of the innate immune system.
The humoral innate immune system consists of several soluble factors, such as the
pentraxins, ficolins, and collectins. The pentraxins are a superfamily of highly evolutionarily
conserved soluble pattern recognition receptors (PRRs) with a wide range of functions in
inflammatory diseases.(Bottazzi and others 2010) The best characterised are the short
pentraxins, which include C-reactive protein (CRP) in humans and serum amyloid P
component (SAP) in mice, which are produced predominantly by hepatocytes in response to
circulating proinflammatory mediators including interleukin (IL)-6. Pentraxin 3 (PTX3) is
the prototypical long pentraxin which is rapidly synthesised and released in response to
both cytokines, including IL-1, tumour necrosis factor-a and IL-10, and toll-like receptor
engagement.(Doni and others 2006; Mantovani, Garlanda, Bottazzi 2003) Diverse effector
functions of PTX3 include complement binding, opsonisation of bacteria, and the handling
of apoptotic cells.(Manfredi and others 2008) Elevated levels of PTX3 have been
demonstrated in a wide variety of proinflammatory conditions including sepsis and acute
myocardial infarction, with PTX3 levels strongly correlating with disease severity in these
conditions.(Fazzini and others 2001; Latini R. and the Lipid Assessment Trial Italian
Network (LATIN) Investigators 2004; Luchetti and others 2000; Muller and others 2001)
Previous studies have suggested that serum CRP levels are relatively suppressed in ALF
patients with concomitant septic complications and that the relatively reduced levels of CRP
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in these patients contributed to the increased risk of infection. (Silvestre, Coelho, Povoa 2010)
PTX3 is produced predominantly by endothelial cells and monocytes,(Alles and others 1994)
whereas CRP is produced almost exclusively by hepatocytes.(Steel and Whitehead 1994) In
ALF, especially when caused by paracetamol, the former cell types are activated and
induced, in contrast with hepatocytes which are significantly injured and necrotic. It was
therefore hypothesised that circulating PTX3 levels would be increased in patients with
acute liver injury, elevated in those with worse outcomes, and reduced in patients with
infective complications.
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6.2 Materials and methods
6.2.1 Patients. Study Design, and Definitions
The study was prospectively approved by the Scotland 'A' Research Ethics Committee. A
total of 60 consecutive adult patients (24 male, 36 female) admitted to the Royal Infirmary of
Edinburgh with ALF or acute liver injury between December 2008 and March 2010 were
entered into the study. Informed consent or assent was obtained from all patients or their
nominated next of kin respectively prior to study inclusion. Acute liver injury and ALF were
defined as in previous chapters. For those patients admitted with presumed paracetamol
hepatotoxicity, admission to the study required the concomitant presence of a serum alanine
aminotransferase (ALT) >1000 IU/L and any degree of coagulopathy. Aetiologies of liver
injury were defined as previously described. Admission laboratory and clinical parameters
were prospectively recorded in a dedicated database as previously described.
Patients were managed according to a standardised clinical protocol as described in
previous chapters. Healthy and pathological control groups consisted of 13 healthy controls
(HC) and 10 clinically stable patients with chronic liver disease (CLD) attending a portal
hypertension outpatient clinic.
6.2.2 Blood sampling
Peripheral serum and plasma samples were collected daily in serum gel and potassium-
ethylenediaminetetraacetic acid containing plastic tubes (Sarstedt, Leicester, UK) and
centrifuged at lOOOg for 15 minutes at 42C within one hour following collection. Plasma and
serum were immediately aliquoted and stored in polypropylene tubes at -80eC until
analysis. In patients undergoing emergency OLT, peripheral blood samples were obtained
within 24 hours following transplantation.
6.2.3 Routine variables
Standard haematological, biochemical, and coagulation parameters were obtained on a daily
basis during admission.
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6.2.4 PTX3 Enzyme-Linked Immunosorbent Assay (ELISA)
Admission plasma PTX3 levels were measured in all patients using a commercial
quantitative sandwich ELISA (R&D Systems Inc, Abingdon, UK) according to the
manufacturer's instructions. PTX3 levels were additionally measured on day 3-4 of
admission in 14 paracetamol-induced ALF patients (see section 6.3.6). A 96-well
streptavidin-coated plate was incubated with a PTX3 biotinylated monoclonal antibody and
incubated for 60 minutes on a microplate shaker. Following washing of the plate, pretreated
ethylenediaminetetraacetic acid plasma samples were added to the plate in duplicate.
Following incubation at room temperature for 2 hours and washing away of any unbound
substances, an enzyme-linked conjugate was added to the wells and incubated for a further 2
hours. Following a wash to remove any unbound conjugate, a substrate solution was added
to the wells and colour development measured at 450 nm using an automatic ELISA reader
(Tecan Spectra, Crailsheim, Germany). Results were determined from a standard curve
prepared from 7 human PTX3 standards, with a lower threshold of detection of 0.31 ng/mL.
All pathological samples were above the detection limit, but a total of 6/13 (46.2%) of HC
samples were below the lower threshold of detection. The coefficient of variation was 3.6%.
6.2.5 Highly sensitive C-reactive protein
Admission serum CRP levels were analysed in liver injury patients using a turbimetric
method using a Beckman AU2700 system (Beckman Coulter Ltd., High Wycombe, UK). CRP
levels were additionally measured on day 3-4 of admission in 14 patients (see section 6.3.6).
The coefficient of variation of this system was 5% at values <2 mg/L and 2-3% at higher
concentrations.
6.2.6 Serum IL-6 and IL-10
Admission cytokine measurements were performed using a cytometric bead array kit and
software (BD Biosciences, San Jose, CA.) as described in chapter 5.
6.2.7 Statistical Analysis
Data values are presented as median and interquartile range or percentages unless otherwise
stated. Statistical analysis was performed using SPSS (SPSS 16.0, Chicago IL, USA) and
Graphpad Prism (GraphPad Software Inc., La Jolla, CA). Continuous data were compared
using either analysis of variance or the Kruskal-Wallis test if inter-group variances were
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unequal, with post-hoc Dunn's testing used to compare selected groups. Categorical data
were analysed using Chi-squared tests or Fishers exact test. Correlations between PTX3
levels and other variables were analyzed using Spearman's rank correlation. Stepwise
logistic regression was used to determine factors predictive of death or OLT in the acute
severe liver injury cohort as a whole, and then separately for the paracetamol patients.
Wilcoxon matched pairs test was used to compare repeated measures. Results were




Table 6.1 illustrates the baseline demographic and admission laboratory variables of the
liver injury study populations. Paracetamol patients were significantly younger than both
non-paracetamol and CLD patients. Paracetamol patients had significantly higher ALT and
PT values on admission compared with non-paracetamol patients, but had lower serum
bilirubin levels and lower leucocyte counts. Of note is the inclusion in the non-paracetamol
group of 2 post-transplant patients with acute liver injury (1 primary non-function, 1 small-
for-size syndrome); subsequent analysis excluding these patients had no effect upon the
reported results. A total of 28/48 (58.3%) of paracetamol and 8/12 (66.7%) non-paracetamol
patients developed HE, and therefore ALF, during the study. Of these patients, 18/28 (64.3%)
paracetamol and 5/8 (62.5%) non-paracetamol ALF patients met the KCC, with 8 (5
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6.3.2 Circulating long and short pentraxin levels in acute liver injury
Median admission plasma PTX3 levels were significantly higher in the acute liver injury
cohort as a whole (median (IQR): 78.2 (14.6-446.8) ng/mL, n=60) compared with both CLD
patients (1.55 (1.22-2.23) ng/mL, n=10, p<0.0001) and HC (0.33 (0.31-0.52) ng/mL, n=13,
pO.OOOl). Levels of PTX3 were significantly higher in paracetamol patients (148.6 (26.6-579)
ng/mL, n=48) compared with non-paracetamol patients (23.7 (9.1-40.0) ng/mL, n=12, p=0.004),
figure 6.1. In contrast with the elevated levels of PTX3 in the paracetamol patients,
admission CRP levels were significantly increased in non-paracetamol acute liver injury
patients (17.55 (3.93-15.38) mg/L, n=12) compared with paracetamol patients (6.05 (3.93-
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6.3.3 Relation of PTX3 levels to outcome and disease severity in paracetamol patients
Admission PTX3 levels in paracetamol patients who died or required emergency OLT (568.2
(176.4-832.7) ng/mL, n=14) were significantly higher compared with spontaneous survivors
(64.3 (10.0-372.3) ng/mL, n=34, p=0.0011). Admission PTX3 levels were also significantly
higher in paracetamol patients who developed HE during their illness (median (interquartile
range) (329.4 (77.7-738.1 ng/mL, n=28) compared with acute liver injury patients (no HE)
(46.1 (6.1-172.4) ng/mL, n=20, p=0.0005). Of those paracetamol patients who developed HE,
admission PTX3 levels showed a trend towards higher levels in patients who met the KCC
(452.9 (142.9-831.4) ng/mL, n=18) compared with patients not meeting the KCC (155.3 (41.3-
599.1), n=10, p=0.0722). The area under the ROC for PTX3 for the outcome of death/
requirement for OLT was 0.80 (95% confidence intervals 0.67- 0.93), figure 6.2.
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Admission PTX3 levels in paracetamol patients correlated with admission APACHE II
(r=0.398, p=0.006) and SOFA (r=0.536, p<0.001) scores. In addition, admission PTX3 levels
were more strongly correlated with the maximal SOFA score during admission (r=0.603,
p<0.001). (Figure 6.3)
6.3.4. Relation of PTX3 levels, systemic inflammation, and infection in paracetamol
patients
Admission PTX3 levels were higher in paracetamol patients who had developed the SIRS by
the time of admission (306.4 (87.4-772.9) ng/mL, n=21) compared with no systemic
inflammatory response (66.1 (7.99-352.3) ng/mL n=27, p=0.018) and with development of the
SIRS at any stage during admission (SIRS 306.4 (113.1-772.9) ng/mL, n=25; no SIRS 50.5 (6.7-
297.7) ng/mL, n=23, p=<0.001), figure 6.3. A total of 17 patients subsequently developed
bacteriologically confirmed infection, including staphylococcal bacteraemia (n=5),
candidaemia (n=4), E. coli (n=4), anaerobic infections (n=2), mycobacterial infection (n=l), and
other Gram positive bacteraemias (n=2). Admission PTX3 levels amongst those patients
subsequently developing an infection (142.9 (41.6-619.6) ng/mL) were not significantly
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6.3.5. Correlation of PTX3 and CRP with other markers of disease severity and systemic
inflammation in paracetamol-induced acute liver injury
The levels of PTX3 and CRP were then correlated with a number of markers of disease
severity in both the paracetamol and non-paracetamol cohorts, with the results shown in
table 6.2. PTX3 showed a strong correlation in both groups of patients with IL-10 and IL-6,
as well as the multiorgan failure markers outlined above. In addition, PTX3 correlated with
serum ALT, creatinine, and INR. In contrast, CRP levels showed little correlation with
indices of disease severity. Multivariate logistic regression was performed to determine
whether PTX3 levels were an independent predictor of outcome. As shown in table 6.3, only
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6.3.6. Time course of PTX3 and impact of liver transplantation
Given that admission PTX3 was correlated with subsequent poor outcomes, it was
hypothesised that PTX3 levels would remain persistently elevated in patients who died or
were transplanted. To test this, PTX3 levels were measured on admission and again at day 3-
4 post-admission in 8 paracetamol-induced ALF patients who died or later underwent
emergency OLT, and compared with 6 paracetamol-induced ALF patients who
spontaneously survived. As shown in figure 6.4, PTX3 levels fell significantly in both
groups by day 3-4. The impact of impaired liver function on circulating PTX3 and CRP was
then explored by measuring circulating levels before and after emergency OLT in 5
paracetamol-induced ALF patients. As shown in figure 6.4, post-operative PTX3 levels fell




Figure 6.4 Serial levels of pentraxins in paracetamol-ALF patients.
Serial PTX3 levels in paracetamol-ALF patients who (A) died or required OLT (n=8) and (B)
spontaneous survivors (n=6). Impact of OLT upon PTX3 (C) and CRP levels (D) in 5




This observational cohort study demonstrates exceptionally high levels of PTX3 following
paracetamol-induced acute liver injury in contrast with non-paracetamol acute liver injury.
In the paracetamol cohort PTX3 levels correlated with liver injury, organ failure, and adverse
outcomes. PTX3 levels were elevated in patients with the SIRS and correlated with the
cytokines IL-6 and IL-10, but were similar in infected and non-infected cohorts. Levels of
PTX3 fell rapidly following admission in both survivors and those who died or were
transplanted. Removal of the injured liver with transplantation resulted in rapid falls in
circulating PTX3. In contrast with PTX3, levels of CRP, a hepatocyte derived short pentraxin
involved in the acute phase response, were most elevated in patients with non-paracetamol
acute liver injury, bore little relationship to eventual outcome, and significantly increased
following liver transplantation. These data demonstrate that the humoral arm of the innate
immune system is strongly and selectively activated following acute liver injury, and may be
implicated in the development of downstream multiorgan failure. These data also support
the hypothesis that it is the degree of immune system activation, rather than the degree of
hepatocyte injury per se, that is the main determinant of outcome following paracetamol-
induced acute liver injury.
The strengths of this study include the simultaneous measurement of two pentraxins in the
same cohort of patients with a wide range of severity of liver injury, and the correlation with
other pro- and anti-inflammatory markers. Additionally, changes in circulating PTX3 over
time have been examined in both spontaneous survivors and patients who died, as well as
assessing the impact on PTX3 levels of removal and replacement of the injured liver with
functional liver mass by OLT. A further strength of this study is its single centre nature,
where all the patients were managed according to a predefined clinical protocol which
remained unchanged throughout the duration of the study.
However, this is a small study and the results will require confirmation in other, larger,
populations of acute liver injury patients. Due to the difficulties with obtaining liver biopsy
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specimens from patients with acute liver injury, the cellular source of PTX3 could not be
histologically confirmed, but, given the soluble nature and cellular sources of PTX3, the
benefits of hepatic tissue examination in this scenario may be limited. Furthermore, the
highest levels of PTX3 were observed on admission and had considerably reduced by the
time patients came to transplantation. It is also recognised that not all of the patients
included in this study developed HE, and therefore ALF. Another caveat to these data is the
small number and heterogeneous nature of the non-paracetamol cohort which reflects the
patient population referred to the SLTU, where less than 30% of cases are secondary to non-
paracetamol causes. There was a clear difference observed in the circulating PTX3 levels in
paracetamol and non-paracetamol cases, but future studies should determine whether
measuring PTX3 is of benefit in excluding paracetamol as a cause in ALF cases of aetiological
uncertainty.
PTX3 is the prototypical long pentraxin which is present at very low levels (<2 ng/mL) in
normal humans, as was observed in our normal controls. Little is currently known
regarding the natural half-life of PTX3 in humans and the effects of organ failure on the
clearance of PTX3.(Zhang, Danas, Preisner 2010) Whilst the short pentraxins human CRP
and murine SAP are produced in the liver in response to IL-6, PTX3 originates
predominantly from extrahepatic sources, in particular vascular endothelium, fibroblasts,
macrophages, and myeloid dendritic cells.(Mantovani, Garlanda, Bottazzi 2003) Recently,
PTX3 was demonstrated to exist in a ready-made form in neutrophilic granules (Garlanda
and others 2002) and to localise in neutrophil extracellular traps (NETs),(Brinkmann and
others 2004) suggesting that neutrophils, one of the first cellular types attracted to the liver
following acute liver injury,(Jaeschke and FFasegawa 2006) may act as a reservoir for PTX3
prior to its biosynthesis by other cell types.
In contrast with the divergence between human and murine species regarding the short
pentraxins, PTX3 is highly conserved in humans and mice. Existing experimental data
suggest that PTX3 plays an important role in the response to infection or tissue injury.
Transgenic mice overexpressing PTX3 display enhanced resistance to caecal ligation and
puncture,(Dias and others 2001) whilst ptx-3 deficient mice have increased susceptibility to
myocardial damage following ischaemia-reperfusion injury, a phenotype which can be
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reversed by exogenous PTX3.(Salio and others 2008) These data show that PTX3 release is
massively upregulated following paracetamol injury and the correlation with organ failure
and outcome suggest a potential pathogenic role for PTX3 in the development of multiorgan
failure in paracetamol-induced ALF. PTX3 may play an important role in the modulation of
local tissue coagulation following infection or inflammation. Levels of PTX3 are increased in
patients with small vessel vasculitides,(Fazzini and others 2001) and PTX3 is known to
modulate the complement system, predominantly through binding of Clq, leading to
activation of the classical complement cascade.fNauta and others 2003) Additionally, PTX3
upregulates tissue factor (TF) expression in both endothelial cells and activated
monocytes,(Napoleone and others 2002; Napoleone and others 2004) suggesting that PTX3
may amplify local clotting cascades and cause a shift towards a procoagulant state. The role
of TF in the mediation of endothelial damage following paracetamol injury is gaining
increasing recognition,(Kerr and others 2003) with the suggestion that TF is rapidly
upregulated following damage to sinusoidal endothelial cells, leading to disruption of
hepatic blood flow and development of localized hypoxia.(Ganey and others 2007b) The
upregulation of PTX3 in this study is intriguing since it occurred rapidly following
paracetamol injury, and frequently before the development of the severe HE, renal
impairment, and coagulopathy required to fulfil the KCC.fO'Grady and others 1989)
Furthermore, since PTX3 levels correlated more strongly with maximal, rather than
admission, SOFA scores, PTX3 may also have a future role as an early biomarker of organ
failure in this condition. Future studies should explore whether the rapid falls in PTX3 levels
seen in both survivors and non-survivors reflects exhaustion of neutrophil production or
alternatively relates to monocyte-macrophage migration into the hepatic milieu.
The pentraxin family plays an important role in the handling of apoptotic cells and the
removal of cellular debris in order to prevent autoimmunity. Pentraxins efficiently bind
dying cells,(Familian and others 2001; Gershov and others 2000) and PTX3 was recently
shown to bind to the plasma membrane of maturing dendritic cells, enhancing the removal
of late apoptotic debris and minimising autoimmunity by reducing cross-presentation to T
cells.(Baruah and others 2006) Importantly, PTX3 did not prevent the presentation of
exogenous microbial ligands to T cells, demonstrating the flexibility of PTX3 when exposed
to external danger signals. These results have bearing upon paracetamol-induced
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hepatotoxicity, in which conflicting in vitro and animal data have emerged to suggest a
potential role for apoptotic cell death in the propagation of liver injury.(El-Hassan and
others 2003; Kass and others 2003; Kon and others 2004; Ray and others 1996; Zhang and
others 2000) Histological examination of explanted and post-mortem liver sections from
patients following paracetamol-induced ALF have demonstrated significant apoptotic
indices.(McGregor and others 2003) Interestingly, in one cohort study, autoantibodies were
absent in cases of paracetamol-induced ALF, compared with 43% of non-paracetamol
cases,(Bernal and others 2007b) and it may be that the extremely elevated PTX3 levels seen
following paracetamol injury may help to minimise subsequent autoimmunity.
Another important role for PTX3 is in defence against pathogens, particularly but not
exclusively as an opsonin. As described above, PTX3 exists readymade in
neutrophils,(Jaillon and others 2007) and plays a non-redundant role in the response to
certain viral, bacterial, and fungal infections.(Garlanda and others 2002). PTX3 over-
expressing mice are also more resistant to LPS toxicity and caecal ligation and puncture.
Bacteriologically proven infection is recorded in up to 80% of ALF patients and fungal
infection (predominantly candidiasis) occurs in 32%,(Rolando and others 1990; Rolando and
others 1991) and it is generally accepted that the immune response to infection is impaired
following acute liver injury. Although there were no significant differences in admission
PTX3 levels between patients developing subsequent infections and those who did not, the
rapid falls in PTX3 levels seen between day 1 and day 3-4 of admission in paracetamol
patients are intriguing, since exhaustion of PTX3 production might contribute to the high
frequency of downstream invasive bacterial or fungal infections in ALF.(Antoniades and
others 2008)
These data raise questions as to why CRP levels, a short pentraxin with diverse
proinflammatory roles including complement activation, upregulation of endothelial
adhesion molecules, and inhibition of nitric oxide synthase, should show only modest
increases despite intense hepatocyte injury. CRP is produced almost exclusively by
hepatocytes, particularly in response to IL-6, yet we found a disassociation between IL-6
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levels and CRP. Several other studies in acute liver injury patients have also noted a
discrepancy between CRP levels and the degree of systemic inflammation. This suggests that
in the presence of intense liver cell necrosis, hepatic synthesis of CRP is impaired, a
hypothesis that is supported by our observations following OLT. Izumi et al noted relatively
suppressed admission levels of CRP in 50 ALF patients, and suggested that the acute phase
response following acute liver injury is restricted due to severe hepatic synthetic
failure.(Izumi and others 1994) Izumi et al also failed to demonstrate a correlation on
admission between CRP and IL-6 levels in paracetamol patients, but did find a correlation in
patients with viral hepatitis, which suggests that the hepatic response to IL-6 may be
particularly impaired following paracetamol injury. Low postoperative CRP levels have
been shown to independently predict poor outcomes following liver resections, and are
inversely correlated with the extent of liver resection.(Rahman and others 2008) Recently, a
small case series of 7 patients with concomitant fulminant hepatic failure and sepsis
reinforced the notion that CRP levels are relatively suppressed following massive liver
injury.(Silvestre, Coelho, Povoa 2010) The lack of association between CRP levels and
eventual outcome suggests that it is the degree of systemic response to hepatic injury, rather
than the extent of hepatocyte necrosis per se, that determines outcome in this condition.
In conclusion, this observational cohort study of acute liver injury patients demonstrates
extremely elevated levels of PTX3 in patients with paracetamol-induced acute liver injury.
PTX3 correlated with the degree of systemic inflammation and with eventual outcome,
including the development of HE and requirement for OLT. Future studies should examine
the role of PTX3 in infectious complications of ALF, whilst animal models should explore
whether modulation of PTX3 affects important histological and systemic outcomes.
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Chapter 7. Conclusions and future directions
ALF is a rare but devastating condition which carries a high mortality rate. Paracetamol-
induced hepatotoxicity remains the most common cause of ALF in developed countries
including the United Kingdom. Existing prognostic scores for this condition are highly
specific, but lack sensitivity, particularly in patients who have taken an unintentional or
staggered paracetamol overdose. It is increasingly recognised that the innate immune
response to sterile tissue injury, such as paracetamol hepatotoxicity, drives systemic
inflammatory responses and results in collateral organ damage. Chapter 4 demonstrates the
strong association between the development of the SIRS, extrahepatic organ failure, and
eventual outcome following paracetamol overdose. This raises the prospect of using SIRS
and SOFA scores as highly sensitive gatekeepers to quantitatively triage paracetamol
overdose patients, and deliver tertiary level care to those most likely to require emergency
OLT.
A greater understanding of the pathophysiological links between the initial hepatic injury
and development of the SIRS could help to identify novel biomarkers for ALF, and help
guide future therapeutic avenues. Where possible, biomarkers should be widely available,
reproducible between laboratories, and cheap. Serum ferritin fulfils many of these desirable
credentials, and chapter 5 demonstrates its potential as an early biomarker of paracetamol
overdose. Chapter 6 outlines the strong association between the long pentraxin PTX3, a
humoral pattern recognition receptor, with outcome following paracetamol hepatotoxicity,
further emphasising the importance of the innate immune response in the pathogenesis of
this condition.
Future studies should expand upon the clinical significance of these novel biomarkers by
examining their diagnostic and prognostic utility in external cohorts of paracetamol-induced
acute liver injury patients, and also in toxicology centres to determine whether these
markers remain valid in populations where the majority of patients sustain only minor
organ injury. Cellular and animal-based studies should attempt to further unravel the links
between the initial hepatotoxic insult and the innate immune response to this injury.
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Acute liver failure is a devastating clinical syndrome with a persistently
high mortality rate despite critical care advances. Orthotopic liver trans¬
plantation (OLT) is a life-saving treatment in selected cases, but effec¬
tive use of this limited resource requires accurate prognostication
because of surgical risks and the requirement for subsequent life-long
immunosuppression.
Aim
To review the aetiology of acute liver failure, discuss the evidence
behind critical care management strategies and examine potential treat¬
ment alternatives to OLT.
Methods
Literature review using Ovid, PubMed and recent conference abstracts.
Results
Paracetamol remains the most common aetiology of acute liver failure
in developed countries, whereas acute viral aetiologies predominate
elsewhere. Cerebral oedema is a major cause of death, and its preven¬
tion and prompt recognition are vital components of critical care sup¬
port, which strives to provide multiorgan support and 'buy time' to
permit either organ regeneration or psychological and physical assess¬
ment prior to acquisition of a donor organ. Artificial liver support sys¬
tems do not improve mortality in acute liver failure, whilst most other
interventions have limited evidence bases to support their use.
Conclusion
Acute liver failure remains a truly challenging condition to manage,
and requires early recognition and transfer of patients to specialist cen¬
tres providing intensive, multidisciplinary input and, in some cases,
OLT.
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INTRODUCTION
Acute liver failure (ALF) is a rare disorder character¬
ized by catastrophic loss of liver cell function. It
remains one of the most challenging medical emergen¬
cies, because of the multiorgan nature of the disease,
the rapid evolution of the clinical condition, the need
for multidisciplinary supportive interventions and the
requirement for the clinician to prognosticate accu¬
rately to best utilize orthotopic liver transplantation
(OLT) as a life-saving treatment. Despite advances in
supportive care, spontaneous survival without OLT is
as low as 20%; therefore, early recognition and
prompt transfer of potential transplant candidates to
tertiary centres with intensive care and liver transplan¬
tation expertise are vital.
DEFINITION
Acute liver failure refers to the abrupt loss of hepatic
cellular function in a patient without pre-existing liver
disease, with the subsequent development of coagulop¬
athy, jaundice and encephalopathy. In 1970, Trey and
Davidson defined fulminant hepatic failure as a
'potentially reversible condition, the consequence of
severe liver injury, with an onset of encephalopathy
within 8 weeks of the appearance of the first symp¬
toms and in the absence of pre-existing liver disease'.1
However, as the initial symptoms of liver failure are
frequently nonspecific and open to subjective bias,
ALF was redefined based on the time taken to develop
hepatic encephalopathy (HE) after the first appearance
of jaundice, with the terms 'hyperacute', 'acute' and
'subacute' liver failure referring to a jaundice-to-
encephalopathy interval of 0-7, 8-28 and 29-84 days
respectively.2 This distinction is useful in guiding
prognosis as, paradoxically, the time to onset of
encephalopathy is negatively correlated with outcome
despite the increased incidence of cerebral oedema in
hyperacute liver failure. Hepatitis A and B, paraceta¬
mol and ischaemic insults typically present as hyper¬
acute liver failure, and have a relatively good
spontaneous survival rate of 36%, whereas idiosyn¬
cratic drug reactions and indeterminate causes present
later, with only a 14% survival rate without OLT.3
Severe acute liver injury, with elevated transaminases
and coagulopathy, typically precedes hyperacute liver
failure but it is HE, the cardinal feature of the progres¬
sion to ALF, which defines the condition and is of
major prognostic significance.
INCIDENCE AND AETIOLOGY
The accurate reporting of ALF is hampered by the het¬
erogeneous nature of the syndrome and by the lack of
an International Classification of Diseases code for
ALF. This means that the incidence is probably under-
reported but has been estimated at 2800 cases per
annum in the US or approximately 3.5 deaths per mil¬
lion population.4'5 Within Scotland, the incidence of
paracetamol-induced ALF has been estimated at 8.4
cases per annum per million population.6 The syn¬
drome of ALF is not a single clinical entity, and may
be precipitated by a wide variety of hepatic insults
(Table l).7 These insults have a marked geographical
and socioeconomic variation, with the most common
aetiologies in Europe and North America being parac¬
etamol and idiosyncratic drug reactions, whereas
developing countries have a higher preponderance of
acute viral aetiologies (Table 2). Specific insults also
demonstrate geographical variation, with staggered
accidental paracetamol overdoses predominating in the
US, whereas single, intentional, overdoses are more
common in the UK.8,9 The early identification, where
possible, of the underlying aetiology of ALF is crucial
as several causes of ALF, such as paracetamol (iV-ace-
tyl cysteine, NAC), Amanita phalloides poisoning
(penicillin and silibinin), fulminant hepatitis B (lami-
vudine), herpes simplex virus (HSV) (acyclovir) and
pregnancy (delivery), have specific treatments and the
prognosis between different aetiologies varies consid-
erably.10-14
CLINICAL FEATURES
The initial clinical features of ALF may be nonspecific
and may include anorexia, fatigue, abdominal pain,
jaundice and fever before progressing to HE.15 The
'type A' HE associated with ALF (types B and C HE are
associated with portosystemic bypass and cirrhosis
respectively) is graded from 1 to 4 on clinical features
and neurological signs (Table 3).16 This grading is
clinically robust, and increasing grades of HE have a
strong negative correlation with outcome. The patho¬
genesis of HE (and subsequent cerebral oedema) in
ALF is incompletely understood, and differs from the
encephalopathy observed in chronic liver disease, but
hyperammonaemia, systemic inflammation and loss of
cerebral blood flow (CBF) autoregulation all appear to
accelerate progression.17-19 Ammonia, produced
from glutamine by enterocytes, enters the systemic
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Table 1. Selected aetiologies of acute liver failure










HAV, HBV +/- HDV, HEV, HSV, human herpes virus 6, CMV, EBV, VZV, parvovirus B19,
yellow fever
Paracetamol, Amantina phalloides, tetracyclines, Bacillus cereus, CC14
Halothane, anti-tuberculous therapy, sulphonamides, coamoxiclav, macrolides, valproate,
NSAIDs, disulfiram, thalidomide, ^-interferon, HAART, Ecstasy, cocaine, herbal remedies, etc.
Ischaemic hepatitis, Budd-Chiari, right heart failure, veno-occlusive disease
Wilson's disease, acute fatty liver of pregnancy, HELLP
Autoimmune hepatitis, malignant infiltration, sepsis, heat stroke
Ciyptogenic
HAV, hepatitis A virus; HBV, hepatitis B virus; HDV, hepatitis delta virus; HEV, hepatitis E virus; HSV, herpes simplex virus;
CMV, cytomegalovirus; EBV, Epstein-Barr virus; VZV, Varicella zoster virus; HLLP, haemolysis, elevated liver enzymes and
low platelets; HAART, Highly Active Anti-Retroviral Treatment.
circulation via the portal vein, but is poorly cleared by
the failing liver, and this is exacerbated by the coexis¬
tent renal failure, reduced hepatic urea synthesis and
impaired skeletal muscle function observed in ALF.20
Astrocytes detoxify ammonia by converting it to glu-
tamine which leads to osmotic swelling; this cytotoxic
process appears to be the main pathophysiological dri¬
ver of cerebral oedema in ALF.3' 21' 22 Flyponatraemia,
frequently seen in patients with ALF, may potentiate
this process, possibly via aquaporin-4.23,24 In additio,
cerebral hyperaemia, potentially mediated by pro¬
inflammatory cytokines, increases intracranial blood
volume, further compromising cerebral perfusion.25,26
Interestingly, case reports have directly implicated
liver-derived toxins in this process.27
The evolution to grade III/IV HE is a grave prognos¬
tic sign as this group is at risk of intracranial hyper¬
tension and subsequent brain herniation.28 In addition,
intracranial hypertension compromises cerebral perfu¬
sion pressure (CPP), defined as the difference between
mean arterial pressure and intracranial pressure (1CP).
A CPP >60 mmHg is considered crucial to maintain
normal neurological functioning and periods >2 h
with a CPP <40 mmHg is considered by some centres
to preclude liver transplantation.5 Clinical signs sug¬
gestive of increasing 1CP include worsening of HE,
systemic hypertension and bradycardia (Cushing
reflex), altered pupillary reflexes and decerebrate
rigidity. All of these clinical signs occur late in the
clinical course, when therapeutic interventions may be
ineffective, and this has led to the direct monitoring of
ICP in patients with ALF.
Intracranial pressure monitoring
The use of ICP monitoring in ALF remains controver¬
sial, because of the lack of consensus over treatment
goals, the associated risks of bleeding and infection
and the lack of randomized trial data supporting
improved survival. However, continuous monitoring
permits rapid, targeted treatment to be initiated and
several groups now include ICP monitoring as part of
their standard ALF protocol, particularly in potential
OLT candidates.5,29 Intracerebral bleeding occurs in 8-
10% of cases, although fatal bleeds occur considerably
less frequently.30,31 Calculation of cerebral oxygen
consumption using a jugular bulb catheter may pro¬
vide additional information through continuous, indi¬
rect assessment of CBF.32 This involves the retrograde
passage of a fine-bore catheter into the jugular vein
until the tip reaches the jugular bulb; venous satura¬
tions >85% (normal range 55-70%) represent a hype-
raemic cerebral circulation.
Treatment for raised ICP
The goal of medical management of cerebral oedema
should be to maintain the ICP <20 mmHg and the CPP
>70 mmHg, by reducing brain volume or CBF. Basic
manoeuvres include elevation of the head of the bed
to no more than 30° and minimizing painful stimuli
including suctioning.33 Hyperventilation produces, at
best, a transient restoration of CBF autoregulation by
lowering PaC02; however, its prolonged use in ALF
patients has been questioned.34 Established therapies
Aliment Pharmacol Ther 31, 345-358
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for raised ICP include the use of mannitol and barbit-
uates such as thiopentone.35,36 More limited evi¬
dence supports the use of hypertonic saline, propofol
sedation and indomethacin.37,38 Unrandomized stud¬
ies from Edinburgh have advocated the use of mod¬
erate hypothermia (32-33 °C) in advanced ALF as a
means of reducing ICP prior to, and during, trans¬
plantation, and this appears to offer a therapeutic
option which targets many of the proposed triggers
for elevated ICP in ALF.20,39-41 Further studies are
required to clarify the optimal extent and duration of
hypothermia and to exclude a negative impact from




Acute liver failure is characterized by a hyperdynam¬
ic circulation, with markedly reduced systemic vascu¬
lar resistance, increased cardiac output and
hypotension, which frequently necessitates vasopres¬
sor support in addition to fluid repletion.42 As yet,
the optimal fluid and vasopressor strategy remains
uncertain, but most centres use crystalloid resuscita¬
tion followed by norepinephrine infusions to main¬
tain adequate perfusion pressures and cerebral
oxygenation, although this strategy may not signifi¬
cantly improve oxygen delivery.43 Overzealous nor¬
epinephrine use should be avoided as this may
exacerbate cerebral hyperaemia because of the loss
of CBF autoregulation in ALF.44 Terlipressin, a vaso¬
pressin synthetic analogue, has been evaluated in
two small studies which produced conflicting results
regarding its effects on CBF, ICP and systemic hae-
modynamic parameters.45, 46
Critical illness-related corticosteroid insufficiency
(CIRCI) may exacerbate the haemodynamic instability
seen in ALF, with a negative correlation between ill¬
ness severity and the response to short synacthen
testing in a cohort of 45 patients with acute liver
injury.47 Corticosteroid treatment of patients with
low baseline Cortisol levels ('hepatoadrenal syn¬
drome') in a liver intensive care unit resulted in
reduced vasopressor requirements and mortality, but
it is worth noting that adrenal insufficiency was
commoner in patients with chronic liver disease or
post-OLT in this study than in the ALF patients.48
There is insufficient evidence at this stage to recom¬
mend routine treatment of CIRCI in liver patients,
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Table 3. Classification of hepatic encephalopathy148
HE Grade Mental status Neurological signs EEG GCS
I Trivial lack of awareness; euphoria or Slight tremor; apraxia; Usually 15
anxiety; shortened attention span; incoordination normal
impairment of addition/subtraction
II Lethargy or apathy; disorientation for Asterixis; ataxia; Generalized 11-15
time; obvious personality change; dysarthria slowing
inappropriate behaviour
III Somnolence to semi-stupor; responsive Asterixis; ataxia Abnormal 8-11
to stimuli; confused; gross disorientation;
bizarre behaviour
IV Coma; unable to test mental state Decerebration Abnormal <8
EEG, electroencephalogram; GCS, glasgow coma scale.
and the use of synacthen tests to diagnose CIRCI is
not recommended.49
Radiographic changes suggestive of pulmonary
oedema occur in a high proportion of ALF cases, and
the development of severe acute lung injury is associ¬
ated with a poor prognosis.50'51 Treatment of ARDS
using a protective ventilatory strategy is more prob¬
lematic in ALF because increases in positive end expi¬
ratory pressure may exacerbate cerebral oedema and
hepatic congestion.7
Renal failure in ALF is multifactorial, and is related
to acute tubular necrosis, hypoperfusion, use of con¬
trast agents and, in paracetamol-induced ALF, direct
nephrotoxicity.52 The systemic inflammatory response
syndrome (SIRS) has recently been shown to predict
renal dysfunction in nonparacetamol-induced ALF.53
Management should focus on prevention of renal fail¬
ure by maintaining adequate systemic blood pressure,
prompt identification and treatment of infections and
judicious use of contrast agents, because once estab¬
lished, the prognosis is considerably poorer. Continu¬
ous, rather than intermittent, methods of
extracorporeal support are preferred to minimize cir¬
culatory and cerebral fluctuations.54 Hypophosphata-
emia is associated with renal failure in ALF and may
also be linked to hepatic regeneration; persistently ele¬
vated phosphate levels may reflect failure of this
regenerative process and have been associated with a
poorer prognosis in paracetamol-induced ALF.55,56
Reduced hepatic glycogen stores and hyperinsulina-
emia contribute to hypoglycaemia, which complicates
up to 40% of ALF cases, and continuous glucose
administration is frequently required. Oral or enteral
feeding is vital, but the markedly increased energy
expenditure observed in ALF makes adequate nutri¬
tional support difficult to institute effectively in estab¬
lished liver failure.57
COAGULOPATHY
The coagulopathy of ALF is complex and remains
poorly characterized, but is undoubtedly of prognostic
significance.58"60 ALF is characterized by prolongation
of prothrombin time and quantitative and qualitative
platelet dysfunction and, in paracetamol-induced ALF,
hypofibrinogenaemia and reductions in coagulation
factors 11, V, VII and X.61 Flowever, despite the sever¬
ity of the coagulopathy, clinically significant sponta¬
neous bleeding is relatively unusual in ALF, even
during liver transplantation.62,63 The defective pro¬
duction of procoagulant factors is compensated for in
part by underproduction of anticoagulant proteins pro¬
tein C, protein S and antithrombin 111, whilst factor
VIII production is upregulated, possibly in extrahepatic
sites.64, 65 Plasminogen activator inhibitor-1 levels are
grossly elevated in ALF, suggesting hypofibrinolysis;
this was supported by a recent murine study where
heparin pre-treatment significantly reduced hepatic
fibrin deposition following paracetamol poisoning and
significantly attenuated paracetamol-induced hepato-
toxicity.66, 67 The bleeding risk in ALF has been over¬
stated, and the prophylactic administration of large
volumes of fresh frozen plasma (FFP) in ALF is unnec¬
essary, interferes with prognostic scoring systems and
may worsen cerebral oedema or volume overload.68, 69
Several pilot studies have suggested that recombinant
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factor VII may be superior to FFP for clinically signifi¬
cant bleeding in ALF, but further evaluation is
required before this expensive treatment can be uni¬
versally recommended.70,71 At present, FFP, platelet
and cryoprecipitate infusions should be reserved for
use in actively bleeding patients or prior to planned
invasive procedures.72
INFECTION
The SIRS and, when precipitated by infection, sepsis
have been shown to have a strong negative impact on
HE progression, renal function and mortality in
ALF.19'53'75 Bacteraemia is present in up to 80% of
ALF patients who have enhanced susceptibility to
infection because of the presence of indwelling lines
and catheters, impaired complement and opsonization
function and impaired innate immunity.74 The major¬
ity of infections are caused by Gram-negative enteric
organisms, staphylococci and fungal infections.75,76
The role of bacterial gut translocation, important in
cirrhosis, is unclear at present, as prospective random¬
ized trials of oral and enteral gut decontamination in
ALF have failed to add additional benefit over paren¬
teral antibiotic regimens alone.77-79 Fungal infections
are commonly underrecognized and are particularly
important in ALF patients who have received pro¬
longed courses of antibiotics or have renal dysfunc¬
tion.76 Close surveillance for infection should be
maintained in all ALF patients with frequent chest
radiographs and cultures of blood, urine and sputum,
but prophylactic antibiotics should probably be
reserved for patients with high-grade encephalopathy
and renal dysfunction or for those awaiting OLT.69,78
SPECIFIC THERAPIES IN ALF
N-acetyl cysteine
When used early as an antidote after a single, inten¬
tional paracetamol overdose, NAC is extremely effec¬
tive at replenishing hepatic glutathione stores and
preventing severe IV-acetyl-p-benzoquinone imine-
induced hepatotoxicity and liver failure.10 The evi¬
dence for NAC in patients with established hepatotox¬
icity or ALF is less robust, and is based on a
retrospective study from King's College Hospital and a
small randomized controlled trial from the same cen¬
tre.80, 81 Initial studies suggested that NAC improved
oxygen deliveiy and consumption in ALF, but this
assertion has subsequently been challenged.82,83 Fur¬
thermore, the optimal duration of NAC therapy
these patients is unclear, as prolonged NAC therapy
was recently shown to impair murine liver regenera¬
tion and worsen outcome following paracetamol poi¬
soning.84 The benefit of NAC in nonparacetamol-
induced ALF is also unclear, and although it appears
to confer benefit in children, a recent multicentre ran-
domized-controlled trial (RCT) in adults only demon¬
strated improvement in spontaneous survival in a
subgroup of patients with Grade I—II HE.85, 86
Penicillin and silibinin
Mycetismus (mushroom poisoning), most commonly
from Amanita genus mushrooms, is a medical emer¬
gency. Amantinin toxin, recycled via the enterohepat-
ic circulation, interrupts hepatocyte messenger RNA
synthesis and causes dose-dependent hepatotoxicity.
Initial promising reports describing charcoal haemop-
erfusion in the treatment of Amanita poisoning have
not been replicated.87 Penicillin G (250 mg/kg/day)
and silibinin (20-50 mg/kg/day), although never sub¬
jected to an RCT, appear to be effective when admin¬
istered early in the course of the disease, but severe
cases may require emergency OLT.11,88
Lamivudine
A small proportion of patients with acute hepatitis B
proceed to develop ALF, which occasionally necessi¬
tates OLT. Previous case reports utilized foscarnet in
the treatment of fulminant hepatitis B, but increasing
attention is being given to nucleoside analogues in
this condition.13,89-91 However, an RCT of lamivudine
involving 71 patients with acute hepatitis B (three of
whom had HE) failed to demonstrate any significant
clinical benefit in the lamivudine arm.12
Delivery of pregnant ALF patients
The syndrome of haemolysis, elevated liver enzymes
and low platelets (HELLP) and acute fatty liver of
pregnancy (AFLP) are the pregnancy-related liver dis¬
orders most commonly associated with ALF, although
pre-eclampsia can occasionally result in hepatic rup¬
ture and infarction. There is increasing evidence that
pre-eclampsia, HELLP and AFLP represent a spectrum
of the same disease, with similar clinical and patho¬
physiological correlations including increased vascular
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tone and platelet aggregation.92 Foetal deficiency of
the mitochondrial enzyme long-chain 3-hydroxyacyl-
CoA dehydrogenase (LCHAD) results in maternal accu¬
mulation of medium- and long-chain fatty acids, and
similar mutations of the mitochondrial trifunction pro¬
tein have been linked to both HELLP and AFLP.93-95
Pre-eclampsia, HELLP and AFLP all carry significant
risk of both maternal and foetal mortality, and severe
cases should be managed in tertiary centres capable of
dealing with the potential obstetric and hepatic
complications. The mainstay of treatment of all the
three conditions is deliveiy, but close postpartum
observations of both mother and infant are important
to detect any haemorrhagic complications or contin¬
ued clinical or biochemical deterioration, which
can occasionally necessitate postpartum emergency
Olt96-"
Acyclovir
Whilst HSV has high seroprevalence amongst the gen¬
eral population, HSV-related hepatitis is a rare cause
of ALF (1.4°/o in one 13-year cohort study) and is most
commonly, but not exclusively, seen amongst immu-
nosuppressed and pregnant patients.100 The diagnosis
of HSV-ALF is frequently made late, with a resultant
high mortality rate. As the characteristic vesicles are
often absent, a high index of suspicion must be main¬
tained to screen for potential cases amongst young,
immunosuppressed, or pregnant individuals presenting
with fever and transaminitis, as prompt treatment with
intravenous acyclovir is safe and has shown benefit in
several cases.14' 101
Plasmapheresis and D-penicillamine
Fulminant Wilson's disease represents a rare, but
important cause of ALF, and the diagnosis can be inti¬
mated by the presence of a low alkaline phosphatase
to bilirubin ratio, AST:ALT ratio >2.2 and haemolytic
anaemia.102' 103 Isolated cases report the successful use
of plasmapheresis and chelation therapy in the treat¬
ment of fulminant Wilson's disease, although these
remain a bridge to transplantation rather than defini¬
tive therapies.104' 105 Plasmapheresis appears to reduce
arterial ammonia levels, and has occasionally been
utilized in the treatment of aetiologies of ALF other
than Wilson's disease, but the side effects of treatment
can be significant and no mortality benefit has been
demonstrated to date.101'-108
Other treatments
Other treatments such as insulin/glucagon, prostaglan¬
din E2 and corticosteroids (even in fulminant autoim¬
mune hepatitis) have failed to show significant benefit
in ALF and are not recommended.82' 109~112 A recent
RCT of L-ornithine-L-aspartate (LOLA) in ALF patients,
predominantly with acute viral hepatitis, found LOLA
to be ineffective in reducing either ammonia levels or
mortality rates, with a trend towards increased seizure
rates in the LOLA arm.113
Artificial and bioartificial liver devices
Liver assist devices have received much attention over
recent years in the hope that they can provide an
effective 'bridge' to transplantation or recovery of liver
function. The initial artificial liver support devices
were essentially filters designed to remove toxins
through haemodialysis or adsorption using charcoal,
and failed to show a survival benefit in A1F.114 The
MARS (Molecular Absorbent and Recirculating System)
utilizes a hollow fibre, double-sided, albumin-impreg¬
nated dialysis membrane to extract protein-bound tox¬
ins into the albumin dialysate.108 Initial reports
suggested improvements in both systemic and cerebral
haemodynamic parameters and improvements in HE in
patients with ALF and acute-on-chronic liver fail¬
ure.115-118 More advanced systems, such as Prome¬
theus, involve fractionated plasma separation and
adsorption, whilst bioartificial liver systems include
living human or porcine hepatocytes incorporated in
an extracorporeal circuit to add synthetic function to
the process of detoxification. At least 12 RCTs of these
devices have been performed and they have been sys¬
tematically reviewed twice; overall, these devices
improve HE but have no mortality benefit in ALF,
but may improve outcome in acute-on-chronic liver
failure.119' 120
Liver transplantation
Although never subjected to an RCT, OLT has been
recommended for the treatment of ALF since 1983.121
Emergency OLT for ALF now accounts for 5-12% of
all liver transplantation activity and is the only treat¬
ment to date to alter substantially the mortality result¬
ing from the condition.122 Patient survival following
OLT for ALF is generally poorer than that in those
transplanted for chronic liver failure, particularly in
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the setting of pre-transplant renal failure, but is of the
order of 65-80% 1 year survival.123-125 Alternatives to
standard OLT are being refmed, including living donor
grafts and auxiliary liver transplantation (where part
of the native liver is left in situ after partial liver
transplantation in the hope that native liver regenera¬
tion can permit later cessation of immunosup¬
pression). 12f>' 127 Whilst a promising therapy for
paracetamol-induced ALF, auxiliary transplantation
fails to remove the diseased native liver, leading to
concerns over continuing haemodynamic and neuro¬
logical instability. The limited timescales and the dra¬
matic nature of the disease progression involved mean
that the possibility of coercion of potential living
donors in the setting of ALF is of significant ethical
concern. In addition, ALF patients are at particular risk
of small-for-size syndrome and therefore the larger
right lobe from the donor is usually transplanted,
increasing the risk of donor morbidity or mortality.128
PROGNOSTICATION TO GUIDE OLT IN ALF
The decision to list emergently an ALF patient for OLT
is rarely easy - the inherent risks associated with
delaying listing for OLT must be balanced against the
potential for spontaneous recovery with medical ther¬
apy alone, the risks of surgery in the context of an
acute critical illness, the scarcity of donor grafts and
the requirement (except after auxiliary liver transplan¬
tation) for life-long immunosuppression.127 Further¬
more, up to 60% of paracetamol-induced ALF patients
meeting poor prognostic criteria are deemed unsuitable
to undergo OLT because of coexistent psychiatric or
medical conditions that are likely to preclude long-
term graft and/or patient survival, such as resistant
alcohol or drug dependence, or previous persistent
treatment noncompliance.129 Accurate prognostication
in ALF is therefore vital, and many proposed mathe¬
matical, serological, radiological and histological vari¬
ables have been proposed, including the MELD (Model
for End-stage Liver Disease) score, which has improved
organ allocation in chronic liver disease
(Table 4).130' 131 Major methodological flaws exist with
many of these studies, which are often unblinded, ret¬
rospective and prone to spectrum bias.132 Furthermore,
many authors equate liver transplantation with death,
falsely elevating the positive predictive value of the
test in question.133 In 1989, O'Grady et al. developed
the 'King's College criteria' from a retrospective cohort
of 588 patients with grade II—IV HE admitted to that
Table 4. Alternative prognostic variables suggested for use in acute liver failure
Prognostic
variable Aetiology Predictor of poor prognostic outcome Sensitivity Specificity Refs
KCC All See Table 5 69 92 58
Clichy criteria All HE + Factor V < 20°/o (age <30 year) - - 149
or <30% (age >30 year) 86 76 60
Grade III—IV HE + Factor V < 20%
Factor V; factor Paracetamol Factor VIII/V ratio >30 91 91 150
VIII/V ratio Factor V < 10% 91 100
Phosphate Paracetamol P043" > 1.2 mmol/L on day 2 or 89 100 56,
3 postoverdose
APACHE II All APACHE II >19 68 87 8
Gc-globulin All Gc-globulin <100 mg/L 73 68 152
Paracetamol 30 100
Nonparacetamol
Lactate Paracetamol Admission arterial lactate >3.5 or 81 95 134
>3.0 mmol/L after fluid resuscitation
a-Fetoprotein Paracetamol AFP <3.9 pg/L 24 h postpeak ALT 100 74 153
MELD Paracetamol MELD >33 at onset of HE 60 69 154
Nonparacetamol MELD >32 76 67 155
KCC, King's College Hospital poor prognostic criteria; MELD, Model for End-stage Liver Disease; HE, hepatic encephalopathy;
APACHE II, Acute Physiology and Chronic Health Evaluation II; AFP, alpha fetoprotein.
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Table 5. The KCH poor prognostic criteria for paracetamol and nonparacetamol acute liver failure aetiologies as applied in
the UK as transplant criteria58, 134
Paracetamol Modified criteria
List for transplantation if:
Arterial pH <7.3
Or all 3 of the following occur within
a 24-h period:
Grade III-IV HE
PT >100 s (INR >6.5)
Serum creatinine >300 pmol/L
Nonparacetamol
Strongly consider listing for OLT if:
Arterial lactate >3.5 mmol/L after early fluid resuscitation
List for transplantation if:
Arterial pH <7.3, or arterial lactate >3.0 mmol/L after adequate
fluid resuscitation
List for transplantation if all 3 of the following occur within a
24-h period:
Grade III-IV HE
PT >100 s (INR >6.5)
Serum creatinine >300 pmol/L
List for transplantation if:
PT >100 s (INR >6.5) irrespective of HE grade
Or any 3 of 5 of the following:
Unfavourable aetiology: (seronegative hepatitis, Wilson's disease, idiosyncratic drug reaction, halothane)
Age <10 or >40 years
Jaundice to encephalopathy interval >7 days
PT >50 s (INR >3.5)
Bilirubin >300 pmol/L
HE, hepatic encephalopathy; OLT, orthotopic liver transplantation; PT, prothrombin time.
institution.58 The criteria recognize the prognostic
importance of the aetiology of ALF, with separate cri¬
teria for paracetamol-induced ALF and other aetiolo¬
gies (Table 5). These criteria are remarkable for their
robustness and accuracy despite numerous attempts to
improve their diagnostic accuracy (Table 4). The par¬
acetamol criteria have recently been modified by the
addition of lactate, although several authors have
questioned the overall benefit of this modification.134"
136 The King's College criteria have also been criticized
for its low sensitivity and negative predictive value,
particularly for nonparacetamol aetiologies.137
CONCLUSIONS
Acute liver failure remains a truly challenging condi¬
tion to manage, and requires close surveillance for
incipient organ failure and early transfer of patients to
specialist centres offering intensive multidisciplinary
input to manage effectively the myriad complications
of the syndrome, and, in some cases, to offer liver
transplantation. The rarity of the syndrome presents
difficulties in performing RCTs and developing a true
evidence base for many of the interventions outlined
in this review. The future challenges are to further elu¬
cidate the pathophysiology behind liver cell death and
the ensuing multiorgan failure of ALF, which in turn
may help improve prognostic models. Further multi¬
centre controlled trials of artificial and bioartificial
liver support systems are needed before recommenda¬
tions can be made regarding their clinical utility in
ALF. Effective reduction of ammonia levels remains an
attractive, but currently elusive, therapeutic goal in
ALF.
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SUMMARY
Background
Paracetamol (acetaminophen) toxicity remains the leading cause of
acute liver failure (ALF) in the developed world. In the UK, the recently
modified King's College Criteria are used to list patients for emergency
liver transplantation, but these criteria have been criticized for their low
sensitivity and for spectrum bias in their application.
Aim
To evaluate existing prognostic criteria critically for predicting death
without transplantation in paracetamol-induced ALF.
Methods
MEDLINE, EMBASE and CINAHL were searched to identify studies con¬
taining adult patients with paracetamol-induced ALF. Selected studies
were evaluated and data were pooled if appropriate, to calculate sensi¬
tivity, specificity and diagnostic odds ratios (DORs) of applied prognos¬
tic tests.
Results
Of 6507 studies identified, 14 were eligible for inclusion, evaluating
1960 patients. The original King's College Criteria had a pooled sensitiv¬
ity of 58.2% and specificity of 94.6%, with a DOR of 27.7. Addition of
arterial lactate to the King's College Criteria reduced the DOR to 26.1.
Several other clinical and laboratory variables had higher DORs than
the King's College Criteria, but were only evaluated in single studies of
limited quality.
Conclusions
The original King's College Criteria remain well-validated criteria with
high prognostic accuracy. Other potential prognostic variables should
be prospectively assessed in multicentre studies to refine the criteria
further.
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INTRODUCTION
Paracetamol (acetaminophen) toxicity remains the
leading cause of acute liver failure (ALF) in the devel¬
oped world, accounting for over 40°/o of cases in
selected case series.1' 2 Whilst a vast majority of
patients recover spontaneously following paracetamol
overdose, a small number develop severe acute liver
injury, hepatic encephalopathy (HE) and consequently,
ALF. Despite significant advances in supportive care,
the only effective treatment for the condition remains
emergency orthotopic liver transplantation (OLT).3
The decision to transplant a patient with paraceta¬
mol-induced ALF involves balancing the inherent risks
associated with delaying listing for OLT against the
potential for spontaneous recovery with medical ther¬
apy alone, the risks of surgeiy in the context of a rap¬
idly evolving critical illness, the scarcity of donor
grafts and the requirement for lifelong immunosup¬
pression. Furthermore, the psychosocial implications of
paracetamol overdose cases are considerable, with over
30% of patients who fulfil transplant criteria unsuit¬
able for OLT because of severe psychological illness or
coexistent chronic alcohol or drug dependency.4 Accu¬
rate prognostication in ALF is therefore vital to utilize
OLT effectively and prevent unnecessary transplanta¬
tion, whilst procuring donor organs in a timely fash¬
ion for those most likely to benefit.
In 1989, O'Grady eta/.5 developed the 'King's Col¬
lege Criteria' (KCC) in an attempt to determine which
patients with paracetamol and nonparacetamol-
induced ALF have a poor prognosis with medical ther¬
apy alone and will therefore benefit most from OLT.
The original KCC for paracetamol-induced ALF were
highly specific, but have been criticized for their rela¬
tively low negative predictive value6 and, as up to
26% of patients with paracetamol toxicity are medi¬
cally unfit to undergo surgery at the point they fulfil
the KCC,4 modifications to these criteria now utilize
arterial lactate (>3.5 mmol/L after early fluid resusci¬
tation or >3.0 mmol/L after adequate fluid resuscita¬
tion) in an attempt to extend the time-window for
acquisition of a suitable graft.7
Over recent years, a plethora of alternative prognos¬
tic variables have been proposed in an attempt to
improve or replace the KCC. These criteria variously
involve radiological,8 histological,9 serological,10, 11 or
mathematical12"14 indices, but their assessment is
complicated by the use of OLT; for reasons of the
inevitably imperfect nature of current listing criteria, a
Aliment Pharmacol Tiber 31, 1064-1076
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small proportion of ALF patients are transplanted who
would have spontaneously survived, invalidating fur¬
ther assessment of that particular patient. Studies eval¬
uating the prognostic accuracy of a particular variable
should therefore exclude transplanted patients from
subsequent analysis. The purpose of this systematic
review was to evaluate critically existing prognostic
criteria for predicting death without transplantation in
paracetamol-induced ALF, to update previous studies
in this area15, 16 and to examine the accuracy of
recently described prognostic variables.
METHODS
Search strategy and study selection
We conducted a systematic review of the medical lit¬
erature using MEDLINE (1950 to June 2009), EM-
BASE (1980 to June 2009) and CINAHL (1982 to
June 2009) to identify studies recruiting adult (>age
16 years) patients that evaluated prognostic markers
of paracetamol-induced ALF. Potential studies were
identified by combining the search terms 'acetamino¬
phen' and 'paracetamol' (as both Medical Subject
Headings (MeSH) and free text terms) using the set
operator OR. Prognostic studies of ALF were identi¬
fied and combined using the set operator OR, by
using the terms 'Kings adj3 College adj3 Criteria',
'Clichy$', 'APACHES', 'lactate', 'Gc-globulin', 'alpha-
fetoprotein', 'phosphate' and 'MELD' (all free text
terms) and the McMaster expert search strategy for
prognostic studies. These studies were combined
using the set operator AND with papers evaluating
studies on 'liver failure', 'hepatic encephalopathy' or
'liver failure, acute' (all MeSH). The search was lim¬
ited to human studies without language restrictions.
Abstracts of the studies identified by the initial
search were evaluated for appropriateness to the
study question by two independent reviewers (DC,
KS) and all potentially relevant papers were obtained
and evaluated in detail. The bibliographies of these
studies and relevant review articles were screened to
perform a recursive search of the literature, and
abstract books of international liver conferences from
the preceding 4 years were hand-searched for poten¬
tially relevant studies.
Selected studies were required to report mortality
data on cohorts of patients admitted to hospital with
acute severe liver injury or ALF secondary to paraceta¬
mol overdose (see Table 1 for study eligibility
1066 D. G. N. CRAIG et al.
Table 1. Eligibility criteria for included studies
Adult patients (aged >16 years) presenting with acute severe
liver injury or ALF attributed to paracetamol hepatotoxicity
Cohort studies
Included >25 patients with paracetamol hepatotoxicity
Mortality data recorded
Data for death and liver transplantation considered
separately
criteria). Acute severe liver injury was defined as
severe hepatotoxicity [serum alanine aminotransferase
(ALT) levels >1000 U/mL and co-existent coagulopa¬
thy], whilst ALF required the additional presence of
FIE, in patients without pre-existing liver disease.
Unselected cohorts of patients with mixed aetiologies
of acute liver injury were eligible for inclusion if sepa¬
rate data for paracetamol overdose patients were avail¬
able. Case control studies and studies comparing ALF
patients with chronic liver disease patients were
excluded because of potential bias in favour of the
prognostic variable in question,17 as were studies
where transplantation and death were combined as a
single end-point. Studies were required to include
more than 25 patients with paracetamol-induced acute
liver injury, as a majority of studies in this area
include the KCC as a prognostic variable in addition to
the main variable studied, and smaller studies may
invalidate analysis.18 All potential articles were
assessed independently by two researchers according
to eligibility criteria, which were defined prospectively
and disagreements were resolved by consensus.
Data extraction and quality assessment
Data were extracted using predesigned forms by two
separate reviewers (DC and KS) on to a Microsoft Excel
spreadsheet (Microsoft Corp, Redmond, WA, USA), and
any discrepancies were resolved by consensus. The fol¬
lowing data were extracted for each study: setting,
country and geographical region, year(s) conducted,
retrospective or prospective design, inclusion criteria,
definitions of paracetamol-induced liver injury, defini¬
tions of ALF, total number of subjects included, total
number of subjects with paracetamol-induced ALF or
acute liver injury, total number of subjects with parac¬
etamol-induced ALF transplanted, duration of follow-
up, prognostic score used, timing of application of the
prognostic score and outcome definitions. Study qual¬
ity was assessed semi-quantitatively according to six
potential sources of bias that can be encountered in
studies of prognostic variables19 and a grade (poor,
moderate, good or excellent) allocated (Table 2).
Data synthesis and analysis
Prognostic tests evaluating the outcomes of survival
without transplantation or death without transplanta¬
tion following paracetamol-induced liver injury were
assessed individually. From each study cohort, we
extracted total number of subjects dying without OLT,
total number of subjects surviving without OLT and
total number of subjects fulfilling or not fulfilling the
prognostic variable in question, and constructed 2x2
contingency Tables. The sensitivity, specificity and
diagnostic odds ratio (DOR) with their 95% confidence







Study population adequately represents the population of interest; source population
adequately described; sampling timeframe, place and period of recruitment described;
inclusion and exclusion criteria described
Adequate study completion rate; loss to follow-up not associated with key characteristics;
reasons for loss to follow-up described; no important differences between participants
completing/not completing study
Prognostic measure clearly defined; continuous data reported and any cut-points described
and appropriate; method and setting of measurement of prognostic factor identical for all
patients; adequate proportion of study population has prognostic factor measured
Clear definition of outcome measure of interest described and recorded, including duration
of follow-up; outcome measure valid; outcome measure identical
All important confounders measured and accounted for at all stages of study design,
performance and analysis
Sufficient presentation of data to permit assessment of analytical analysis; appropriate
model-building, study design etc.; no selective reporting of results
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intervals (CIs) were calculated for each test using
Microsoft Excel (Microsoft Corp) and checked using
Meta-DiSc version 1.4 (Universidad Complutense,
Madrid, Spain). The value of a DOR ranges from zero
to infinity, with higher values indicating better dis¬
criminatory test performance and is calculated from
the following formula: sensitivity/(l - sensitivity)/
(1 - specificity)/specificity.20 Where required, a zero
cell correction of 0.5 was added to all cells to prevent
computational problems arising where proportions
were equal to zero.21 Where two or more studies anal¬
ysed a particular prognostic marker, data were pooled
using a random effects model and the pooled DOR cal¬
culated. Heterogeneity between studies was assessed
using the I2 statistic with a cut off of 50%, and the y2
test with a P-value <0.10, used to define a statistically
significant degree of heterogeneity. We explored study
setting and study design as potential reasons for
heterogeneity.22 These are exploratory analyses only
and the results should therefore be interpreted with
caution.
RESULTS
The search strategy identified 6507 studies of which 105
were potentially eligible for inclusion and were
retrieved for further analysis (Figure 1). Of these, 14
were considered eligible for inclusion5, 7" 10, 23-33
including two studies published in abstract form
only.32' 33 Characteristics of included studies are
Figure 1. Flow diagram of
assessment of studies identi¬
fied in the systematic review.
provided in Table 3. Cohen's kappa test for inter-obser-
ver agreement was excellent at 0.86 (95% CI 0.75-0.98).
The eligible studies evaluated a total of 1960 patients
with paracetamol-induced acute liver injury or ALF.
Three10, 24, 27 studies had complete temporal overlap
with other studies from the same unit; however, these
studies were included for their evaluation of unique
prognostic markers separate to the KCC. There was only
one multicentre study.29 Five25' 26, 28' 31' 32 studies
evaluated patient cohorts retrospectively, whereas
five10, 26, 27' 30, 33 studies developed prognostic test
thresholds retrospectively [usually from receiver opera¬
tor characteristics (ROC) curve analysis]. No study
blinded observers to patient outcome or other poten¬
tially confounding prognostic data and only two5' 7 val¬
idated their prognostic marker in a separate cohort.
Consequently, six24"26, 31-33 of the 14 studies were
graded as poor and seven5' 7' 10' 23' 28-30 as moderate
quality (Table 3). The 14 eligible studies analysed a total
of 22 different prognostic markers or variations thereof.
The sensitivity, specificity and DORs of these are
reported in Table 4.
King's college criteria
A total of 13 studies evaluated the original KCC for
paracetamol-induced ALF, either as separate elements
[arterial pH <7.3 or concurrent grade III/IV HE, serum
creatinine >300 pmol/L and prothrombin time (PT)
>100 s]5, 25 or as a whole,7' 10' 23, 24' 26-32 including a
'
Studies eligible for inclusion (n = 14)
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total of 1929 patients. One study29 evaluated the KCC
only on admission. After exclusion of studies with
complete temporal overlap with other studies,10' 24, 27
pooled specificity of the KCC was high, at 94.6% (95%
CI 93.0-95.9), but the pooled sensitivity was relatively
poor at 58.2% (95% CI 53.1-63.3). The pooled DOR for
the KCC was 27.7 (95% CI 9.2-83.5; Table 4). The
summary ROC curve is shown in Figure 2. The area
under the curve (ADC) was calculated as 0.91 (95% CI
0.79-0.99), suggesting good performance of the KCC
overall.34 The accuracy of the KCC improved when
studies originating from King's College Hospital (KCH)
were analysed separately from those outside KCH
[DOR 43.9 (95% CI 17.6-109.3) for KCH-based studies
vs. DOR 16.5 (95% CI 3.5-77.8) for non-KCH-based
studies]. Statistically significant heterogeneity
(I2 = 87%) existed between individual study results,
although this fell to 79% after exclusion of the single
multicentre study,29 and to 64% after exclusion of
studies from outside KCH.
Lactate modifications to the KCC
The original study7 that evaluated arterial lactate in
the prognosis of paracetamol-induced ALF reported
similar specificity, but improved sensitivity, when
compared with the original KCC. However, two30' 32
subsequent studies evaluating arterial lactate alone
failed to replicate this high prognostic accuracy
(Table 4), with pooled DORs of 12.2 (95% CI 4.0-37.4)
and 22.8 (95% CI 2.5-210.0) for the early and postre-
suscitation lactate values respectively. This was mainly
because of the reduced specificity seen in the two
studies from outside KCH. Combination of the KCC
with a postresuscitation lactate value >3.0 offered a
higher prognostic accuracy in the original lactate
study,7 but this was not replicated in a subsequent
evaluation.!H
Other prognostic markers
Several other markers, all evaluated in single studies,
appeared to offer improved prognostic accuracy when
compared with the KCC, with low-serum alpha-feto-
protein (AFP) (DOR 419.1),10 24-h post-admission
Acute Physiology and Chronic Health Evaluation II
(APACHE II) score (DOR 143.0),27 serum interleukin-6
(IL-6) levels (DOR 66.0),33 Model for End-Stage
Liver Disease (MELD) score (DOR 58.8),31 and serum
phosphate (DOR 33.9)28 all outperforming the KCC
Aliment Pharmacol Ther 31, 1064-1076
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Figure 2. Summary receiver operator curve (SROC) of
studies evaluating the original KCC. AUC, area under the
curve; S.E., standard error; Q, heterogeneity.
(Table 4). However, further studies would be required
to replicate these findings to confirm or refute
whether these other markers are indeed superior to
the KCC.
DISCUSSION
This systematic review and meta-analysis has demon¬
strated that the original KCC for paracetamol-induced
ALF have high pooled specificity (94.6%), but low
pooled sensitivity (58.2%) in determining prognosis in
patients with paracetamol-induced ALF. Additionally,
the benefit of the arterial lactate modifications to the
KCC7 is questionable according to these data. Other
proposed prognostic markers, in particular AFP,
APACHE II scores and serum IL-6 levels, showed
encouraging prognostic accuracy, but were only evalu¬
ated in single studies of variable quality.
This review is limited by the quality of the
included studies, which had significant heterogeneity
and were generally of poor or moderate quality, with
only two5' 7 studies validating their prognostic model
prospectively in a separate cohort. ALF is a rare syn¬
drome and, as a result, many studies were small and
retrospective in nature. Continuous variables were
frequently analysed retrospectively using cut-off val¬
ues designed to maximize AUC values, a method
which assumes constant risk amongst the 'high' and
Aliment Pharmacol Ther 31, 1064-1076
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'low' risk groups.18 Several studies attempted to
evaluate multiple prognostic markers retrospectively
using the same cohort, an approach which increases
the risk of obtaining a statistically significant result
by chance. Another potentially confounding issue is
the lack of international standardization of laboratory
variables, such as prothrombin time and creatinine,
and changes to assay reagents over the time course
of these studies.35 We also appreciate that exclusion
of studies where transplantation and death were
deemed equivalent may have introduced spectrum
bias, as prognostic tests are usually applied in set¬
tings where OLT is available. This problem is difficult
to circumvent given that emergency OLT will never
be subjected to a clinical trial, but, given the reduced
quality-of-life seen following transplantation for par¬
acetamol-induced ALF, the accumulated risks of
immunosuppression and the scarcity of liver
donors,16 accurate calculation of the specificity of
each prognostic test is vital in order to minimize
inappropriate transplantation.
This study expands upon a recent systematic
review16 evaluating the KCC for paracetamol-induced
ALF by including additional prognostic markers. The
former study found spectrum bias in studies originat¬
ing from KCH, with increased spontaneous survival
amongst patients listed for transplantation, but not
receiving a graft, compared with those meeting crite¬
ria, but never listed, suggesting that a 'healthier'
cohort may be preferentially transplanted in KCH. The
current data confirm the increased prognostic accuracy
of the original KCC in studies originating from KCH
compared with studies from other units, with a higher
pooled DOR in KCH-based studies compared with that
from studies conducted in other units. This raises fur¬
ther questions regarding the overall generalizability of
the KCC to patients with paracetamol-induced ALF
treated outside KCH.
The heterogeneity of the included studies evaluating
the KCC was partly because of a multicentre US
study29 which explicitly applied the KCC solely at the
time of admission, rather than dynamically throughout
admission as originally intended.5' 36 Whilst early and
accurate prognostication in ALF is vital to permit
timely listing for OLT, application of the KCC solely at
admission reduces the time available for the disease to
evolve and may introduce spectrum bias. Given that
the median time taken to fulfil the KCC following
admission to a tertiary liver transplant unit is 12 h,7
application of the KCC solely at admission may
1074 D.G.N. CRAIG ef al.
explain the low sensitivity of the criteria in the US
study, whilst concerns have also been expressed about
the prophylactic use of fresh frozen plasma in this US
study and the potential confounding effects upon pro¬
thrombin time.37 Furthermore, 48% of cases resulted
from unintentional overdoses in this US study, a type
of overdose seen less frequently in the UK.38 It may be
that repeated ingestion of supratherapeutic doses of
paracetamol over a protracted time course disrupts
liver function subacutely, so that patients are less
likely to develop the profound acidosis or concurrent
severe coagulopathy, renal dysfunction, and encepha¬
lopathy required to fulfil the KCC, but have at least as
poor a prognosis as an intentional overdose at a single
time point. Future prognostic scoring systems may
therefore need to take the pattern of paracetamol over¬
dose into account in addition to traditional biochemi¬
cal parameters.
The addition of postresuscitation arterial lactate to
the KCC7 is questioned by this study. Only two addi¬
tional30' 32 studies, one of which was reported in
abstract-form, that reported this modification fulfilled
eligibility criteria for inclusion, but these studies sug¬
gest little benefit from this. Furthermore, the reduced
specificity of the lactate criteria undermines the tradi¬
tional benefit of the KCC in 'ruling in' a hopeless prog¬
nosis. The presence of systemic inflammation, with or
without sepsis, is increasingly recognized as important
in ALF,39 but hyperlactataemia can result from numer¬
ous other organ sources and therefore perhaps not sur¬
prisingly, arterial lactate is a relatively nonspecific
prognostic indicator in paracetamol-induced ALF.
Within critical care settings, the use of APACFIE II and
Sequential Organ Failure Assessment (SOFA) scores to
monitor organ dysfunction have greater recognition
than the KCC and are attractive as early prognostic
markers in ALF.40 APACHE II, in particular, showed
encouraging prognostic accuracy, but was only evalu¬
ated in a single eligible study.27 One29 additional study
evaluating APACHE II scores was excluded from this
particular analysis, as the prognostic scoring reported
in the study could not be reconstructed into a 2 x 2
table; this study is also notable for the atypical nature
of the patient cohort as outlined above. Given that
APACHE III, systemic inflammatoiy response syndrome
(SIRS) and SOFA scores all performed less well than the
KCC (albeit in single studies), the role of these markers
may be to permit earlier identification of a high-risk
cohort requiring transfer to tertiary centres that offer
liver transplantation, rather than as definitive trans¬
plant listing criteria.
Persistently elevated serum phosphate or reduced
AFP levels may reflect failure of hepatic regeneration
and therefore could help predict a poorer outcome in
paracetamol-induced ALF. Serum AFP showed high
prognostic performance in one10 study, whereas
serum phosphate showed equivalence with the KCC
in one28 retrospective study from KCH. Other authors
(in studies where transplantation was equated with
death and hence excluded from this study) have demon¬
strated conflicting results with serum phosphate41-44
and therefore further evaluation of both serum AFP
and phosphate in future studies would be worthwhile.
The MELD scoring system has been widely adopted
for organ allocation in chronic liver disease and has
shown encouraging prognostic accuracy in nonparac-
etamol ALF.12' 45-47 More limited data exist regarding
the use of MELD in paracetamol-induced ALF, but
one additional study (excluded from this analysis as
the 2x2 table was not reconstructable) suggested
that its use may be limited by a high false positive
rate.48
In summary, this systematic review and meta-analy¬
sis has demonstrated that the original KCC for paracet¬
amol-induced ALF have high pooled specificity, but
low pooled sensitivity in determining prognosis in
patients with paracetamol-induced ALF. The KCC had
reduced prognostic accuracy when applied outside
KCH and were occasionally applied only at admission.
The reduced specificity of the KCC following the addi¬
tion of arterial lactate calls into question the benefit of
this modification, suggesting that re-evaluation of this
as a prognostic marker is required. Urgent consider¬
ation should be given to the design of a high-quality,
prospective study evaluating the KCC, APACHE II
scores and markers of hepatic regeneration, such as
serum AFP and phosphate, in paracetamol-induced
ALF. Given the relatively rare nature of ALF, such a
study is likely to require cooperation between several
large centres and argues the need for a collaborative
network of tertiary hospitals experienced in the man¬
agement and prognostication of ALF, similar to that
developed by the Acute Respiratoiy Distress Syndrome
Network program.49
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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT wsmswmm
■ Paracetamol hepatotoxicity is the
commonest cause of acute liver failure (ALF)
in the UK.
• Conflicting data exist regarding the impact
of overdose pattern upon subsequent
mortality or need for emergency liver
transplantation.
WHAT THIS STUDY ADDS
• Unintentional paracetamol overdose is
independently associated with reduced
survival compared with intentional
overdose.
• Unintentional paracetamol overdoses
should be treated as high-risk for the
development ofmultiorgan failure, and
should be considered for A/-acety! cysteine
treatment irrespective of admission serum
paracetamol concentrations.
• The King's College poor prognostic criteria
have reduced sensitivity in unintentional
overdose patients and alternative
prognostic criteria may be required.
AIMS
Paracetamol (acetaminophen) hepatotoxicity is the commonest cause of
acute liver failure (ALF) in the UK. Conflicting data regarding the outcomes
of paracetamol-induced ALF resulting from different overdose patterns are
reported.
METHODS
Using prospectively defined criteria, we have analysed the impact of
overdose pattern upon outcome in a cohort of 938 acute severe liver injury
patients admitted to the Scottish Liver Transplantation Unit.
RESULTS
Between 1992 and 2008,663 patients were admitted with
paracetamol-induced acute severe liver injury. Of these patients, 500
(75.4%) had taken an intentional paracetamol overdose, whilst 110 (16.6%)
had taken an unintentional overdose. No clear overdose pattern could be
determined in 53 (8.0%). Unintentional overdose patients were significantly
older, more likely to abuse alcohol, and more commonly overdosed on
compound narcotic/paracetamol analgesics compared with intentional
overdose patients. Unintentional overdoses had significantly lower
admission paracetamol and alanine aminotransferase concentrations
compared with intentional overdoses. However, unintentional overdoses
had greater organ dysfunction at admission, and subsequently higher
mortality (unintentional 42/110 (38.2%), intentional 128/500 (25.6%), P <
0.001).The King's College poor prognostic criteria had reduced sensitivity
in unintentional overdoses (77.8%, 95% confidence intervals (CI) 62.9,88.8)
compared with intentional overdoses (89.9%, 95% CI 83.4,94.5).
Unintentional overdose was independently predictive of death or liver
transplantation on multivariate analysis (odds ratio 1.91 (95% CI 1.07,3.43),
P = 0.032).
CONCLUSIONS
Unintentional paracetamol overdose is associated with increased mortality
compared with intentional paracetamol overdose, despite lower admission
paracetamol concentrations. Alternative prognostic criteria may be required
for unintentional paracetamol overdoses.
9 2011 The Authors
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Introduction
Acute liver failure (ALF) occurs following sudden extensive
loss of liver cell mass, resulting in hepatic encephalopathy
(HE) and coagulopathy, and can lead to multiple organ
failure with a high associated mortality rate. Previous
studies have highlighted the major contribution of parac¬
etamol (acetaminophen) as a cause of ALF in the UK, North
America and Europe [1-3]. However, there are significant
differences in the epidemiology of paracetamol-induced
ALF in North America compared with the UK. Data from the
USA, covering 1990-99, suggested paracetamol overdose
was responsible for 56 000 emergency department visits,
26 000 hospital admissions and 458 deaths each year [4].
Approximately 12 650 (22.6%) emergency department
visits, 2240 (8.6%) admissions and 100 (21.8%) deaths were
due to unintentional paracetamol ingestion [4]. Against
this background the US Acute Liver Failure Study group
reported that unintentional overdose was the most
common pattern of ingestion in patients with ALF, respon¬
sible for 48% of all overdoses, and reported similar out¬
comes between intentional and unintentional overdoses
[2], These data contrast with the pattern of overdose
reported in the UK. In the King's College Hospital series,
92% of paracetamol-induced ALF occurred after ingestion
at a single time point with suicidal intent [5],Contradictory
data have also been presented regarding the outcome of
ALF induced by accidental (unintentional) overdose of
paracetamol, with increased mortality [6], or similar out¬
comes [2, 7], being reported. Lastly, in those series report¬
ing increased mortality in patients following accidental
paracetamol poisoning, it is unclear if this excess mortality
is associated with this pattern of overdose per se or other
clinical features such as organ failure or alcohol consump¬
tion prevalent in this population [6].
The aim of this cohort study was to analyse the
incidence and outcome of unintentional paracetamol
overdoses compared with intentional overdoses utilizing
prospectively defined data collected from 938 patients




The cohort retrospectively analysed was from 938 patients
admitted to the SLTU between 1 November 1992 and 31
October 2008 with suspected severe acute liver injury.
Severe acute liver injury was defined as sudden deteriora¬
tion in liver function with associated coagulopathy in the
absence of a history of chronic liverdisease,whilst the term
ALF (i.e. fulminant liver failure) was restricted to those
patients developing hepatic encephalopathy (HE) [8].
Guidelines for accepting patients from referring hospitals
were based on previously published criteria and have
remained unchanged over the time course of the study [9],
These admission criteria included: HE, progressive coagul¬
opathy with a prothrombin time (PT) > 50 s, international
normalized ratio (INR) > 5 or in the case of paracetamol
overdose, PT in seconds greater than time in hours post
overdose, persistent metabolic acidosis despite adequate
fluid resuscitation, hypoglycaemia or deteriorating renal
function in the presence of severe liver injury. Following
admission a detailed clinical history, examination and
laboratory investigations were performed, with imag¬
ing studies and transjugular liver biopsy undertaken
where clinically indicated. Laboratory investigations were
repeated at daily intervals or more frequently in patients
with rapidly progressive liver failure. Patients admitted to
the SLTU are managed using a standard protocol as previ¬
ously described, which is reviewed on an annual basis [10].
The King's College Hospital poor prognostic criteria (KCC)
are used in this unit and throughout the UK to determine
patients who will most likely die without liver transplanta¬
tion (LT) [11].The KCC were modified in 2006 within the UK
to include arterial lactate concentration in patients with
paracetamol overdose [12]. Liver transplantation (LT) was
considered in all patients meeting KCC in conjunction with
their medical condition and psychological assessment.
If accepted as transplant candidates, patients are 'super-
urgently' listed with UK Transplant and prioritized for the
next available compatible organ.
Methods
Details of patient history, clinical examination and labora¬
tory results along with therapeutic interventions, including
intensive care admission, need for renal replacement
therapy or inotropic support, were prospectively recorded
in the ALF database.The following variables were recorded
at the time of admission: temperature, pulse, white cell
count (WCC), platelet count, INR, serum electrolytes, serum
bilirubin, alanine aminotransferase (ALT), serum albumin,
arterial hydrogen ion, bicarbonate and arterial lactate.
Where available, the paracetamol preparation, number
of tablets, type (whether accidental or intentional) and
timing of overdose, delay to presentation and use of
^-acetylcysteine (NAC) were all recorded. Background
information such as alcohol use and dependency, illicit
drug use, pre-existing psychiatric history and employment
was obtained by the admitting medical team from a
variety of sources including, where possible, the patient,
the patient's family and the patient's general medical prac¬
titioner. The suicidal ideation of each patient was assessed
by detailed interview of the patient (when the absence of
HE permitted this) by the specialist transplant psychiatric
liaison team prior to any decisions regarding listing for LT,
with corroborating evidence obtained from the patient's
family and general practitioner where possible. Where
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available, further information was obtained from review
of the medical and psychiatric notes from the referring
hospital.
Definitions
Paracetamol overdose was prospectively assigned as the
cause of acute severe liver injury if there was a clear history
of ingestion of potentially toxic amounts of paracetamol
(>4g day^1) within 7 days of presentation, serum parace¬
tamol concentrations were >10 mg I"1 or serum ALT con¬
centration was >1000 IU I"1 within 7 days of a history of
paracetamol ingestion irrespective of the serum paraceta¬
mol concentration [2]. Paracetamol overdose was only
accepted as the cause of acute severe liver injury after
exclusion of other potential aetiologies, in particular the
presence of other hepatotoxic drugs or substances, hepa¬
titis A and B, autoimmune hepatitis and Wilson's disease.
An intentional overdose was defined as a cumulative
dose of paracetamol >4 g ingested over 4 h or less with the
objective of self-harm; unintentional overdose was defined
as a paracetamol overdose ingested when self-harm was
not the aim. Single overdose was an overdose (>4 g) taken
at a single defined time point whilst a staggered overdose
described ingestion of two or more supratherapeutic
paracetamol doses over a time interval of greater than 8 h
resulting in a cumulative dose of >4 g day \Mixed overdose
described more than one type of tablet being taken at or
during the time of the overdose, whilst compound overdose
described overdose of compound tablets which included
paracetamol such as co-proxamol or co-dydramol. Alcohol
abuse was defined as active and resistant alcohol depen¬
dence in excess of 56 units week 1 for men and 42 units
week-1 for women.
Outcome was defined as spontaneous survival to
discharge without transplant, death without transplant,
survival with transplant and death with transplant. When
undertaking survival analysis, death and LT were con¬
sidered equivalent.
Statistical analysis
All patient data were prospectively recorded in the SLTU
ALF database. Statistical analysis was retrospectively per¬
formed using SPSS software (SPSS 16.0, Chicago IL, USA)
and Graphpad Prism (GraphPad Software Inc., La Jolla,CA).
Data values are presented as median and interquartile
range (IQR) or percentages unless otherwise stated. Con¬
tinuous data were compared using analysis of variance or
the Kruskal-Wallis test for non-normally distributed vari¬
ables. Categorical data were analysed using Chi-squared
tests or Fisher's exact test. The Bonferroni method was
used to adjust P values to account for multiple compari¬
sons. Stepwise logistic regression was used to determine
factors predictive of death or LT in paracetamol-induced
acute severe liver injury patients. Only variables with
P < 0.10 were included in the multivariate analysis.
Actuarial probability curves were constructed using
the Kaplan-Meier method and compared with log-rank




Over a 16 year period (12 November 1992-11 November
2008) 938 patients were admitted to the SLTU with sus¬
pected severe acute liver injury, ofwhom 663 (70.7%) were
prospectively classified as having paracetamol-induced
hepatotoxicity. Six hundred and fourteen (92.6%) had a
history of potentially toxic paracetamol consumption (>4 g
day-1). Six hundred and twenty-eight patients (94.7%) had
an ALT >1000IU I"1 [ALT >3500 in 526 (79.3%)] and 512
(77.2%) had detectable paracetamol in serum.Only four of
these 663 patients (0.6%) fulfilled only one criterion for
paracetamol-induced liver injury. All four of these patients
had a history of ingestion of potentially toxic quantities of
paracetamol but serum paracetamol was undetectable
and ALT < 1000 IU I"1. Two of these patients had a clear
history of a single ingestion of a large quantity of parac¬
etamol with suicidal intent and two had a history of stag¬
gered unintentional paracetamol ingestion.The latter two
became encephalopathic, one fulfilled KCC and both died
without transplant. The two former patients survived
without LT.These four patients have been included in sub¬
sequent analysis as paracetamol cases. Baseline demo¬
graphic and clinical characteristics of the paracetamol
study group are outlined in Table 1.
Clinical presentation
Of the 663 paracetamol cases, 520 (78.4%) had been
transferred to the SLTU from a total of 14 separate health
authorities, with the remaining 143 patients transferred
from local hospitals or from wards within the Royal Infir¬
mary of Edinburgh. In those patients (414/663, 62.4%) in
whom accurate timings could be obtained, presentation to
emergency services occurred at a median of 23 h post final
paracetamol ingestion (range 1-130 h). Female admissions
accounted for 348 (52.5%) of admissions, with 315 (47.5%)
males admitted. The median age at admission was 35
(IQR 27-45) years for males and 34 (IQR 24-44) years for
females. Information regarding NAC use in the referring
hospital was available for 644/663 (97.1%) of patients, of
whom 559 (86.8%) had received intravenous NAC, at a
median time from last paracetamol ingestion of 23.75 (IQR
10-44) h. A total of 263/581 (45.3%) patients had a history
of chronic alcohol abuse, with 264/590 (44.7%) of patients
taking alcohol concomitantly with their overdose. In those
patients (n = 606) in whom an employment history could
be obtained, 289 (47.7%) patients were unemployed, 220
(36.3%) were employed, and 27 (4.5%) were in full time
education. A total of 244/577 (42.3%) patients had a prior
history of psychiatric illness and 242/619 (39.1%) had
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Table 1
Admission characteristics of 663 subjects with paracetamol-induced
acute severe liver injury
Admission characteristic
(n = 663 unless otherwise stated)
Sex (male/female) 315/348 (47.5/52,5%)















Paracetamol concentration (mg I-1) (n = 561) 60.5 (20-130)
Mixed overdose (n = 620) 316 (51.0%)
Associated alcohol with overdose (n = 590) 264 (44.7%)
Alcohol abusef (n = 581) 263 (45.3%)
Previous psychiatric history (n = 577) 244 (42.3%)
Active drug abuse (n = 623) 96 (15.4%)
Previous overdose (n = 619) 242 (39.1%)
Unemployed at time of overdose (n = 606) 289 (47.7%)
Time from overdose to SLTU admission
(h) (n = 414)
52 (40-67)
Received NAC in referring hospital (n = 644) 559 (86.8%)
^ WCC (x109 l~1)
2 Platelets (x1091-1)
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Ever encephalopathic 344 (51.9%)
Never encephalopathic 319 (48.1%)
Not encephalopathic on admission 362 (54.6%)
Developed encephalopathy during












Data are presented as median (IQR) or numbers (%) as appropriate. t>56 units
week'1 (male); >42 units week-1 (female). Abbreviations: WCC, white cell count;
ALT, alanine aminotransferase; PT, prothrombin time.
taken a previous overdose. A total of 96/623 (15.4%)
patients admitted to current recreational drug use. A total
of 301 (45.4%) of paracetamol-induced acute liver injury
patients were encephalopathic on admission,and a further
43/362 (11.9%) went on to develop HE during admission.
A total of 344 (51.9%) of patients therefore developed HE,
and thus ALF, at some point during their illness.
Intentional vs. unintentional overdoses
Of the 610 (92%) patients in whom a clear psychiatric
history could be obtained, 500/610 (82%) reported
an intentional (suicidal) overdose, whilst 110/610 (18%)
subjects denied suicidal ideation and were classified as
unintentional overdoses (Table 2). Unintentional overdose
subjects were significantly older (median 40 (IQR 30-48)
years) compared with intentional overdose patients (33
(24-43) years, P < 0.001), had a lower admission para¬
cetamol concentration (34.7 (15.9-57.5) mg I"1 vs. 75.6
(25.4-148.2) mg I'. P < 0.001), and were more likely to
have consumed narcotic/paracetamol compound analge¬
sics (37.6% vs. 24.7%, P < 0.001). Information regarding the
reasons for overdose was available for 82/110 (74.5%) of
unintentional overdoses.The most common rationale for
overdose was for relief of pain, including abdominal pain
(n = 26), headache (n = 17), musculoskeletal pain (n = 17),
toothache (n = 5), chest pain (n = 2) and dysmenorrhoea
(n = 1). Other causes for overdose included accidental
overdose during chemical intoxication (n = 5), non¬
specific systemic illness (n = 4), limb abscess (n = 2),
iatrogenic overdose (n = 2) and one overdose taken unin¬
tentionally by a patient with cognitive impairment. Of the
52 subjects who had consumed compound analgesics or
taken mixed overdoses unintentionally, the majority (29/
52, 55.8%) had used codeine phosphate/paracetamol
compounds (co-codamol), an analgesic available over
the counter (OTC) in pharmacies in the UK at a dose
of 8/500 mg, and only by prescription at higher doses.
A total of eight subjects had overdosed on prescribed
compound analgesics, namely dextropropoxyphene/
paracetamol (coproxamol, n = 5) and dihydrocodeine
tartrate/paracetamol (codydramol, n = 3). A total of five
cases had overdosed on both co-codamol and coprox¬
amol. The remaining compound overdose cases had used
aspirin/paracetamol OTC compounds (n = 6). Of the mixed
overdoses, three cases had taken non-steroidal anti¬
inflammatories and paracetamol, two had used aspirin
and paracetamol, whilst a further three cases had taken
paracetamol with benzodiazepines. The remaining six
cases had taken mixed overdoses of other prescription
medications and paracetamol.
Unintentional overdose patients were significantly
more likely to have consumed paracetamol in a staggered
fashion (90.8% vs. 10.6%, P < 0.001), and to have taken a
lower cumulative paracetamol dose (11 (5-29) g vs. 27.5
(20-45) g,P< 0.001). Unintentional overdose subjects were
also more likely to have a history of chronic alcohol abuse
(40.8% vs. 20.8%, P< 0.001), and to have consumed alcohol
with their overdose (52.5% vs. 42.7%, P = 0.037), but were
less likely to have a prior psychiatric history (24.5% vs.
46.2%, P < 0.001). Unintentional overdose subjects had
significantly lower admission ALT concentrations (3931
(2036-7184) IU I"1 vs. 8295 (5257-10 920) IU I"1, P < 0.001)
but had significantly more deranged serum sodium (133
(130-137) mmol M vs. 136 (133-138) mmol I"1, P = 0.001),
creatinine (203 (110-327) pmol I"1 vs. 114 (81-207)
pmol I"1, P < 0.001) and albumin (31 (24-35) g I"1 vs. 37
(33-41) g I"1, P < 0.001) concentrations. Subjects con¬
suming paracetamol unintentionally were significantly
less likely to have received treatment with NAC prior to
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Table 2
Admission clinical and laboratory data in patients with intentional or unintentional paracetamol overdose
Variable Intentional n Unintentional n P
Sex (male/female) 248/252 (49.6/50.4%) 500 50/60 (45.5/54.5%) 110 0.431
Age (years) 33 (24-43) 40 (30-48) <0.001
Paracetamol concentration (mg l~1) 75.6 (25.4-148.2) 432 34.7 (15.9-57.5) 88 <0.001
Paracetamol dose ingested (g) (range) 27.5 (20-45) 500 11 (5-29) 97 <0.001
Range (4-150) Range(4-70)
Paracetamol only 237 (48.1%) 493 43 (45.3%) 95 <0.001
Compound narcotic/paracetamol use 122 (24.7%) 38 (40%)
Mixed overdose 134(27.2%) 14 (14.7%)
Associated alcohol* 196 (42.7%) 459 52 (52.5%) 99 0.037
Alcohol abuset 101 (20.8%) 485 42 (40.8%) 103 <0.001
Staggered overdose 53 (10.6%) 499 99 (90.8%) 109 <0.001
Previous psychiatric history 206 (46.2%) 446 23 (24.5%) 94 <0.001
Active drug use 80 (16.7%) 478 (10.5%) 105 0.110
Received NAC in referring hospital 441 (89.6%) 492 86 (80.4%) 107 0.008
Platelets (x109 I-1) 129 (81-176) 500 113 (62-169) 110 0.043
2 Sodium (mmol I-1) 136 (133-138) 133 (130-137) 0.001
5 S Creatinine (pmol I"1)
<0 dJ
-
| ALT (IU I"')
114 (81-207) 203 (110-327) <0.001
8295 (5 257-10 920) 3931 (2036-7184) <0.001
•§ ii Bilirubin (pmol I"1) 84(58-112) 75 (58-118) 0.530
1 Albumin (g I-1) 37 (33-41) 31 (24-35) <0.001
5 PT (s) 48 (34-67) 47 (33-64) 0.540
Developed encephalopathy 237 (47.4%) 65 (59.1%) 0.027
Met King's College Criteria 130 (26%) 40 (36.4%) 0.034
CWH 141 (28.4%) 46 (41.8%) 0.048
Mechanical ventilation 190 (38%) 58 (52.7%) 0.005
Transplanted 42 (8.4%) 6 (5.5%) 0.044
Spontaneously survived 372 (74.4%) 63 (57.3%) <0.001
Data are on admission to the SLTU unless otherwise stated and are presented as median (IQR) or numbers (%) as appropriate. +>56 units week"1 (male); >42 units week"1 (female).
*Alcohol taken with paracetamol overdose.
transfer to the SLTU (80.4% vs. 89.6%, P = 0.008). Uninten¬
tional overdose patients were more likely to develop HE
(59.1% vs.47.4%, P = 0.027) and had more systemic organ
failure, such as requirement for renal replacement therapy
(41.8% vs. 28.4%, P = 0.048), or need for mechanical venti¬
lation (52.7% vs. 38%, P = 0.005), than intentional overdose
patients. Unintentional overdose subjects were also more
likely to fulfil the KCC (36.4% vs. 26%, P = 0.034), but were
subsequently less likely to undergo LT (15% vs. 32.3%,
P = 0.044). Overall spontaneous survival (57.3% vs. 74.4%,
P < 0.001) was significantly worse in the unintentional
patient group (Figure 1).
Patients with unobtainable overdose history
In 53 (8.0%) patients, no clear history of suicidal intention
(or otherwise) could be obtained, despite attempts to
interview the patient, the patient's family and by liaison
with the referring hospital. In the majority (72%) of cases,
this was due to the patient having HE on arrival and being
unable to provide a history. Of the 53 patients in whom a
history was unobtainable, 19 (35.8%) were mechanically
ventilated on arrival, seven (13.2%) were in grade lll-IV HE
and 12 (22.6%) had grade l-ll HE. Compared with inten¬







0 5 10 15 20 25 30
Days post-admission
Number of patients at risk
Intentional 500 445 416 405 401 397 396
Unintentional 110 84 73 70 69 68 67
Unknown 53 28 22 20 19 19 18
Figure 1
Survival curves of patients with paracetamol-induced acute severe liver
injury according to the pattern of overdose. Survival curves were signifi¬
cantly different when compared using log-rank testing (P < 0.0001).
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significantly lower admission ALT concentrations (5057
(2365-8770) IU I"1 vs. 8295 (5257-10 920) IU I"1, P < 0.001)
but had significantly more deranged serum creatinine (241
(147-362) jamol I"1 vs. 114 (81-207) ^mol I1, P < 0.001) and
albumin (32 (29-37) g I"1 vs. 37 (33-41) g I"1, P < 0.001)
concentrations. These 53 patients required significant
levels of organ support, with 39 (73.6%) requiring
mechanical ventilation, 29 (54.7%) renal replacement
therapy and 30 (56.6%) pressor support. These patients
had a particularly poor clinical outcome, with 27 (50.9%)
fulfilling the KCC,31 (58.5%) dying without transplantation
and only 17 (32.1%) spontaneously surviving (Figure 1).
Prognostic accuracy of the KCC in different
patterns of paracetamol overdose
The prognostic accuracy of the KCC was determined for
the entire paracetamol ALF cohort (n = 344), then sepa¬
rately for ALF patients with intentional (n = 237) and unin¬
tentional (n = 65) overdoses (Table 3). Although the KCC
had high specificity for both overdose patterns, the sensi¬
tivity in predicting outcome was considerably better for
intentional overdoses (89.9%,95% confidence intervals (CI)
83.4,94.5) compared with unintentional overdoses (77.8%,
95% CI 62.9,88.8).
Contraindications to LT in patients meeting the
KCC according to pattern of overdose
Similar proportions of patients meeting the KCC had
contraindications to LT in the intentional (74/130,56.9%),
unintentional (28/40, 70%) and 'unknown' (14/27, 51.9%,
P = 0.247) overdose cohorts. In the intentional cohort, 29
(39.2%) patients were rejected for listing for LT because of
medical contraindications to LT, 25 (33.8%) due to active
and resistant alcohol dependence and 11 (14.9%) due to a
previous history of non-compliance with psychiatric
therapy or a consistently stated wish to die without clinical
psychiatric illness. Other reasons for not listing for LT
included active intravenous drug use (six patients) and
multiple episodes of self-harm (three patients). In the unin¬
tentional cohort, 14 (50%) patients were excluded because
they were medically unfit to survive LT. A total of 12 (42.9%)
patients were rejected due to active and resistant alcohol
dependence and the remaining two (7.1%) patients due to
active intravenous drug use. In the unknown cohort, six
(42.9%) patients were excluded due to alcohol abuse, five
(35.7%) patients due to medical contraindications and
three (21.4%) patients for psychosocial reasons.
Temporal changes in the patterns of overdose
To determine if there had been temporal changes in
the overdose pattern over the period of observation, we
compared the initial 5 complete years of the observation
period (1993-97) with the last 5 complete years of the
observation period (2003-07). Fewer patients were admit¬
ted with paracetamol-induced acute liver injury in the later
cohort (179 patients) compared with the earlier cohort
(240 patients). However, a significantly greater proportion
of the patients in the later cohort had overdosed uninten¬
tionally (1993-97:27/240 patients, 11.3%; 2003-07:37/179
patients, 20.7%; P = 0.009).
Predictors of death in paracetamol-induced
acute liver injury
In view of the significant differences in a number of
prognostic variables between the different overdose
subgroups, logistic regression analysis of 5LTU admission
parameters including patterns of overdose was performed
to determine independent predictors of death or LT in
paracetamol-induced acute severe liver injury (Table 4).
Univariate analysis identified increasing age (P < 0.001),
WCC (P< 0.001), PT (P< 0.001), serum creatinine (P< 0.001),
H+ (P < 0.001), and hyponatraemia (P = 0.011) as potential
predictors of death/LT. Unintentional overdoses (P=0.001),
the absence of clinical history (P < 0.001), the presence of
any grade of encephalopathy on admission (P< 0.001) and
thrombocytopaenia (P < 0.001) were also potentially sig¬
nificant after univariate analysis. Acute or chronic alcohol
abuse was not predictive of a poorer outcome, nor was lack
of treatment with NAC in the referring hospital. Multivari¬
ate analysis identified the presence of encephalopathy on
admission (odds ratio (OR) 4.50,95% CI 2.76,7.34), increas¬
ing WCC (OR 1.04,95% CI 1.02,1.06),admission PT (OR 1.03,
95% CI 1.02,1.04), and admission creatinine (OR 1.00,95%
CI 1.00,1.01) as independently predictive of death/LT. Both
unintentional overdoses (OR 1.91, 95% CI 1.07, 3.43), and
overdoses where there was no reliable history (OR 6.65,
95% CI 1.78, 24.81) were independently predictive of
a poor outcome. Other independent predictors were
Table 3
Prognostic accuracy of the KCC in paracetamol-induced ALF
Sensitivity Specificity LR+ LR- DOR
KCC+ve/ deaths Total deaths (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Paracetamol ALF cases (n = 344) 197/180 213 84.5 (81.3, 87.0) 87.0 (81.8, 91.1) 6.5 (4.5, 9.8) 0.18 (0.14, 0.23) 36.6(19.5, 68.4)
Intentional (n = 237) 126/116 129 89.9 (83.4, 94.5) 90.7 (83.6, 95.5) 9.7 (5.4, 17.6) 0.11 (0.07, 0.19) 87.4 (36.7, 208.1)
Unintentional (n = 65) 38/35 45 77.8 (62.9, 88.8) 85.0(62.1, 96.8) 5.2 (1.8, 14.9) 0.26 (0.15, 0.47) 19.8(4.8,81.6)
Transplanted patients have been included as having died. +LR/-LR: +ve/-ve likelihood ratio; DOR: diagnostic odds ratio.
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Table 4
Factors predictive of mortality on univariate and multivariate analysis of admission parameters in patients with paracetamol-induced acute severe liver
injury
Variable Univariate OR (95% CI) P value Multivariate OR (95% CI) P value
Unintentional overdose 1.29 (1.09, 1.53) 0.001 1.91 (1.07, 3.43) 0.032
Overdose history unavailable 2.52 (1.98, 3.21) <0.001 6.65 (1.78, 24.81) 0.005
Age 1.04 (1.02, 1.05) <0.001 1.04 (1.02, 1.06) <0.001
Concomitant alcohol with OD 1.00 (1.00, 1.00) 0.527 NA
Chronic alcohol abuse 1.34(0.79,2.26) 0.274 NA
Not given NAC in referring hospital 1.37 (0.84, 2.24) 0.210 NA
Encephalopathy on admission (any grade) 5.50 (3.55, 8.53) <0.001 4.50 (2.76, 7.34) <0.001
Admission WCC 1.11 (1.08, 1.15) <0.001 1.04 (1.02, 1.06) <0.001
Admission platelet count 0.99 (0.99, 1.00) <0.001 0.99 (0.99, 1.00) 0.012
Admission PT 1.03 (1.02, 1.03) <0.001 1.03 (1.02, 1.04) <0.001
Admission sodium 0.96 (0.92, 0.99) 0.011 0.99 (0.94, 1.03) 0.572
Admission creatinine 1.01 (1.01, 1.01) <0.001 1.00 (1.00, 1.01) <0.001
Admission H+ 1.08(1.06, 1.10) <0.001 1.08(0.97, 1.21) 0.180
BTCP
LT was considered equivalent to death.
increasing age (OR 1.04,95% C11.02,1.06),and thrombocy-
topaenia (OR 0.99,95% CI 0.99,1.00).
Discussion
In this large cohort study of paracetamol-induced acute
severe liver injury we have analysed the impact of suicidal
ideation upon patient outcome. Using prospective defini¬
tions of overdose pattern, intentional (suicidal) overdose
was the commonest pattern of paracetamol ingestion,
accounting for 75.4% of all paracetamol cases. However,
despite lower admission paracetamol and ALT concen¬
trations, patients with unintentional overdose had signi¬
ficantly reduced survival compared with intentional
overdoses. Additionally, the KCC were less sensitive in
predicting outcome in unintentional overdose cases. Both
unintentional overdoses and 'unknown' overdoses, where
no clear history could be obtained, were independently
associated with increased mortality. These data suggest
that the pattern of overdose should be taken into account
when assessing patients with paracetamol-induced hepa-
totoxicity, and that, irrespective of their admission parac¬
etamol concentrations, those patients with unintentional
overdose should be managed as high-risk cases due to
their significantly increased mortality.
The strengths of this study include the large number
of patients, the single centre nature of the study and the
prospectively defined criteria of overdose.The SLTU repre¬
sents a single referral and management facility for all
patients in Scotland with ALF irrespective of their suitabil¬
ity for LT, and the Scottish population has remained rela¬
tively stable at 5.1 million over the period of the study.
However, we recognize that not all ALF cases occurring in
Scotland will have been transferred to the SLTU during the
course of the study due to medical instability precluding
safe patient transfer [13]. Criteria for patient admission
have remained largely unchanged during the time course
of the study, further reducing patient heterogeneity, a rec¬
ognized problem in previous cohort studies of paraceta¬
mol hepatotoxicity [14, 15]. Our overall mortality rate of
32.7% represents selection bias for the more severe parac¬
etamol cases in Scotland, since admissions to the SLTU are
determined by severity of liver dysfunction, rather than
on the basis of a history of paracetamol consumption or
number of tablets consumed.This latter point is of particu¬
lar note since intentional and unintentional paracetamol
overdoses represent considerably different patient popu¬
lations with regards to demographics, timing of presenta¬
tion and degree of organ dysfunction at presentation.
Suicidal patients often present to a hospital setting as a
direct result of the psychological consequences of their
overdose, rather than as a result of symptoms; in contrast,
unintentional overdoses usually present because of mor¬
bidity and therefore tend to be systemically unwell at
presentation. Our study partially eliminates this problem
through a gatekeeper mechanism, but inevitably intro¬
duces referral bias, since only those patients with poten¬
tially reversible organ failure are accepted.
Defining paracetamol as a cause of hepatotoxicity is
recognized as particularly difficult in cases where there is
no obvious suicidal intent or patients are unable to give a
history.We prospectively defined paracetamol hepatotox¬
icity and overdose subgroups, but acknowledge that some
of the unintentional overdoses in our cohort may repre¬
sent other, unidentified, primary causes of hepatotoxicity
in whom paracetamol was taken to relieve systemic
malaise. However, paracetamol overdose was not simply
used as a 'catch-all' diagnosis in the absence of an alterna¬
tive diagnosis. Seronegative hepatitis represented 63/938
(6.7%) of all cases during this study, none of whom were
classified as paracetamol-induced hepatotoxicity (data not
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shown). We also recognize that some unintentional cases
will have been disguised suicides,especially since'acciden-
tal' overdoses are associated with both chronic alcohol
abuse and underlying depression [7], Indeed, our analysis
would suggest potential suicidal motives behind large
overdoses of paracetamol, particularly if not taken as a
compound analgesic. However, we were careful to ascer¬
tain as much information as possible regarding prior sui¬
cidal ideation, timings, and circumstances of overdose,
associated acute and chronic alcohol consumption, and
previous psychiatric history before classifying each over¬
dose to a particular subgroup. This assessment included
experienced psychiatric review.The ability and time avail¬
able to obtain a detailed psychiatric history to confirm
intent is limited by the rapid clinical progression of
paracetamol-induced ALF, and by the development of HE,
but, given that the lack of a detailed history regarding sui¬
cidal intent is in itself an independent predictor of poor
prognosis, this further emphasizes that such cases should
be treated as high risk.
Previous studies have suggested that accidental para¬
cetamol overdose is associated with increased mortality
[6, 14]. However, this poorer prognosis is not a universal
finding in other cohort studies of paracetamol hepatotox-
icity [2,7].The recently published multicentre cohort analy¬
sis from the US Acute Liver Failure Study group found
similar survival in 131 unintentional patients (72% 3 week
survival) compared with 122 intentional patients (71% 3
week survival) [2]. This difference in survival compared
with our data does not relate to differences in transplant
rates, but may be due to the increased frequency of renal
dysfunction in our cohort compared with the US series. We
have recently reported that renal dysfunction on admis¬
sion in patients with ALF is a significant predictor of poor
outcome [16]. Another important potential confounding
factor is alcohol abuse, given that unintentional overdose
patients in our cohort were not only more likely to abuse
alcohol chronically, but were also more likely to consume
alcohol acutely at the time of overdose. However, neither
acute nor chronic alcohol abuse was an independent pre¬
dictor of death or LT on multivariate analysis. The associa¬
tion of alcoholism with other confounding factors, such as
delayed presentation, increased paracetamol dosage, and
older age, may account for the poorer outcomes previously
reported in alcoholics following paracetamol overdose
[17,18]. Furthermore, since alcoholism is a recognized risk
factor for disguised suicidal overdose [19], some parasui-
cidal attempts in alcoholic patients may have been mis-
classified as unintentional overdoses. Another important
element in the prognosis of unintentional overdoses is
likely to be the time period prior to treatment with NAC
('time to NAC'). Our data demonstrate that unintentional
overdoses are less likely to receive NAC in the referring
hospital, although this was not an independent risk factor
for poor outcome. Delayed 'time to NAC' is a recognized
independent risk factor for poor outcome following single
time point paracetamol overdose [18], and delayed pre¬
sentation is thought to be more common amongst
alcoholics [20].Given the increased frequency of both alco¬
holism and staggered overdoses amongst the uninten¬
tional overdose cohort, it is likely that absence of, or
delayed treatment with, NAC in the referring hospital was
at least partially responsible for the poorer outcome in
this group. As a result, we would suggest that patients
with acute liver injury and a history of supratherapeutic
paracetamol ingestion should be treated as high risk
irrespective of serum paracetamol concentrations, and
commenced on NAC treatment whilst other aetiological
investigations are pending.
Admission HE, coagulopathy, renal failure, thrombocy-
topaenia, leucocytosis and increasing age, as well as unin¬
tentional or unknown patterns of overdose, predicted a
poorer outcome in the paracetamol overdose patients as a
whole. Many of these factors are well established as pre¬
dicting a poorer outcome in paracetamol-induced ALF
[11], and the increasingly recognized deleterious effects of
the systemic inflammatory response following paraceta¬
mol hepatotoxicity may explain the predictive nature of
leucocytosis seen in this study [21-23], Increasing age has
previously been recognized as an independent risk factor
for poor outcome following paracetamol overdose [24],
and the older age of the unintentional overdose cohort
may represent either an increased frequency of this delete¬
rious overdose pattern amongst older patients, or a lower
threshold for the development of severe hepatotoxicity
following paracetamol overdose in older subjects.
We have observed an increased frequency of uninten¬
tional overdose in our cohort compared with data previ¬
ously published from King's College in which only 8% of
paracetamol overdoses were due to accidental ingestion
[5]. Due to the potential selection bias associated with our
study, we cannot conclude that the nationwide incidence
of unintentional paracetamol overdoses is increasing, but
this question deserves attention due to the poor outcome
seen in this overdose subgroup.The increased proportions
of unintentional overdoses seen in this study compared
with the King's College study may also reflect temporal
changes associated with legislation affecting the availabil¬
ity and packaging of paracetamol that followed the publi¬
cation of the King's College series [25], particularly given
the increased proportion of this overdose type seen in the
later years of this cohort study. Alternative explanations for
these differences include socioeconomic factors and the
increased rates of chronic alcohol abuse in the Scottish
population compared with the rest of the UK [26].The KCC
identify patients with increased risk of death following
paracetamol poisoning and are the 'transplant criteria' in
use throughout the UK to determine patient prognosis [11,
12], Within our unintentional cohort the KCC are specific,
but lack sensitivity, for paracetamol-induced ALF, suggest¬
ing that alternative prognostic criteria may be required
following this pattern of overdose [27-33],
280 / 71:2 / Br J Clin Pharmacol
Outcome following unintentional paracetamol overdose
In conclusion, unintentional paracetamol overdose is
independently associated with increased mortality com¬
pared with intentional overdose.This pattern of overdose
is associated with older age, acute and chronic alcohol
abuse and a staggered pattern of overdose. Despite lower
admission ALT and paracetamol concentrations, unin¬
tentional overdose patients have increased systemic dys¬
function and poorer clinical outcomes compared with
intentional overdoses.The KCC are less sensitive in predict¬
ing outcome in unintentional overdose and alternative
prognostic criteria may be required.
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SUMMARY
Background
The systemic inflammatory response syndrome (SIRS) and sequential organ
failure assessment (SOFA) scores are widely used as prognostic markers in
critical care settings and could improve triage of high-risk paracetamol
(acetaminophen) overdose patients.
Aim
To evaluate the prognostic accuracy of the SIRS and SOFA scores following
single time point paracetamol overdose.
Methods
Analysis of 100 single time point paracetamol overdoses admitted to a ter¬
tiary liver centre, with subsequent prospective validation of identified
thresholds. Individual laboratory samples were correlated with the corre¬
sponding clinical parameters in relation to time post-overdose, and the
daily SOFA and SIRS scores calculated.
Results
A total of 74 (74%) patients developed the SIRS, which occurred signifi¬
cantly earlier in patients who died (n = 21) compared with spontaneous
survivors (n = 53, P = 0.05). The SIRS occurred in 70 (70%) patients by
96 h post-overdose, with a 30% mortality rate; compared with 0% mortality
in the 30 non-SIRS patients (P = 0.001). Median SOFA scores were signifi¬
cantly higher in nonsurvivors at 48 (P = 0.009), 72 (P < 0.001), and 96 h
(P < 0.001). A SOFA score >7 during the first 96 h post-overdose predicted
death/transplantation with a sensitivity of 95.0 (95% CI 78.5-99.1) and
specificity of 70.5 (95% CI 66.3-71.6). A validation cohort of 38 single time
point paracetamol overdoses confirmed the extremely high negative predic¬
tive value of both the SIRS and SOFA thresholds.
Conclusions
The absence of either a SOFA score >7 or a SIRS response during the first
96 h following paracetamol overdose could improve triage and reduce
transfers of lower risk patients to tertiary liver centres.
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INTRODUCTION
Paracetamol (acetaminophen) overdose remains the main
aetiological factor responsible for acute liver failure
(ALF) in the developed world.1 The only effective treat¬
ment for the condition remains emergency orthotopic
liver transplantation (OLT).2 Paracetamol-induced ALF
is strongly associated with the development of the sys¬
temic inflammatory response syndrome (SIRS) and a
subsequent cascade of complications including hepatic
encephalopathy (HE), coagulopathy and multiple organ
dysfunction syndrome.3 In human studies, development
of the SIRS following paracetamol-induced hepatotoxicity
has been associated with both an increased risk of wors¬
ening HE grade,4 and with poorer overall outcome, irre¬
spective of the presence of infection.3 Existing prognostic
systems, such as the King's College Criteria (KCC), uti¬
lise features of HE and extrahepatic organ injury to pre¬
dict a hopeless prognosis without OLT, but their use has
been criticised for their relatively low negative predictive
value5 and by the inherent requirement for multiorgan
failure to have developed before considering definitive
treatment. Several studies have therefore examined the
prognostic accuracy of multiorgan failure assessment
scores such as the Sequential Organ Failure Assessment
(SOFA) and Acute Physiology and Chronic Health Eval¬
uation (APACHE) II scores to predict outcome following
paracetamol hepatotoxicity,6"8 but these studies have
tended to apply the prognostic test in question at the
point of hospital admission, rather than in relation to
the time from overdose.9 This inevitably introduces tem¬
poral confounding, as many patients present to hospital
following paracetamol overdose due to psychological,
rather than physical, morbidity. Therefore, a better
understanding of the temporal evolution of the SIRS and
multiorgan failure following paracetamol overdose could
improve prognostication in this condition and could aid
early identification of high-risk patients.
To our knowledge, no studies exist which examine the
temporal relationship between the initial hepatotoxic
insult (i.e. paracetamol overdose) and development of
the SIRS and multiorgan failure. The aims of this study
were to examine these temporal changes in a cohort of
patients who required tertiary level care after taking a
single intentional paracetamol overdose. It was hypothes¬
ised that the absence of a SIRS response or extrahepatic
organ injury following overdose would be associated with
a low risk of in hospital mortality and that the SIRS and
SOFA scores could therefore act as quantitative triage
instruments to identify those patients at lower risk of
requiring emergency OLT.
PATIENTS, METHODS AND DEFINITIONS
Since its inception in 1992, the Scottish Liver Transplan¬
tation Unit (SLTU) has prospectively collected and main¬
tained a dedicated database of all acute liver injury
patients admitted to the unit. Data recorded in this data¬
base include details of patient history, clinical examina¬
tion and laboratory results along with therapeutic
interventions, including intensive care admission, need
for renal replacement therapy (RRT) or inotropic sup¬
port. Where possible the paracetamol preparation, num¬
ber of tablets, type (whether intentional, accidental,
single time point or staggered) and timing of overdose,
delay to presentation and use of N-acetyl cysteine (NAC)
are all recorded. The cohort analysed were 100 consecu¬
tive single time point intentional [defined as a paraceta¬
mol overdose (>4 g) taken at a single defined time point
with the objective of self-harm] paracetamol overdoses
admitted to the SLTU with acute liver injury between
April 2003 and February 2009 and a prospectively col¬
lected cohort of 38 patients admitted between March
2009 and July 2010. Ethical approval for the study was
obtained from the Scotland 'A' Research and Ethics
Committee. We specifically excluded patients with stag¬
gered overdoses or overdoses taken accidentally in an
attempt to relieve pain, because of the confounding tem¬
poral and diagnostic problems associated with these
overdoses.10
Paracetamol overdose was defined as at least 2/3 of: a
history of ingestion of potentially toxic amounts of par¬
acetamol (>4 g/day); detection of paracetamol in the
serum >10 mg/L; or a serum alanine aminotransferase
(ALT) level >1000 IU/L within 7 days of a history of
paracetamol ingestion irrespective of the serum paraceta¬
mol concentration.1 All 138 patients fulfilled all of these
three criteria. Severe acute liver injury was defined as
sudden deterioration in liver function with associated co¬
agulopathy in the absence of a history of chronic liver
disease, while the term ALF (i.e. fulminant liver failure)
was restricted to those patients developing HE.11 Guide¬
lines for accepting patients from referring hospitals were
based on previously published criteria from the British
Society of Gastroenterology and remained unchanged
over the time course of the study.12 Patients admitted to
the SLTU are managed using a standard protocol as pre¬
viously described,13 the main goals of which have
remained similar over the duration of this cohort study.
The KCC are used in this unit and throughout the UK
to determine patients who will most likely die without
OLT.14 As the purpose of this study was not to develop
2 Aliment Pharmacol Ther
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transplantation listing criteria, death and OLT were con¬
sidered equivalent when undertaking survival analysis.
Laboratory parameters
Retrospective analysis of all hospital electronic laboratory
records was performed to obtain all standard haemato-
logical, biochemical and coagulation samples obtained
for each patient during the first 10 days of admission.
Each sampling time point was noted from either the
clinical notes and/or the laboratory receipt and the cor¬
responding haemodynamic and clinical parameters for
each sampling time point retrieved from the clinical
notes. These data were then individually compared
against the reported time from overdose for each patient,
and the corresponding laboratory and clinical values
recorded in a dedicated database.
Systemic inflammatory response syndrome
The presence of the SIRS was defined as two or more of:
temperature <36 °C or >38 °C, heart rate >90 beats/min,
leucocyte count <4 x 109/L or >12 x 109/L and tachyp-
noea >20 breaths/min or PaC02 < 4.3 kPa.15 The daily
presence or absence of the SIRS and the number of the
SIRS components fulfilled were retrospectively calculated
for each patient by correlating the daily leucocyte count
with the most abnormal temperature and heart rate
recorded during each corresponding day of admission.
Respiratory rate was only included for nonventilated
patients, as the majority of patients in our unit are elec-
tively mechanically ventilated following the development
of grade III or IV HE.
Sofa score and organ failure
Organ failure was assessed using the SOFA score, which
assesses six organ systems - hepatic; renal; coagulation;
cardiovascular; respiratory; and central nervous - and
provides a graded score from 0 to 4 points for each
organ system (Table l).16 The SOFA score was calculated
for each 24-h period following overdose, using the most
deranged values for each parameter in each 24 h period.
Organ failure was defined as a SOFA score >3 points for
the organ concerned (Table 1). As a result of potential
confounding, SOFA scores were not calculated following
the administration of platelet transfusions.
Statistical analysis
Statistical analysis was performed using spss (SPSS 16.0,
Chicago, IL, USA) and graphpad prism (GraphPad Soft¬
ware Inc., La Jolla, CA, USA). Data values are presented
as median ± interquartile range (IQR) or percentages
unless otherwise stated. When undertaking survival anal¬
ysis, death and OLT were considered equivalent. Receiver
operating characteristic (ROC) analysis was used to iden¬
tify optimum threshold values to discriminate nonsurvi-
Table 1 | The sequential organ failure assessment (SOFA) score
SOFA score
Score
Organ system 0 1 2 3 4
Respiratory: Pa02/Fi02 >400 <400 <300 <200 <100
Renal: creatinine, /tmol/L
(mg/dL)







<20 (<1.2) 20-32 (1.2-1.9) 33-101 (2.0-5.9) 102-204 (6.0-12.0) >204 (>12.0)
Cardiovascular: hypotension No
hypotension










Haematological: platelet count >150 <150 <100 <50 <20
Neurological: Glasgow Coma
Scale score
15 13-14 10-12 6-9 <6
Fi02, fractional inspired oxygen; MAP, mean arterial pressure; Pa02, arterial oxygen tension.
* Adrenergic agents administered for at least 1 h (doses given are in /<g/kg per minute).
Aliment Pharmacol Ther
© 2011 Blackwell Publishing Ltd
3
D. G. N. Craig et al.
vors. Continuous data were compared using either analy¬
sis of variance or the Kruskal-Wallis test if inter-group
variances were unequal, with post hoc Dunn's testing
used to compare selected groups. Categorical data were
analysed using Chi-squared tests or Fishers exact test.
Bonferroni corrections were undertaken for repeated
measures. Missing data were treated in a last observation
carried forward manner. Results were considered statisti¬
cally significant when P < 0.05.
RESULTS
Patients and details of overdose
A total of 100 patients (46 men, 54 women) admitted to
the SLTU between April 2003 and February 2009 were
included in the study. During this period, a total of 347
patients had been admitted, of whom 111 were classified
as 'nonparacetamol' cases, 62 patients had taken a stag¬
gered paracetamol overdose, 45 patients had overdosed
on paracetamol accidently and in the remaining 29 cases,
the details of the paracetamol overdose were unclear.
The median patient age of the 100 included patients was
34 (IQR 24-43) years. A total of 83 patients were trans¬
ferred to the SLTU from outlying health boards, at a
median time of 50 (36-66.5) h following overdose. The
remaining patients were admitted to the SLTU from
wards within the Royal Infirmary of Edinburgh or from
local hospitals. The median ingested paracetamol dose
was 25 (17.5-41) g. All 100 patients received NAC treat¬
ment at their local hospital, at a median time from over¬
dose of 22.75 (9.5-42.25) h. A total of 47 (47%) of
patients had taken a mixed overdose. As shown in
Table 2, none of these demographic parameters or
potential confounders differed significantly between sur¬
vivors and patients who died/required OLT. Other base¬
line demographic and clinical characteristics of the
paracetamol study group are shown in Table 2.
Hepatic encephalopathy and other outcomes
A total of 29 (29.0%) of paracetamol-induced acute liver
injury patients were encephalopathic on admission to the
SLTU and a further 18/71 (25.4%) went on to develop
FIE during admission. A total of 47 (47%) patients there¬
fore developed HE and thus ALF, at some point during
their illness. Of these patients, 22 (46.8%) subsequently
met the modified KCC, at a median time from overdose
of 51.5 (39.0-73.0) h from overdose. Of these 22
patients, 3 were transplanted, 14 died without OLT and
5 recovered spontaneously. Four patients died without
meeting the modified KCC. The sensitivity, specificity
and diagnostic odds ratios (DOR) of the KCC were 81.0
[95% confidence intervals (CI) 65.0-90.7], 93.7 (95% CI
89.4-96.3) and 62.9 (95% CI 15.7-251.3) respectively. Of
the nontransplanted patients who met the KCC, 13
patients were excluded from listing for OLT because of
active and resistant alcohol dependence (11 patients) and
active intravenous drug abuse (2 patients). Four patients
were listed but subsequently deemed medically unfit to
survive OLT, while a further two patients showed clear
signs of spontaneous recovery and were delisted prior to
an organ becoming available. On admission, patients
who later died or were transplanted were significantly
more coagulopathic [PT 80 (53-103) s vs. 48 (33-70) s,
P = 0.002], had lower serum albumins (30 (23-35) g/L
Table 2 | Demographics of study population and details of paracetamol overdose
Variable Dead/OLT n Spontaneous survival n P
Gender (male/female) 6/15 (28.6%/71.4%) 21 40/39 (50.6%/49.4%) 79 0.071
Age (years) 37 (28-44) 33 (22-43) 0.115
Ingested paracetamol dose (g) 27.5 (15.5-40.0) 25.0 (17.0-40.5) 0.226
Admission paracetamol level (/tmol/L) 56 (37-146) 70 (24-145) 0.545
Mixed OD 8 (38.1%) 39 (49.4%) 0.115
Previous OD 8 (57.1%) 14 29 (46.0%) 63 0.388
Active drug abuse 3 (14.3%) 21 11 (14.5%) 76 0.654
Weekly alcohol consumption (units) 50 (4-140) 13 20 (2-68) 57 0.182
Time from OD to NAC (h) 15.5 (10.0-34.5) 21 23.5 (11.0-43.5) 79 0.791
Time from OD to SLTU admission (h) 41.0 (29.5-49.0) 53.0 (45.5-67.0) 0.045
Data are presented as median (± interquartile range) or percentages as appropriate.
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vs. 34 (31-37) g/L, P = 0.013) and had significantly
higher serum creatinine levels [174 (118-239) /tmol/L vs.
94 (75-145) /rmol/L, P = 0.006] compared with sponta¬
neous survivors. A significantly greater proportion of
patients who died or were transplanted required multiple
organ support, such as RRT, inotropic support and
mechanical ventilation (Table SI).
SIRS and temporal relationship to overdose
Examination of the cumulative incidence of the SIRS
revealed that by 48 h post-overdose, 27/40 (67.5%)
patients had mounted a SIRS response, with a mortality
rate in the SIRS group of 44.4%, compared with 7.7% for
those patients not mounting a SIRS response (Fisher's
P = 0.020). By 72 h post-overdose, 59/86 (68.6%)
patients had developed a SIRS during admission, with a
mortality rate of 28.8%, compared with a mortality rate
of only 3.7% (1/27 patients, Fisher's P = 0.007) in
patients without a SIRS at this point. By 96 h, the cumu¬
lative incidence of the SIRS had risen to 70 (70%)
patients, with a mortality rate of 30% in this group; com¬
pared with a mortality rate of 0% in the 30 patients
without the SIRS (Fisher's P = 0.001). The sensitivity,
specificity, negative predictive values and DORs of the
SIRS occurring by each time point post-overdose are
shown in Table 3. In total, 74 (74%) of patients devel¬
oped the SIRS post-overdose, but this occurred signifi¬
cantly earlier following overdose in patients who died
[median 43.0 (28.5-61.0) h, n = 21] compared with
patients who survived [60.0 (36.5-81.0) h, n = 53,
P = 0.05]. By contrast, the presence of the SIRS at the
time of hospital admission, or at the development of HE,
resulted in reduced sensitivity and DORs compared with
the values obtained at 48, 72 and 96 h post-overdose
(Table 3). The number of SIRS components fulfilled fol¬
lowing overdose was significantly related to increasing
mortality at 48 (P = 0.047), 72 (P = 0.0057) and 96
(P < 0.0001) h post-overdose.
Temporal relationship between overdose and SOFA
score
SOFA scores could be calculated for 99/100 patients.
SOFA scores ranged from 1 to 15 by 48 h post-over¬
dose, 0 to 17 by 72 h and 1 to 18 by 96 h post-over-
dose. Median SOFA score (± IQR) was significantly
higher in patients who died or were transplanted at
each of these three time points [48 h: 9 (6.25-12.25) vs.
5 (3-7), P = 0.009; 72 h; 12.5 (8.75-17) vs. 5 (3-7),
P < 0.001; 96 h: 15 (9-19) vs. 5 (3-8), P < 0.001], The
number of organ systems failing by both 72
(P = 0.0003) and 96 (P < 0.0001) h post-overdose was
significantly related to mortality, which ranged from
5.9% for patients without any organ system failure at
72 h post-overdose to 71.4% for those patients with
three or more organ system failures at this time point,
Figure 1. ROC analysis of SOFA scores showed an area
under the curve of 0.80 (95% CI 0.65-0.95), 0.90 (95%
CI 0.82-0.97) and 0.91 (95% CI 0.85-0.98) at 48, 72
and 96 h post-overdose respectively. The optimal SOFA
score thresholds for discriminating nonsurvivors at these
three time points were >4 at 48 h, >6 at 72 h and >7 at
96 h respectively, Table 4.
Table 3 | Predictive accuracy of the presence of the systemic inflammatory response syndrome (SIRS) following single

















48 40/13 27/12 92.3 (64.0-99.8) 44.4 (25.5-64.7) 92.3 (71.9-98.6) 9.6 (1.1-84.6)
72 86/18 59/17 94.4 (76.7-99.0) 38.2 (33.5-39.4) 96.3 (84.5-99.3) 10.5 (1.7-64.8)
96 100/21 70/21 100.0 (83.9-100.0) 38.0 (27.3-49.6) 100.0 (90.3-100.0) °° (3.3-°°)
At SLTU
admission
100/21 52/17 81.0 (62.4-92.1) 55.7 (50.8-58.7) 91.7 (83.6-96.5) 5.3 (1.7-16.5)
At onset of HE 47/21 30/18 85.7 (70.7-94.6) 53.8 (41.7-61.0) 82.4 (63.8-93.4) 7.0 (1.7-27.6)
Modified KCC 100/21 KCC +ve/ 81.0 (65.0-90.7) 93.7 (89.4-96.3) 94.9 (90.6-97.5) 62.9 (15.7-251.3)
deaths 22/17
CI, confidence intervals; HE, hepatic encephalopathy; SLTU, Scottish Liver Transplantation Unit.
The SIRS was defined as the presence of >2 SIRS components in any 24-h period. The accuracy of the SIRS is compared with the
modified King's College Hospital poor prognostic criteria (KCC).
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72 h post overdose
x2 = 12.8, P= 0.0003
No of organ failures 0







96 h post overdose
x2 = 21.1, P <0.0001
No of organ failures 0













Figure 11 Association between mortality rate and the
number of organ failures identified by the sequential
organ failure assessment (SOFA) score at (a) 48, (b)
72 and (c) 96 h following single time point paracetamol
overdose. Numbers above the bars indicate number of
deaths. Death and liver transplantation were considered
equivalent.
A SOFA score >7 at any time during the first 96 h
post-overdose predicted outcome with excellent accuracy,
with a significantly higher median maximum SOFA score
among patients who died [17 (12-18.75)] compared with
spontaneous survivors [6 (3-8), P < 0.0001] and an area
under the ROC of 0.92 (95% CI 0.86-0.98). Further anal¬
ysis using this SOFA threshold of >7 during the first
96 h post-overdose revealed that only 2/56 (3.6%)
patients not fulfilling this criteria required RRT and only
1/56 (1.8%) patients required intracranial pressure moni¬
toring.
A previous report also evaluated SOFA scores follow¬
ing paracetamol overdose and reported that a SOFA
score >8 early after admission and >12 at the onset of
HE were the most discriminatory thresholds for deter¬
mining prognosis.8 At admission, the area under the
ROC for SOFA was 0.80 (95% CI 0.68-0.93), but using
the previously reported threshold of >8 to predict a poor
prognosis resulted in a low sensitivity of 38.1 (95% CI
23.7-48.7). The area under the ROC for a SOFA >12 at
the onset of HE (n = 47) was 0.71 (95% CI 0.56-0.86),
with a low sensitivity of 23.8 (95% CI 12.2-34.2).
SOFA score and outcome
Univariate analysis of the individual components of the
SOFA score at 72 and 96 h post-overdose was performed
to identify those components which best predicted an
adverse outcome (Table S2). All the organ failure com¬
ponents except the hepatic failure element were strongly
associated with mortality, so a modified SOFA score,
which excluded points for hepatic failure, was computed.
ROC analysis of this modified SOFA score showed an
area under the curve of 0.81 (95% CI 0.67-0.95), 0.90
(95% CI 0.84-0.97) and 0.91 (95% CI 0.84-0.98) at 48,
72 and 96 h post-overdose respectively. A modified
SOFA threshold score of >3 at 48 h and >4 at 72 h,
improved upon the specificity of the original SOFA score
at both these time points without affecting sensitivity. A
modified SOFA threshold score of >5 at any point dur¬
ing the first 96 h following overdose was highly predic¬
tive of death or OLT, with a sensitivity of 95.0 (95% CI
78.7-99.1), specificity of 76.9 (95% CI 72.8-78.0) and
negative predictive value of 98.4 (95% CI 93.0-99.7)
(Table 4).
Association between SIRS and SOFA scores
We then explored whether those patients with high
SOFA scores also manifested a SIRS response. By 96 h
post-overdose, the median (± IQR) SOFA score in those
patients who manifested a SIRS response was signifi¬
cantly higher [8 (5-15)] compared with those patients
with no SIRS at that point [5 (3-6.25), P = 0.0011],
There was a strong correlation between these two vari¬
ables (Spearman's r = 0.474, P < 0.0001), as shown in
Figure 2, with those patients who died tending to have
both a SIRS response and a higher SOFA score than
spontaneous survivors.
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predictive value odds ratio
(95% CI) (95% CI)
48 >4 37/12 25/11 91.7 (61.5-99.8)
72 >6 84/18 40/17 94.4 (72.7-99.9)
96 >7 92/15 35/14 93.3 (68.1-99.8)
Up to 96 >7 98/20 42/19 95.0 (78.5-99.1)
48 (Modified SOFA) >3 37/12 19/11 91.7 (61.5-99.8)
72 (Modified SOFA) >4 84/18 33/17 94.4 (72.7-99.9)
96 (Modified SOFA) >4 92/15 38/14 93.3 (68.1-99.8)











91.7 (70.2-98.5) 8.6 (1.0-77.5)
97.7 (90.4-99.6) 31.8 (4.0-254.2)
98.2 (92.8-99.7) 37.3 (4.6-301.8)
98.2 (92.3-99.7) 45.4 (7.2-278.7)
94.4 (79.9-99.0) 23.4 (3.1-160.4)
98.0 (91.9-99.6) 53.1 (8.2-332.1)
98.1 (92.3-99.7) 31.7 (4.9-196.7)
98.4 (93.0-99.7) 63.3 (9.9-391.4)
100/21 KCC +ve/ 81.0 (65.0-90.7) 93.7 (89.4-96.3) 94.9 (90.6-97.5) 62.9 (15.7-251.3)
deaths
22/17
CI, confidence intervals; HE, hepatic encephalopathy; SITU, Scottish Liver Transplantation Unit; N/A, not applicable.
The accuracy of the SOFA score is compared with the modified King's College Hospital poor prognostic criteria (KCC). The modi¬
fied SOFA score excludes the hepatic failure component.
Optimal thresholds for predicting death or liver transplantation were derived from receiver operator characteristic analysis.
■ Dead/OLT
□ Survived
Figure 2 | Association between sequential organ failure
assessment (SOFA) scores and the number of systemic
inflammatory response syndrome (SIRS) components
fulfilled by 96 h following single time point paracetamol
overdose. OLT, orthotopic liver transplantation.
Prospective validation of multiorgan failure scores
The prognostic accuracy of the SIRS and SOFA thresh¬
olds outlined above was then examined in a prospec¬
tively collected cohort of paracetamol-induced acute liver
injury patients admitted to the Royal Infirmary of Edin¬
burgh between March 2009 and July 2010. A total of 38
patients were included and their demographic details,
admission laboratory parameters and clinical outcomes
are shown in Table 5. All seven patients who died or
underwent emergency OLT manifested a SIRS response,
had a SOFA score >7 and had a modified SOFA >5
within 96 h of overdose. The specificity of the two SOFA
predictors was 77.4 (95% CI 70.5-77.4) and the specific¬
ity of the SIRS was 74.2 (95% CI 67.2-74.2).
DISCUSSION
This study has explored the temporal relationship
between paracetamol overdose and the development of
systemic inflammation and organ failure. Development
of the SIRS and extrahepatic organ failure are both
strongly associated with adverse clinical outcomes and
both SOFA and SIRS scores are highly sensitive markers
of poor outcome following paracetamol overdose. A
SOFA score <7 during the first 96 h post-overdose is
highly predictive of spontaneous survival, with a risk of
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Variable (n = 38) Value
Gender (male/female)
Age (years)
Received NAC in referring hospital








Grade 3-4 HE encephalopathy
Mechanical ventilation
KCC met
SIRS response by 96 h post-overdose
SOFA score >7 by 96 h post-overdose










117 (61-241) (1.3 (0.7-2.7)
5198 (2974-7978)












Table 5 | Validation cohort of
38 single time point paraceta¬
mol overdoses
Data are presented as median (± interquartile range) or percentages as appropriate.
death of <2%, and these patients also have a low risk of
requiring specialist intracranial pressure monitoring or
renal support. As a result of the high negative predictive
values of both SOFA and SIRS, these scores may have a
future role as 'gatekeepers' when considering patient
transfer to tertiary liver centres.
Predicting individual prognosis accurately following
paracetamol overdose is fraught with difficulty.1 For a
predictive model to be clinically useful, it should be easy
to use, accurate, reproducible and accepted by clinical
staff. Both SOFA and SIRS scores are dynamic tests,
which can be rapidly recalculated throughout admission
and are attractive as prognostic indicators because of
their widespread use in intensive care units and their
ease of use. Recently, the SOFA score was demonstrated
to outperform liver-specific prognostic scores in predict¬
ing outcome among a cohort of critically ill chronic liver
disease patients.18 While both the SOFA and SIRS scores
have similarly high negative predictive values following
paracetamol overdose, the SOFA score is more attractive
as a quantitative triage tool as, unlike the SIRS, it is an
ordinal rather than dichotomous variable and therefore a
rising SOFA score may help to identify deteriorating
patients. Although neither SIRS nor SOFA were origi¬
nally developed to predict outcome, the high sensitivity
of these scores makes them attractive as a means of iden¬
tifying all those high-risk paracetamol overdose patients
who might die without transplant, although their rela¬
tively lower specificity suggests that they should not
replace the KCC as definitive listing criteria. Addition¬
ally, there are some specific limitations of both SOFA
and SIRS scores that should be addressed. The SIRS does
not incorporate a hepatic failure component at all, while
the hepatic failure component (serum bilirubin) of the
SOFA score lacks specificity or the ability to differentiate
acute from chronic hepatic dysfunction. Indeed, of all
the six organ failure components combined in the SOFA
score, only the hepatic failure element was not associated
with an increased risk of death, a finding in keeping with
several previous studies of this scoring system.19' 20
Future studies should validate whether the modified
SOFA score outlined above, which excludes hepatic
organ failure, is a more accurate triage marker in this
setting than the original SOFA score.
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The principal strength of this study lies in its novel
evaluation of SIRS and SOFA scores in relation to the
timing of overdose, rather than in relation to the time of
admission or the onset of HE. The initial symptoms of
ALF are often vague and as a result there may be a sig¬
nificant delay between the overdose and subsequent hos¬
pitalisation. Additionally, some patients present as a
result of the psychological consequences of their overdose
rather than as a result of physical morbidity. Thirdly, as
the majority of previous studies of prognostic variables of
paracetamol-induced ALF have been performed at aca¬
demic referral centres following patient transfer from
smaller hospitals,9 attempting to apply a prognostic score
at the time of 'hospital admission' is considerably hin¬
dered by patient heterogeneity. Equally, accurately apply¬
ing a prognostic score at the onset of HE may be
problematic as the presence or absence of HE is subjec¬
tive and subtle encephalopathy may be wrongly inter¬
preted as resulting from alcohol or narcotic withdrawal.
We have therefore attempted to minimise clinical hetero¬
geneity by selecting single time point overdoses and have
examined the evolution of systemic inflammation and
organ failure in relation to this fixed time point. Using
this approach, we demonstrate that the prognostic accu¬
racy of both SIRS and SOFA scores are enhanced com¬
pared with previous reports which applied these markers
at either the time of hospital admission or the onset of
HE.9 We recognise that this approach is dependent upon
the temporal accuracy of the patients' overdose history,
but previous studies have suggested that the patient his¬
tory is usually reliable following paracetamol overdose.21
Heterogeneity is further reduced by the single centre nat¬
ure of this study, where both criteria for patient admis¬
sion and clinical management protocols have remained
unchanged during the time course of the study.
However, we recognise that this study has several
important limitations. Clearly, the results of this study are
not directly applicable to patients who have taken a stag¬
gered overdose, an increasingly recognised subtype of par¬
acetamol overdose,22 or in cases where accurate timings of
the overdose are unavailable. Although we have examined
the applicability of multiorgan failure scores in relation to
time from overdose, patients access treatment at different
time points in their clinical evolution, which may influ¬
ence the development of the SIRS or organ failure. A fur¬
ther caveat is that some patients were transferred to the
SLTU from a number of surrounding hospitals, each of
which may have had different management protocols,
clinical expertise and referral thresholds following parac¬
etamol overdose. While the SLTU is the single referral
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point for all severe paracetamol overdoses in Scotland, we
recognise the possibility of selection bias and that some
patients with severe organ failure secondary to paraceta¬
mol overdose may not have been transferred to the
SLTU.23 We also recognise that not all of the patients in
this study developed HE, and therefore ALF. However,
predicting the development of HE can be equally prob¬
lematic, and the mere absence of HE following severe
acute liver injury does not preclude the development of
other complications such as acute kidney injury.24
A potential application for SIRS and SOFA scores
may be as gatekeepers to tertiary level care. In the SLTU,
transfer criteria are based broadly upon guidelines previ¬
ously published by the British Society of Gastroenterol¬
ogy.12 These guidelines recognise that 'A significant
proportion of cases will make an unremarkable recovery
without intensive measures but this level of unnecessary
transfer is justified if the potential for transplantation, in
what is often a narrow window of time, is to be realised'.
As a result of the rapid progression of paracetamol-
induced ALF and the risks involved in transferring
patients with HE or with incipient cerebral oedema, up
to 50% of UK liver centre patients never develop HE.
Developing sensitive markers to identify high-risk
patients at an earlier time point, prior to HE developing,
could accelerate safe patient transfer, but equally the high
negative predictive value of the multiorgan scores out¬
lined above could effectively rule out the need for emer¬
gency OLT by identifying those patients highly likely to
survive with supportive care alone, thereby potentially
avoiding patient transfer.
In conclusion, this retrospective cohort study of 100
severe acute paracetamol-induced acute liver injury
patients has evaluated the incidence and temporal kinet¬
ics of both the SIRS and SOFA scores following single
time point paracetamol overdose and demonstrates that
these markers are highly sensitive at identifying patients
with a poor prognosis. The high negative predictive value
of these markers was validated in a prospective cohort.
Both the SIRS and SOFA scores deserve further evalua¬
tion and external validation as potential gatekeepers to
improve clinical decision-making models following par¬
acetamol overdose.
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Table SI. Admission laboratory parameters and clini¬
cal outcomes for study population. ALT, alanine amino¬
transferase; PT, prothrombin time.
Table S2. Risk factors for inhospital mortality at 72
and 96 h postparacetamol overdose: results of univariate
analysis.
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